Compounds and methods for inhibiting mitotic progression

ABSTRACT

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

PRIORITY CLAIM

This application is a continuation of U.S. patent application Ser. No.14/810,225, filed on Jul. 27, 2015, now U.S. Pat. No. 9,765,078, whichis a continuation of U.S. patent application Ser. No. 13/644,216, filedon Oct. 3, 2012, now U.S. Pat. No. 9,102,678, which is a continuation ofU.S. patent application Ser. No. 12/472,583, filed May 27, 2009, nowU.S. Pat. No. 8,399,659, which is a continuation of U.S. patentapplication Ser. No. 11/127,855, filed May 12, 2005, now U.S. Pat. No.7,572,784, which claims priority from U.S. Provisional PatentApplication Ser. No. 60/571,653, filed on May 14, 2004, and U.S.Provisional Patent Application Ser. No. 60/617,221, filed on Oct. 8,2004, each of which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION Field of the Invention

This invention relates to compounds and methods for the treatment ofcancer. In particular, the invention provides compounds that inhibitAurora kinase enzymes, pharmaceutical compositions comprising thecompounds, and methods of using the compounds for the treatment ofcancer.

Background of the Invention

According to the American Cancer Society, an estimated 1.4 millionAmericans were newly-diagnosed with cancer in 2004 and about 560,000victims died from the disease. While medical advance have improvedcancer survival rates, there is a continuing need for new and moreeffective treatment.

Cancer is characterized by uncontrolled cell reproduction. Mitosis is astage in the cell cycle during which a series of complex events ensurethe fidelity of chromosome separation into two daughter cells. Severalcurrent cancer therapies, including the taxanes and vinca alkaloids, actto inhibit the mitotic machinery. Mitotic progression is largelyregulated by proteolysis and by phosphorylation events that are mediatedby mitotic kinases. Aurora kinase family members (e.g., Aurora A, AuroraB, Aurora C) regulate mitotic progression through modulation ofcentrosome separation, spindle dynamics, spindle assembly checkpoint,chromosome alignment, and cytokinesis (Dutertre et al., Oncogene, 21:6175 (2002); Berdnik et al., Curr. Biol., 12: 640 (2002)).Overexpression and/or amplification of Aurora kinases have been linkedto oncogenesis in several tumor types including those of colon andbreast (Warner et al., Mol. Cancer Ther., 2: 589 (2003); Bischoff etal., EMBO, 17: 3062 (1998); Sen et al., Cancer Res., 94: 1320 (2002)).Moreover, Aurora kinase inhibition in tumor cells results in mitoticarrest and apoptosis, suggesting that these kinases are importanttargets for cancer therapy (Ditchfield, J. Cell Biol., 161: 267 (2003);Harrington et al., Nature Med., 1 (2004)). Given the central role ofmitosis in the progression of virtually all malignancies, inhibitors ofthe Aurora kinases are expected to have application across a broad rangeof human tumors. There is thus a need for new Aurora kinase inhibitors.

DESCRIPTION OF THE INVENTION

This invention provides compounds that inhibit Aurora kinase. Thesecompounds are useful for inhibiting Aurora kinase in vitro or in vivo,and are especially useful for the treatment of cell proliferativedisorders, including cancer. The Aurora kinase inhibitors of theinvention have the formula (A):

-   -   or a pharmaceutically acceptable salt thereof, wherein Ring A,        Ring C, and each of the variables R^(a), R^(e), R^(f1), R^(f2),        R^(x), R^(y), and G have the values described below.    -   R^(f1) is hydrogen, or R^(f1) and R^(f2) together form a bond.    -   R^(f2) is hydrogen, or R^(f2) forms a bond with either R^(f1) or        R^(x).    -   Each of R^(x) and R^(y) independently is hydrogen, fluoro, or an        optionally substituted C₁₋₆ aliphatic; or R^(x) and R^(y), taken        together with the carbon atom to which they are attached, form        an optionally substituted 3- to 6-membered cycloaliphatic ring;        or R^(x) and R^(f2) together form a bond.    -   G is hydrogen, an optionally substituted aliphatic, or Ring B        when R^(f1) is hydrogen; and G is hydrogen, —OR⁵, —N(R⁴)₂, —SR⁵,        an optionally substituted aliphatic, or Ring B when R^(f1) and        R^(f2) together form a bond.    -   Ring A is a substituted or unsubstituted 5- or 6-membered aryl,        heteroaryl, cycloaliphatic, or heterocyclyl ring.    -   Ring B is a substituted or unsubstituted aryl, heteroaryl,        cycloaliphatic, or heterocyclyl ring.    -   Ring C is a substituted or unsubstituted aryl, heteroaryl,        heterocyclyl, or cycloaliphatic ring.    -   R^(a) is hydrogen, —C(O)R¹, —CO₂R¹, —SO₂R¹, or a C₁₋₃ aliphatic        having 0-2 substituents independently selected from R³ or R⁷.    -   R^(e) is hydrogen, —OR⁵, —N(R⁴)₂, —SR⁵, —NR⁴C(O)R⁵,        —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, or a        C₁₋₃ aliphatic optionally substituted with R³ or R⁷.    -   R¹ is C₁₋₆ aliphatic or an optionally substituted aryl,        heteroaryl, or heterocyclyl group.    -   Each R³ independently is selected from the group consisting of        -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl),        —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl).    -   Each R⁴ independently is hydrogen or an optionally substituted        aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R⁴ on        the same nitrogen atom, taken together with the nitrogen atom,        form an optionally substituted 5- to 6-membered heteroaryl or 4-        to 8-membered heterocyclyl ring having, in addition to the        nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S.    -   Each R⁵ independently is hydrogen or an optionally substituted        aliphatic, aryl, heteroaryl, or heterocyclyl group.    -   Each R⁶ independently is an optionally substituted aliphatic or        aryl group.    -   Each R⁷ independently is an optionally substituted aryl,        heterocyclyl, or heteroaryl group.

The invention further provides pharmaceutical compositions comprising acompound of formula (A), as well as uses of the claimed compounds forinhibiting Aurora kinase activity and for treating Aurorakinase-mediated disorders.

Compounds of this invention include those described generally above, andare further illustrated by the classes, subclasses, and speciesdisclosed herein. Terms used herein shall be accorded the followingdefined meanings, unless otherwise indicated.

As used herein, the term “Aurora kinase” refers to any one of a familyof related serine/threonine kinases involved in mitotic progression. Avariety of cellular proteins that play a role in cell division aresubstrates for phosphorylation by Aurora kinase enzymes, including,without limitation, histone H3, p 53, CENP-A, myosin II regulatory lightchain, protein phosphatase-1, TPX-2, INCENP, survivin, topoisomerase IIalpha, vimentin, MBD-3, MgcRacGAP, desmin, Ajuba, XIEg5 (in Xenopus),Ndc10p (in budding yeast), and D-TACC (in Drosophila). Aurora kinaseenzymes also are themselves substrates for autophosphorylation, e.g., atThr288. Unless otherwise indicated by context, the term “Aurora kinase”is meant to refer to any Aurora kinase protein from any species,including, without limitation, Aurora A, Aurora B, and Aurora C,preferably Aurora A or B. Preferably, the Aurora kinase is a humanAurora kinase.

The term “Aurora kinase inhibitor” or “inhibitor of Aurora kinase” isused to signify a compound having a structure as defined herein, whichis capable of interacting with an Aurora kinase and inhibiting itsenzymatic activity. Inhibiting Aurora kinase enzymatic activity meansreducing the ability of an Aurora kinase to phosphorylate a substratepeptide or protein. In various embodiments, such reduction of Aurorakinase activity is at least about 50%, at least about 75%, at leastabout 90%, at least about 95%, or at least about 99%. In variousembodiments, the concentration of Aurora kinase inhibitor required toreduce an Aurora kinase enzymatic activity is less than about 1 μM, lessthan about 500 nM, less than about 100 nM, or less than about 50 nM.

In some embodiments, such inhibition is selective, i.e., the Aurorakinase inhibitor reduces the ability of an Aurora kinase tophosphorylate a substrate peptide or protein at a concentration that islower than the concentration of the inhibitor that is required toproduce another, unrelated biological effect, e.g., reduction of theenzymatic activity of a different kinase. In some embodiments, theAurora kinase inhibitor also reduces the enzymatic activity of anotherkinase, preferably one that is implicated in cancer.

The term “about” is used herein to mean approximately, in the region of,roughly, or around. When the term “about” is used in conjunction with anumerical range, it modifies that range by extending the boundariesabove and below the numerical values set forth. In general, the term“about” is used herein to modify a numerical value above and below thestated value by a variance of 10%.

As used herein, the term “comprises” means “includes, but is not limitedto.”

The term “aliphatic”, as used herein, means straight-chain, branched orcyclic C₁₋₁₂ hydrocarbons which are completely saturated or whichcontain one or more units of unsaturation, but which are not aromatic.For example, suitable aliphatic groups include substituted orunsubstituted linear, branched or cyclic alkyl, alkenyl, or alkynylgroups and hybrids thereof, such as (cycloalkyl)alkyl,(cycloalkenyl)alkyl or (cycloalkyl)alkenyl. In various embodiments, thealiphatic group has 1 to 12, 1 to 8, 1 to 6, 1 to 4, or 1 to 3 carbons.

The terms “alkyl”, “alkenyl”, and “alkynyl”, used alone or as part of alarger moiety, refer to a straight and branched chain aliphatic grouphaving from 1 to 12 carbon atoms. For purposes of the present invention,the term “alkyl” will be used when the carbon atom attaching thealiphatic group to the rest of the molecule is a saturated carbon atom.However, an alkyl group may include unsaturation at other carbon atoms.Thus, alkyl groups include, without limitation, methyl, ethyl, propyl,allyl, propargyl, butyl, pentyl, and hexyl.

For purposes of the present invention, the term “alkenyl” will be usedwhen the carbon atom attaching the aliphatic group to the rest of themolecule forms part of a carbon-carbon double bond. Alkenyl groupsinclude, without limitation, vinyl, 1-propenyl, 1-butenyl, 1-pentenyl,and 1-hexenyl.

For purposes of the present invention, the term “alkynyl” will be usedwhen the carbon atom attaching the aliphatic group to the rest of themolecule forms part of a carbon-carbon triple bond. Alkynyl groupsinclude, without limitation, ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl,and 1-hexynyl.

The terms “cycloaliphatic”, “carbocycle”, “carbocyclyl”, “carbocyclo”,or “carbocyclic”, used alone or as part of a larger moiety, refer to asaturated or partially unsaturated cyclic aliphatic ring system havingfrom 3 to about 14 members, wherein the aliphatic ring system isoptionally substituted. Cycloaliphatic groups include, withoutlimitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl,cyclooctenyl, and cyclooctadienyl. In some embodiments, the cycloalkylhas 3 to 6 carbons. The terms “cycloaliphatic”, “carbocycle”,“carbocyclyl”, “carbocyclo”, or “carbocyclic” also include aliphaticrings that are fused to one or more aromatic or nonaromatic rings, suchas decahydronaphthyl or tetrahydronaphthyl, where the radical or pointof attachment is on the aliphatic ring.

The terms “haloaliphatic”, “haloalkyl”, “haloalkenyl” and “haloalkoxy”refer to an aliphatic, alkyl, alkenyl or alkoxy group, as the case maybe, substituted with one or more halogen atoms. As used herein, the term“halogen” or “halo” means F, Cl, Br, or I.

The terms “aryl” and “ar-”, used alone or as part of a larger moiety,e.g., “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refer to a C₆ to C₁₄aromatic moiety comprising one to three aromatic rings, which areoptionally substituted. Preferably, the aryl group is a C₆₋₁₀ arylgroup. Aryl groups include, without limitation, phenyl, naphthyl, andanthracenyl. The term “aryl”, as used herein, also includes groups inwhich an aromatic ring is fused to one or more heteroaryl,cycloaliphatic, or heterocyclyl rings, where the radical or point ofattachment is on the aromatic ring. Nonlimiting examples of such fusedring systems include indolyl, isoindolyl, benzothienyl, benzofuranyl,dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl,isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, fluorenyl, indanyl,phenanthridinyl, tetrahydronaphthyl, indolinyl, phenoxazinyl,benzodioxanyl, and benzodioxolyl. An aryl group may be mono-, bi-, tri-,or polycyclic, preferably mono-, bi-, or tricyclic, more preferablymono- or bicyclic. The term “aryl” may be used interchangeably with theterms “aryl group”, “aryl ring”, and “aromatic ring”.

An “aralkyl” or “arylalkyl” group comprises an aryl group covalentlyattached to an alkyl group, either of which independently is optionallysubstituted. Preferably, the aralkyl group is C₆₋₁₀ aryl(C₁₋₆)alkyl,including, without limitation, benzyl, phenethyl, and naphthylmethyl.

The terms “heteroaryl” and “heteroar-”, used alone or as part of alarger moiety, e.g., heteroaralkyl, or “heteroaralkoxy”, refer toaromatic groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array;and having, in addition to one or more carbon atoms, from one to fourheteroatoms. The term “heteroatom” refers to nitrogen, oxygen, orsulfur, and includes any oxidized form of nitrogen or sulfur, and anyquaternized form of a basic nitrogen. Heteroaryl groups include, withoutlimitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl,triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl,isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl,pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. Theterms “heteroaryl” and “heteroar-”, as used herein, also include groupsin which a heteroaromatic ring is fused to one or more aryl,cycloaliphatic, or heterocyclyl rings, where the radical or point ofattachment is on the heteroaromatic ring. Nonlimiting examples includeindolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl,indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl,cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl,carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, andpyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be mono-,bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, morepreferably mono- or bicyclic. The term “heteroaryl” may be usedinterchangeably with the terms “heteroaryl ring”, “heteroaryl group”, or“heteroaromatic”, any of which terms include rings that are optionallysubstituted. The term “heteroaralkyl” refers to an alkyl groupsubstituted by a heteroaryl, wherein the alkyl and heteroaryl portionsindependently are optionally substituted.

As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclicradical”, and “heterocyclic ring” are used interchangeably and refer toa stable 3- to 7-membered monocyclic, or to a fused 7- to 10-membered orbridged 6- to 10-membered bicyclic heterocyclic moiety that is eithersaturated or partially unsaturated, and having, in addition to carbonatoms, one or more, preferably one to four, heteroatoms, as definedabove. When used in reference to a ring atom of a heterocycle, the term“nitrogen” includes a substituted nitrogen. As an example, in asaturated or partially unsaturated ring having 0-3 heteroatoms selectedfrom oxygen, sulfur or nitrogen, the nitrogen may be N (as in3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or +NR (as inN-substituted pyrrolidinyl).

A heterocyclic ring can be attached to its pendant group at anyheteroatom or carbon atom that results in a stable structure, and any ofthe ring atoms can be optionally substituted. Examples of such saturatedor partially unsaturated heterocyclic radicals include, withoutlimitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl,pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl,dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl,and quinuclidinyl. The terms “heterocycle”, “heterocyclyl”,“heterocyclyl ring”, “heterocyclic group”, “heterocyclic moiety”, and“heterocyclic radical”, are used interchangeably herein, and alsoinclude groups in which a heterocyclyl ring is fused to one or morearyl, heteroaryl, or cycloaliphatic rings, such as indolinyl,3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, wherethe radical or point of attachment is on the heterocyclyl ring. Aheterocyclyl group may be mono-, bi-, tri-, or polycyclic, preferablymono-, bi-, or tricyclic, more preferably mono- or bicyclic. The term“heterocyclylalkyl” refers to an alkyl group substituted by aheterocyclyl, wherein the alkyl and heterocyclyl portions independentlyare optionally substituted.

As used herein, the term “partially unsaturated” refers to a ring moietythat includes at least one double or triple bond between ring atoms. Theterm “partially unsaturated” is intended to encompass rings havingmultiple sites of unsaturation, but is not intended to include aryl orheteroaryl moieties, as herein defined.

The term “linker group” or “linker” means an organic moiety thatconnects two parts of a compound. Linkers typically comprise an atomsuch as oxygen or sulfur, a unit such as —NH—, —CH₂—, —C(O)—, —C(O)NH—,or a chain of atoms, such as an alkylene chain. The molecular mass of alinker is typically in the range of about 14 to 200, preferably in therange of 14 to 96 with a length of up to about six atoms. In someembodiments, the linker is a C₁₋₆ alkylene chain.

The term “alkylene” refers to a bivalent alkyl group. An “alkylenechain” is a polymethylene group, i.e., —(CH₂)_(n)—, wherein n is apositive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylenegroup in which one or more methylene hydrogen atoms is replaced with asubstituent. Suitable substituents include those described below for asubstituted aliphatic group. An alkylene chain also may be substitutedat one or more positions with an aliphatic group or a substitutedaliphatic group.

An alkylene chain also can be optionally interrupted by a functionalgroup. An alkylene chain is “interrupted” by a functional group when aninternal methylene unit is replaced with the functional group. Examplesof suitable “interrupting functional groups” include —C(R*)═C(R̂)—,—C≡C—, —O—, —S—, —S(O)—, —S(O)₂—, —S(O)_(2N)(R⁺)—, —N(R*)—, —N(R⁺)CO—,—N(R⁺)C(O)N(R⁺)—, —N(R⁺)CO₂—, —C(O)N(R⁺)—, —C(O)—, —C(O)—C(O)—, —CO₂—,—OC(O)—, —OC(O)O—, —OC(O)N(R⁺)—, —C(NR⁺)═N, —C(OR*)═N—, —N(R⁺)—N(R⁺)—,or —N(R⁺)S(O)₂—. Each R⁺, independently, is hydrogen or an optionallysubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group, or twoR⁺ on the same nitrogen atom, taken together with the nitrogen atom,form a 5-8 membered aromatic or non-aromatic ring having, in addition tothe nitrogen atom, 0-2 ring heteroatoms selected from N, O, and S. EachR* independently is hydrogen or an optionally substituted aliphatic,aryl, heteroaryl, or heterocyclyl group. Each R̂independently is hydrogen—CO₂R*, —C(O)N(R⁺)₂, or an optionally substituted aliphatic, aryl,heteroaryl, or heterocyclyl group.

Examples of C₃₋₆ alkylene chains that have been “interrupted” with —O—include —CH₂OCH₂—, —CH₂O(CH₂)₂—, —CH₂O(CH₂)₃—, —CH₂O(CH₂)₄—,—(CH₂)₂OCH₂—, —(CH₂)₂O(CH₂)₂—, —(CH₂)₂O(CH₂)₃—, —(CH₂)₃O(CH₂)—,—(CH₂)₃O(CH₂)₂—, and —(CH₂)₄O(CH₂)—. Other examples of alkylene chainsthat are “interrupted” with functional groups include —CH₂GCH₂—,—CH₂G(CH₂)₂—, —CH₂G(CH₂)₃—, —CH₂G(CH₂)₄—, —(CH₂)₂GCH₂-, —(CH₂)₂G(CH₂)₂—,—(CH₂)₂G(CH₂)₃—, —(CH₂)₃G(CH₂)—, —(CH₂)₃G(CH₂)₂—, and —(CH₂)₄G(CH₂)—,wherein G is one of the “interrupting” functional groups listed above.

The term “substituted”, as used herein, means that one or more hydrogensof the designated moiety are replaced, provided that the substitutionresults in a stable or chemically feasible compound. A stable compoundor chemically feasible compound is one in which the chemical structureis not substantially altered when kept at a temperature from about −80°C. to about +40° C., in the absence of moisture or other chemicallyreactive conditions, for at least a week, or a compound which maintainsits integrity long enough to be useful for therapeutic or prophylacticadministration to a patient. The phrase “one or more substituents”, asused herein, refers to a number of substituents that equals from one tothe maximum number of substituents possible based on the number ofavailable bonding sites, provided that the above conditions of stabilityand chemical feasibility are met.

An aryl (including the aryl moiety in aralkyl, aralkoxy, aryloxyalkyland the like) or heteroaryl (including the heteroaryl moiety inheteroaralkyl and heteroaralkoxy and the like) group may contain one ormore substituents. Examples of suitable substituents on the unsaturatedcarbon atom of an aryl or heteroaryl group include -halo, —NO₂, —CN,—R*, —C(R*)═C(R*)(R̂), —C≡C—R^(̂), —OR*, —SR^(o), —S(O)R^(o), —SO₂R^(o),—SO₃R*, —SO₂N(R⁺)₂, —N(R⁺)₂, —NR⁺ C(O)R*, —NR⁺C(O)N(R⁺)₂, —NR⁺CO₂R^(o),—O—CO₂R*, —OC(O)N(R⁺)₂, —O—C(O)R*, —CO₂R*, —C(O)—C(O)R*, —C(O)R*,—C(O)N(R⁺)₂, —C(O)N(R⁺)C(═NR⁺)—N(R⁺)₂, —N(R⁺)C(═NR⁺)—N(R⁺)—C(O)R*,—C(═NR⁺)—N(R⁺)₂, —C(═NR⁺)—OR*, —N(R⁺)—N(R⁺)₂, —N(R⁺)C(═NR⁺)—N(R⁺)₂,—NR⁺SO_(2R) ^(o), —NR⁺SO₂N(R⁺)₂, —P(O)(R*)₂, —P(O)(OR*)₂, —O—P(O)—OR*,and —P(O)(NR⁺)—N(R⁺)₂, or two adjacent substituents, taken together withtheir intervening atoms, form a 5-6 membered unsaturated or partiallyunsaturated ring having 0-3 ring atoms selected from the groupconsisting of N, O, and S. In such substituents, R^(o) is an optionallysubstituted aliphatic or aryl group, and R⁺, R*, and R̂ are as definedabove.

An aliphatic group or a non-aromatic heterocyclic ring may besubstituted with one or more substituents. Examples of suitablesubstituents on the saturated carbon of an aliphatic group or of anon-aromatic heterocyclic ring include, without limitation, those listedabove for the unsaturated carbon of an aryl or heteroaryl group and thefollowing: ═O, ═S, ═C(R*)₂, ═N—NHR*, ═N—N(R*)₂, ═N—OR*, ═N—NHC(O)R*,═N—NHCO₂R^(o), ═N—NHSO₂R^(o), or ═N—R*, where each R* and R^(o) is asdefined above.

Suitable substituents on the nitrogen atom of a non-aromaticheterocyclic ring include —R*, —N(R*)₂, —C(O)R*, —CO₂R*, —C(O)—C(O)R*—C(O)CH₂C(O)R*, —SO₂R*, —SO₂N(R*)₂, —C(═S)N(R*)₂, —C(═NH)—N(R*)₂, and—NR*SO₂R*; wherein each R* is as defined above.

It will be apparent to one skilled in the art that certain compounds ofthis invention may exist in tautomeric forms, all such tautomeric formsof the compounds being within the scope of the invention. Unlessotherwise stated, structures depicted herein are also meant to includeall stereochemical forms of the structure; i.e., the R and Sconfigurations for each asymmetric center. Therefore, singlestereochemical isomers as well as enantiomeric and diastereomericmixtures of the present compounds are within the scope of the invention.By way of example, the compounds of formula (A) wherein R^(f1) ishydrogen can have R or S configuration at the carbon atom bearing RingB. Both the R and the S stereochemical isomers, as well as all mixturesthereof, are included within the scope of the invention.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructure except for the replacement of a hydrogen atom by a deuteriumor tritium, or the replacement of a carbon atom by a ¹³C- or¹⁴C-enriched carbon are within the scope of the invention.

Unless otherwise stated, structures depicted herein are also meant toinclude solvated and hydrated forms of the depicted compounds. Alsoincluded within the scope of the invention are pharmaceuticallyacceptable salts of compounds of formula (A), as well as solvated andhydrated forms of such salts.

Some embodiments of the invention relate to compounds of formula (A)where R^(e) is hydrogen, —OR⁵, —N(R⁴)₂, —SR⁵, —NR⁴C(O)R⁵,—NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, or a C₁₋₃aliphatic optionally substituted with R³ or R⁷. In some embodiments,R^(e) is hydrogen or a C₁₋₃ aliphatic optionally substituted with one R³or R⁷. In certain embodiments, R^(e) is hydrogen.

In some embodiments, R^(x) and R^(y) are each independently selectedfrom hydrogen, fluoro, or a C₁₋₆ aliphatic optionally substituted withone or two R³. In some other embodiments, R^(x) and R^(y), takentogether with the carbon atom to which they are attached, form anoptionally substituted 3- to 6-membered cycloaliphatic ring. In someother embodiments, R^(x) and R^(f2) together form a bond. In someembodiments, R^(x) and R^(y) are each hydrogen. In certain embodiments,R^(x), R^(y), and R^(e) are each hydrogen.

Some embodiments of the invention relate to compounds of formula (A)where R^(f1) is hydrogen, R^(f2) is hydrogen or R^(f2) and R^(x)together form a bond, and G is hydrogen, an optionally substitutedaliphatic, or Ring B.

Some other embodiments relate to compounds of formula (A), where R^(f1)and R^(f2) together form a bond, and G is hydrogen, —SR⁵, —OR⁵, —N(R⁴)₂,or an optionally substituted aliphatic. In such embodiments, Gpreferably is hydrogen, —OR⁵, —N(R⁴)₂, or an optionally substitutedaliphatic. More preferably, G is —H, —OH, —NH₂, —O(C₁₋₃ alkyl), —NH(C₁₋₃alkyl), —N(C₁₋₃ alkyl)₂, C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, —O-L¹-R⁷, —N(C₁₋₃alkyl)-L¹-R⁷, or -L¹-R⁷, where L¹ is a covalent bond or C₁₋₃ alkylene.

Other embodiments of the invention relate to a subgenus of the compoundsof formula (A) characterized by formula (A-1):

-   -   or a pharmaceutically acceptable salt thereof, where the        variables R^(e), R^(x), and R^(y) are as defined above for        formula (A). Values and preferred values for Rings A, B, and C        in formulae (A) and (A-1) are described below.

Ring A is a substituted or unsubstituted 5- or 6-membered aryl,heteroaryl, cycloaliphatic, or heterocyclyl ring. Examples of Ring Ainclude furano, dihydrofurano, thieno, dihydrothieno, cyclopenteno,cyclohexeno, 2H-pyrrolo, pyrrolo, pyrrolino, pyrrolidino, oxazolo,thiazolo, imidazolo, imidazolino, imidazolidino, pyrazolo, pyrazolino,pyrazolidino, isoxazolo, isothiazolo, oxadiazolo, triazolo, thiadiazolo,2H-pyrano, 4H-pyrano, benzo, pyridino, piperidino, dioxano, morpholino,dithiano, thiomorpholino, pyridazino, pyrimidino, pyrazino, piperazino,and triazino, any of which groups may be substituted or unsubstituted.Preferred values for Ring A include, without limitation, substituted orunsubstituted rings selected from the group consisting of furano,thieno, pyrrolo, oxazolo, thiazolo, imidazolo, pyrazolo, isoxazolo,isothiazolo, triazolo, benzo, pyridino, pyridazino, pyrimidino, andpyrazino.

Ring A may be substituted or unsubstituted. In some embodiments, eachsubstitutable saturated ring carbon atom in Ring A is unsubstituted oris substituted with ═O, ═S, ═C(R⁵)₂, ═N—N(R⁴)₂, ═N—OR⁵, ═N—NHC(O)R⁵,═N—NHCO₂R⁶, ═N—NHSO₂R⁶, ═N—R⁵ or —R^(b), where R^(b), R⁴, R⁵, and R⁶ areas defined below. Each substitutable unsaturated ring carbon atom inRing A is unsubstituted or substituted with —R^(b). Each substitutablering nitrogen atom in Ring A is unsubstituted or is substituted with—R^(9b), and one ring nitrogen atom in Ring A optionally is oxidized.Each R^(9b) independently is —C(O)R⁵, —C(O)N(R⁴)₂, —CO₂R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, or a C₁₋₄ aliphatic optionally substituted with R³ or R⁷.

Each R^(b) independently is R^(2b), an optionally substituted aliphatic,or an optionally substituted aryl, heterocyclyl, or heteroaryl group; ortwo adjacent R^(b), taken together with the intervening ring atoms, forman optionally substituted fused 4- to 8-membered aromatic ornon-aromatic ring having 0-3 ring heteroatoms selected from the groupconsisting of O, N, and S.

Each R^(2b) independently is -halo, —NO₂, —CN, —C(R⁵)═C(R⁵)₂,—C(R⁵)═C(R⁵)(R¹⁰), —C≡C—R⁵, —C≡C—R¹⁰, —OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵,—OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂, N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, —P(O)(R⁵)₂, or —P(O)(OR⁵)₂.

Each R³ independently is selected from the group consisting of -halo,—OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl), —CO₂H, —CO₂(C₁₋₃alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl).

Each R⁴ independently is hydrogen or an optionally substitutedaliphatic, aryl, heteroaryl, or heterocyclyl group; or two R⁴ on thesame nitrogen atom, taken together with the nitrogen atom, form anoptionally substituted 5- to 6-membered heteroaryl or 4- to 8-memberedheterocyclyl ring having, in addition to the nitrogen atom, 0-2 ringheteroatoms selected from N, O, and S.

Each R⁵ independently is hydrogen or an optionally substitutedaliphatic, aryl, heteroaryl, or heterocyclyl group;

Each R⁶ independently is an optionally substituted aliphatic or arylgroup;

Each R⁷ independently is an optionally substituted aryl, heterocyclyl,or heteroaryl group;

Each R¹⁰ independently is —CO₂R⁵ or —C(O)N(R⁴)₂.

In some embodiments, each R^(b) independently is selected from the groupconsisting of C₁₋₆ aliphatic, C₁₋₆ fluoroaliphatic, —R^(2b), —R^(7b),-T¹-R^(2b), and -T¹-R^(7b); or two adjacent R^(b), taken together withthe intervening ring atoms, form an optionally substituted fused 4- to8-membered aromatic or non-aromatic ring having 0-3 ring heteroatomsselected from the group consisting of O, N, and S. The variable R^(2b)is as described above, and T¹ and R^(7b) are described below.

-   -   T¹ is a C₁₋₆ alkylene chain optionally substituted with R³ or        R^(3b), wherein T¹ or a portion thereof optionally forms part of        a 3- to 7-membered ring.    -   Each R³ independently is selected from the group consisting of        -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl),        —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl).    -   Each R^(3b) independently is a C₁₋₃ aliphatic optionally        substituted with R³ or R⁷, or two substituents R^(3b) on the        same carbon atom, taken together with the carbon atom to which        they are attached, form a 3- to 6-membered carbocyclic ring.    -   Each R^(7b) independently is an optionally substituted aryl,        heteroaryl, or heterocyclyl group.

In some embodiments, Ring A is substituted with 0-3, 0-2, or 0-1substituents R^(b), wherein the substituents R^(b) may be the same ordifferent. In some embodiments, each R^(b) independently is selectedfrom the group consisting of C₁₋₃ aliphatic, R^(2b), R^(7b), -T¹-R^(2b),and -T¹-R⁷, where T¹ is a C₁₋₃ alkylene chain optionally substitutedwith fluoro. In some embodiments, two adjacent R^(b), taken togetherwith the intervening ring carbon atoms, form an optionally substitutedfused 4- to 8-membered aromatic or non-aromatic ring having 0-3 ringheteroatoms selected from the group consisting of O, N, and S. In someembodiments, each R^(b) independently is selected from the groupconsisting of C₁₋₃ aliphatic, R^(2b), and -T¹-R^(2b), where T¹ is a C₁₋₃alkylene chain, optionally substituted with fluoro. In some suchembodiments, each R^(2b) independently is selected from the groupconsisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and —N(R⁴)₂.

In some embodiments, Ring A is substituted by 0-2 substituents R^(b). Insome such embodiments, each R^(b) independently is C₁₋₃ aliphatic orR^(2b), and each R^(2b) independently is selected from the groupconsisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and —N(R⁴)₂. Insome embodiments, each R^(b) independently is selected from the groupconsisting of -halo, C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and —OR⁵,where R⁵ is hydrogen or C₁₋₃ aliphatic. In certain preferredembodiments, Ring A is substituted with 0, 1, or 2 substituents,preferably 0 or 1 substituents, independently selected from the groupconsisting of chloro, fluoro, bromo, methyl, trifluoromethyl, andmethoxy.

Certain examples of Ring A moieties are shown in Table 1. For ease ofviewing, the optional substituents R^(b) on ring carbon atoms and R^(9b)on ring nitrogen atoms are not shown.

TABLE 1 Examples of Ring A Moieties

A-1

A-2

A-3

A-4

A-5

A-6

A-7

A-8

A-9

A-10

A-11

A-12

A-13

A-14

A-15

A-16

A-17

A-18

A-19

A-20

A-21

A-22

A-23

A-24

A-25

A-26

A-27

A-28

A-29

A-30

A-31

A-32

A-33

A-34

A-35

A-36

A-37

A-38

A-39

A-40

A-41

A-42

A-43

A-44

A-45

A-46

A-47

In some embodiments, two adjacent R^(b) on one of the above Ring Amoieties, taken together with the intervening ring atoms, form anoptionally substituted fused 4- to 8-membered aromatic or nonaromaticfused ring, so that Ring A is a bicyclic moiety. Certain examples ofsuch bicyclic moieties are shown in Table 2, any of which moietiesoptionally is substituted on any substitutable ring carbon atom and anysubstitutable ring nitrogen atom.

TABLE 2 Examples of Bicyclic Ring A Moieties

A-48

A-49

A-50

A-51

A-52

A-53

A-54

A-55

A-56

A-57

A-58

A-59

A-60

A-61

A-62

A-63

A-64

In some embodiments, the invention relates to a compound of formula (B):

-   -   or a pharmaceutically acceptable salt thereof, wherein Ring A is        substituted with 0-3 R^(b). Rings B and C, and the variables        R^(e), R^(x), and R^(y) are as defined above for formula (A).

In certain such embodiments, Ring A has the formula A-i:

-   -   wherein each of R^(b2) and R^(b3) independently is hydrogen or        R^(b). In some embodiments, each of R^(b2) and R^(b3)        independently is selected from the group consisting of hydrogen,        -halo, C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and —OR⁵, where R⁵        is hydrogen or C₁₋₃ aliphatic. In certain embodiments, each of        R^(b2) and R^(b3) independently is selected from the group        consisting of hydrogen, chloro, fluoro, bromo, methyl,        trifluoromethyl, and methoxy. In some other embodiments, R^(b2)        and R^(b3), taken together with the intervening ring carbon        atoms, form an optionally substituted fused 4- to 8-membered        aromatic or non-aromatic ring having 0-3 ring heteroatoms        selected from the group consisting of O, N, and S.

In the compounds of formulae (A), (A-1), and (B) above, Ring B is amono-, bi-, or tricyclic ring system. In some embodiments, the point ofattachment for Ring B to the rest of the formula is on an aryl orheteroaryl ring of the Ring B moiety. In other embodiments, the point ofattachment is on an heterocyclyl or cycloaliphatic ring. Preferably,Ring B is mono- or bicyclic.

Each substitutable saturated ring carbon atom in Ring B is unsubstitutedor is substituted with ═O, ═S, ═C(R⁵)₂, ═N—N(R⁴)₂, ═N—OR⁵, ═N—NHC(O)R⁵,═N—NHCO₂R⁶, ═N—NHSO₂R⁶, ═N—R⁵ or —R^(c). Each substitutable unsaturatedring carbon atom in Ring B is unsubstituted or substituted with —R^(c).Each substitutable ring nitrogen atom in Ring B is unsubstituted or issubstituted with —R^(9c), and one ring nitrogen atom in Ring Boptionally is oxidized. Each R^(9c) independently is —C(O)R⁵,—C(O)N(R⁴)₂, —CO₂R⁶, —SO₂R⁶, —SO₂N(R⁴)₂, or a C₁₋₄ aliphatic optionallysubstituted with R³ or R⁷. Ring B may be unsubstituted or may besubstituted on any one or more of its component rings, wherein thesubstituents may be the same or different. In some embodiments, Ring Bis substituted with 0-2 independently selected R^(c) and 0-3independently selected R^(2c) or C₁₋₆ aliphatic groups. The variablesR³, R⁴, R⁵, R⁶, and R⁷ are as defined above for Ring A, and R^(c) andR^(2c) are defined below.

Each R^(c) independently is R^(2c), an optionally substituted C₁₋₆aliphatic, or an optionally substituted aryl, heteroaryl, orheterocyclyl group.

Each R^(2c) independently is -halo, —NO₂, —CN, —C(R⁵)═C(R⁵)₂,—C(R⁵)═C(R⁵)(R¹⁰), —C≡C—R⁵, —C≡C—R¹⁰, —OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵,—OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, —P(O)(R⁵)₂, or —P(O)(OR⁵)₂.

In some embodiments, each R^(c) independently is selected from the groupconsisting of C₁₋₆ aliphatic, R^(2c), R^(7c), -T¹-R^(2c), and-T¹-R^(7c), where R^(2c) is as described above and T¹ and R^(7c) aredescribed below.

-   -   T¹ is a C₁₋₆ alkylene chain optionally substituted with R³ or        R^(3b), wherein T¹ or a portion thereof optionally forms part of        a 3- to 7-membered ring.    -   Each R³ independently is selected from the group consisting of        -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl),        —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl).    -   Each R^(3b) independently is a C₁₋₃ aliphatic optionally        substituted with R³ or R⁷, or two substituents R^(3b) on the        same carbon atom, taken together with the carbon atom to which        they are attached, form a 3- to 6-membered carbocyclic ring.    -   Each R^(7c) independently is an optionally substituted aryl,        heterocyclyl, or heteroaryl group.

In some embodiments, each R^(c) independently is selected from the groupconsisting of C₁₋₃ aliphatic, R^(2c), R^(7c), -T¹-R^(2c), and-T¹-R^(7c), where T¹ is a C₁₋₃ alkylene chain optionally substitutedwith fluoro. In some embodiments, each R^(c) independently is selectedfrom the group consisting of C₁₋₃ aliphatic, R^(2c), and -T¹-R^(2c),where T¹ is a C₁₋₃ alkylene chain optionally substituted with fluoro. Insome such embodiments, each R^(2c) independently is selected from thegroup consisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and—N(R⁴)₂.

In some embodiments, Ring B is a substituted or unsubstituted mono- orbicyclic aryl or heteroaryl ring selected from the group consisting offuranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl,isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, phenyl,pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl,indolyl, isoindolyl, indazolyl, benzo[b]furanyl, benzo[b]thienyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, purinyl, quinolyl,isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,naphthyridinyl, and pteridinyl.

In some embodiments, Ring B is a monocyclic 5- or 6-membered aryl orheteroaryl ring, substituted with 0-2 independently selected R^(c) and0-2 independently selected R^(2c) or C₁₋₆ aliphatic groups. In certainsuch embodiments, Ring B is a substituted or unsubstituted phenyl orpyridyl ring.

In some embodiments, Ring B is substituted with 0-2 substituents R^(c).In some such embodiments, each R^(c) independently is C₁₋₃ aliphatic orR^(2c), and each R^(2c) independently is selected from the groupconsisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and —N(R⁴)₂. Insome embodiments, each R^(c) independently is selected from the groupconsisting of -halo, C₁₋₃ aliphatic, C₁₋₃ haloaliphatic, and —OR⁵, whereR⁵ is hydrogen or C₁₋₃ aliphatic. In certain preferred embodiments, RingB is substituted with 0, 1, or 2 substituents, independently selectedfrom the group consisting of chloro, fluoro, bromo, methyl,trifluoromethyl, and methoxy.

In some embodiments, Ring B has the formula B-i:

-   -   wherein each of R^(c1) and R^(c5) independently is hydrogen or        R^(c). In some embodiments, each of R^(c1) and R^(c5)        independently is selected from the group consisting of hydrogen,        -halo, C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and —OR⁵, where R⁵        is hydrogen or C₁₋₃ aliphatic. In certain embodiments, each of        R^(c1) and R^(c5) independently is selected from the group        consisting of hydrogen, chloro, fluoro, bromo, methyl,        trifluoromethyl, and methoxy.

In the compounds of formulae (A), (A-1), and (B) above, Ring C is asubstituted or unsubstituted mono-, bi-, or tricyclic ring system. Insome embodiments, the point of attachment for Ring C to the rest of theformula is on an aryl or heteroaryl ring of the Ring C moiety. In otherembodiments, the point of attachment is on a heterocyclyl orcycloaliphatic ring. Preferably, Ring C is mono-, or bicyclic.

Each substitutable saturated ring carbon atom in Ring C is unsubstitutedor is substituted with ═O, ═S, ═C(R⁵)₂, ═N—N(R⁴)₂, ═N—OR⁵, ═N—NHC(O)R⁵,═N—NHCO₂R⁶, ═N—NHSO₂R⁶, ═N—R⁵ or —R^(d). Each substitutable unsaturatedring carbon atom in Ring C is unsubstituted or substituted with —R^(d).Each substitutable ring nitrogen atom in Ring C is unsubstituted or issubstituted with —R^(9d), and one ring nitrogen atom in Ring Coptionally is oxidized. Each R^(9d) independently is —C(O)R⁵,—C(O)N(R⁴)₂, —CO₂R⁶, —SO₂R⁶, —SO₂N(R⁴)₂, or a C₁₋₄ aliphatic optionallysubstituted with R³ or R⁷. Ring C may be unsubstituted or may besubstituted on any one or more of its component rings, wherein thesubstituents may be the same or different. In some embodiments, Ring Cis substituted with 0-2 independently selected R^(d) and 0-3independently selected R^(2d) or C₁₋₆ aliphatic groups. The variablesR³, R⁴, R⁵, R⁶, and R⁷ are as described above for Rings A and B. Thevariables R^(d) and R^(2d) are described below.

Each R^(d) independently is R^(2d), an optionally substituted aliphatic,or an optionally substituted aryl, heteroaryl, or heterocyclyl group.

Each R^(2d) independently is -halo, —NO₂, —CN, —C(R⁵)═C(R⁵)₂,—C(R⁵)═C(R⁵)₂(R¹⁰), —C≡C—R⁵, —C_C—R¹⁰, —OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵,—OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, —P(O)(R⁵)₂, or —P(O)(OR⁵)₂. Additionally,R^(2d) can be —SO₃R⁵, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂ or—N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵.

In some embodiments, each R^(d) independently is selected from the groupconsisting of C₁₋₆ aliphatic, R^(2d), R^(7d), -T²-R^(2d), -T²-R^(7d),—V-T³-R^(2d), and —V-T³-R^(7d), wherein R^(2d) is as described above,and T², T³, V, and R^(7d) are described below.

-   -   T² is a C₁₋₆ alkylene chain optionally substituted with R³ or        R^(3b), wherein the alkylene chain optionally is interrupted by        —C(R⁵)═C(R⁵)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)₂—, —SO₂N(R⁴)—,        —N(R⁴)—, —N(R⁴)C(O)—, —NR⁴C(O)N(R⁴)—, —N(R⁴)CO₂—, —C(O)N(R⁴)—,        —C(O)—, —C(O)—C(O)—, —CO₂—, —OC(O)—, —OC(O)O—, —OC(O)N(R⁴)—,        —N(R⁴)—N(R⁴)—, —N(R⁴)SO₂—, or —SO₂N(R⁴)—, and wherein T² or a        portion thereof optionally forms part of a 3-7 membered ring.    -   T³ is a C₁₋₆ alkylene chain optionally substituted with R³ or        R^(3b), wherein the alkylene chain optionally is interrupted by        —C(R⁵)═C(R⁵)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)₂—, —SO₂N(R⁴)—,        —N(R⁴)—, —N(R⁴)C(O)—, —NR⁴C(O)N(R⁴)—, —N(R⁴)CO₂—, —C(O)N(R⁴)—,        —C(O)—, —C(O)—C(O)—, —CO₂—, —OC(O)—, —OC(O)O—, —OC(O)N(R⁴)—,        —N(R⁴)—N(R⁴)—, —N(R⁴)SO₂—, or —SO₂N(R⁴)—, and wherein T³ or a        portion thereof optionally forms part of a 3-7 membered ring.    -   V is —C(R⁵)═C(R⁵)—, —C≡C—, —O—, —S—, —S(O)—, —S(O)₂—,        —SO₂N(R⁴)—, —N(R⁴)—, —N(R⁴)C(O)—, —NR⁴C(O)N(R⁴)—, —N(R⁴)CO₂—,        —C(O)N(R⁴)—, —C(O)—, —C(O)—C(O)—, —CO₂—, —OC(O)—, —OC(O)O—,        —OC(O)N(R⁴)—, —C(NR⁴)═N—, —C(OR⁵)═N—, —N(R⁴)—N(R⁴)—, —N(R⁴)SO₂—,        —N(R⁴)SO₂N(R⁴)—, —P(O)(R⁵)—, —P(O)(OR⁵)—O—, —P(O)—O—, or        —P(O)(NR⁵)—N(R⁵)—.    -   Each R^(3b) independently is a C₁₋₃ aliphatic optionally        substituted with R³ or R⁷, or two substituents R^(3b) on the        same carbon atom, taken together with the carbon atom to which        they are attached, form a 3- to 6-membered carbocyclic ring.    -   Each R^(7d) independently is an optionally substituted aryl,        heterocyclyl, or heteroaryl group.

In some embodiments, each R^(2d) independently is selected from thegroup consisting of -halo, —OR⁵, —N(R⁴)₂, —N(R⁴)C(O)—, —CO₂R⁵,—C(O)N(R⁴)₂, and —SO₂N(R⁴)₂. In some other embodiments, each R^(2d)independently is -halo, —OR⁵, —N(R⁴)₂, —N(R⁴)C(O)—, —CO₂R⁵, —C(O)N(R⁴)₂,and —SO₂N(R⁴)₂, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂ or —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵.

In some embodiments, T² is a C₁₋₆ alkylene chain, which optionally issubstituted with one or two substituents R^(3b) independently selectedfrom the group consisting of -halo, —C₁₋₃ aliphatic, —OH, and —O(C₁₋₃aliphatic), or two substituents R^(3b) on the same carbon atom, takentogether with the carbon atom to which they are attached, form a 3- to6-membered carbocyclic ring. In some embodiments, T² optionally isinterrupted by —C(R⁵)═C(R⁵)—, —C≡C—, —O—, —C(O)—, —C(O)N(R⁴)—,—N(R⁴)C(O)— or —N(R⁴)—.

In some embodiments, V is —C(R)═C(R⁵)—, —C≡C—, —O—, —N(R⁴)—, —C(O)—,—N(R⁴)C(O)—, or —C(O)N(R⁴)—. In some embodiments, T³ is a C₁₋₄ alkylenechain, which optionally is substituted with one or two R^(3b)independently selected from the group consisting of -halo, —C₁₋₃aliphatic, —OH, and —O(C₁₋₃ aliphatic), or two substituents R^(3b) onthe same carbon atom, taken together with the carbon atom to which theyare attached, form a 3- to 6-membered carbocyclic ring. In someembodiments, T³ is a C₁₋₄ alkylene chain, which optionally isinterrupted by —C(R⁵)═C(R⁵)—, —C≡C—, —O—, —C(O)—, —C(O)N(R⁴)—,—N(R⁴)C(O)— or —N(R⁴)—.

In some embodiments, each R^(d) independently is selected from the groupconsisting of C₁₋₃ aliphatic, R^(2d), R^(7d), -T²-R^(2d), -T²-R^(7d),—V-T³-R^(2d), and —V-T³-R^(7d), where R^(2d) is selected from the groupconsisting of -halo, —OR⁵, —N(R⁴)₂, —N(R⁴)C(O)—, —CO₂R⁵, —C(O)N(R⁴)₂,and —SO₂N(R⁴)₂. Additionally, R^(2d) can be —SO₃R⁵,—C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂ or —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵.

In some embodiments, Ring C is substituted with at least one R^(7d)selected from the group consisting of:

-   -   any of which groups optionally is substituted on any        substitutable ring carbon or ring nitrogen atom.

In some embodiments, Ring C is substituted with at least one -T²-R^(2d)or -T²-R^(7d), where:

-   -   T² is a C₁₋₆ alkylene chain, wherein T² optionally is        substituted with one or two substituents R^(3b) independently        selected from the group consisting of -halo, —C₁₋₃ aliphatic,        —OH, and —O(C₁₋₃ aliphatic), or two substituents R^(3b) on the        same carbon atom, taken together with the carbon atom to which        they are attached, form a 3- to 6-membered carbocyclic ring, and        wherein T² optionally is interrupted by —C(R⁵)═C(R⁵)—, —C≡C—,        —O—, —C(O)—, —NR⁴C(O)R⁵, —N(R⁴)C(O)— or —N(R⁴)—; and    -   R^(2d) is selected from the group consisting of -halo, —OR⁵,        —N(R⁴)₂, —N(R⁴)C(O)—, —CO₂R⁵, —C(O)N(R⁴)₂, —SO₂N(R⁴)₂,        —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂, and —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵.

In certain such embodiments, Ring C is substituted with one -T²-R^(2d)or -T²-R^(7d), and optionally one other substituent selected from thegroup consisting of hydrogen, -halo, C₁₋₃ aliphatic, and —OR⁵, where R⁵is hydrogen or C₁₋₃ aliphatic. In some embodiments, T² is a C₁₋₆alkylene chain, which optionally is interrupted by —C(O)N(R⁴)— or—N(R⁴)C(O)—.

In some embodiments, Ring C is substituted with at least one—V-T³-R^(2d) or —V-T³-R^(7d), where:

-   -   V is —N(R⁴)—, —O—, —C(O)N(R⁴)—, —C(O)—, or —C≡C—;    -   T³ is a C₁₋₄ alkylene chain, which is optionally substituted by        one or two substituents R^(3b) independently selected from the        group consisting of -halo, —C₁₋₃ aliphatic, —OH, and —O(C₁₋₃        aliphatic), or two substituents R^(3b) on the same carbon atom,        taken together with the carbon atom to which they are attached,        form a 3- to 6-membered carbocyclic ring; and    -   R^(2d) is selected from the group consisting of -halo, —OR⁵,        —N(R⁴)₂, —NR⁴C(O)R⁵, —CO₂R⁵, —C(O)N(R⁴)₂, and —SO₂N(R⁴)₂.

In certain such embodiments, Ring C is substituted with one —V-T³-R^(2d)or —V-T³-R^(7d), and optionally one other substituent selected from thegroup consisting of hydrogen, -halo, C₁₋₃ aliphatic, and —OR⁵, where R⁵is hydrogen or C₁₋₃ aliphatic.

In some embodiments, Ring C is substituted with —V-T³-R^(2d), where V is—C(O)N(R⁴)—, T³ is a C₂₋₄ alkylene chain, and R^(2d) is —N(R⁴)₂. Each R⁴independently is hydrogen or C₁₋₃ aliphatic, or —N(R⁴)₂ is an optionallysubstituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclylring having, in addition to the nitrogen, 0-2 ring heteroatoms selectedfrom N, O, and S. In certain such embodiments, —N(R⁴)₂ is an optionallysubstituted heterocyclyl selected from the group consisting ofpiperidinyl, piperazinyl, and morpholinyl. In certain other suchembodiments, —N(R⁴)₂ is an optionally substituted heterocyclyl selectedfrom pyrrolidinyl and azetidinyl.

In other embodiments, Ring C is substituted with —V-T³-R^(7d), where Vis —C(O)N(R⁴)—, T³ is a C₂₋₄ alkylene chain, and R^(7d) is an optionallysubstituted 4- to 8-membered heterocyclyl or an optionally substituted5- to 6-membered heteroaryl. In certain such embodiments, R^(7d) isselected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl,pyrazinyl, pyrrolyl, oxazolyl, imidazolyl, and pyrazolyl. In certainother such embodiments, R^(7d) is a 6- to 8-membered bicyclicheterocyclyl.

In some embodiments, Ring C is substituted with one or two substituentsindependently selected from the group consisting of C₁₋₃ aliphatic,-halo, —OR⁵, —CO₂R⁵, —C(O)N(R⁴)₂, and —SO₂N(R⁴)₂. Additional selectionspossible for Ring C substituents in these embodiments include—C(═NR⁴)N(R⁴)₂, —NR⁴C(O)R⁵, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂ and—N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵. In some embodiments, Ring C is substitutedwith at least one substituent selected from the group consisting of—CO₂R⁵, —C(O)N(R⁴)₂, —C(═NR⁴)N(R⁴)₂, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵, and —NR⁴C(O)R⁵. In certain embodiments, RingC is substituted with at least one —CO₂R⁵, where R⁵ is hydrogen or C₁₋₆aliphatic.

In some embodiments, Ring C is substituted with at least one—C(O)—N(R⁴)₂, —C(═NR⁴)N(R⁴)₂, or —NR⁴C(O)R⁵, where —N(R⁴)₂ is anoptionally substituted 4- to 8-membered heterocyclyl ring having, inaddition to the nitrogen atom, 0-2 ring heteroatoms selected from N, O,and S, and R⁵ is an optionally substituted 4- to 8-memberednitrogen-containing heterocyclyl ring. In some such embodiments, —N(R⁴)₂is an optionally substituted heterocyclyl selected from the groupconsisting of piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, andazetidinyl. In some other such embodiments, —N(R⁴)₂ is a bridged orspiro bicyclic heterocyclyl.

In certain embodiments, Ring C is substituted with at least onesubstituent having the formula D-i:

-   -   wherein:    -   Ring D optionally is substituted on one or two ring carbon        atoms;    -   X is O or NH;    -   W¹ is hydrogen, —C(O)R⁵, —C(O)N(R⁴)₂, —CO₂R⁶, —SO₂R⁶,        —SO₂N(R⁴)₂, or an optionally substituted aliphatic, aryl,        heteroaryl, or heterocyclyl group.

In some embodiments, Ring D in formula D-i is substituted with one ortwo substituents selected from the group consisting of C₁₋₃ aliphatic,—CO₂R⁵, —C(O)N(R⁴)₂, and -T⁵-R^(m), where T⁵ is a C₁₋₃ alkylene chainand R^(m) is —OR⁵, —N(R⁴)₂, —CO₂R⁵, or —C(O)N(R⁴)₂. In some suchembodiments, Ring D in formula D-1 is substituted with one or twosubstituents selected from the group consisting of C₁₋₃ aliphatic,—CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)N(C₁₋₃ alkyl)₂, —C(O)NH(C₁₋₃ alkyl),—C(O)NH₂, —(C₁₋₃ alkyl)-OH, —(C₁₋₃ alkylene)-O(C₁₋₃ alkyl), —(C₁₋₃alkylene)-NH₂, —(C₁₋₃ alkylene)-NH(C₁₋₃ alkyl), —(C₁₋₃ alkylene)-N(C₁₋₃alkyl)₂, —(C₁₋₃ alkylene)-CO₂H, —(C₁₋₃ alkylene)-CO₂(C₁₋₃ alkyl), —(C₁₋₃alkylene)-C(O)NH₂, —(C₁₋₃ alkylene)-C(O)NH(C₁₋₃ alkyl), and —(C₁₋₃alkylene)-C(O)N(C₁₋₃ alkyl)₂.

In certain other embodiments, Ring C is substituted with at least onesubstituent having one of the formulae D-ii to D-v below:

-   -   wherein:    -   Ring D optionally is substituted on one or two substitutable        ring carbon atoms;    -   X is O or NH;    -   W² is R^(n) or -T⁶-R^(n);    -   T⁶ is a C₁₋₃ alkylene chain optionally substituted with R³ or        R^(3b); and    -   R^(n) is —N(R⁴)₂ or —C(O)N(R⁴)₂; and    -   R^(z) is hydrogen, —CO₂R⁵, C(O)N(R⁴)₂, —C(O)R⁵, or a C₁₋₃        aliphatic optionally substituted with R³ or R⁷; or R^(z) and W²,        taken together with the carbon atom to which they are attached,        form a 4- to 7-membered cycloaliphatic or heterocyclyl ring.

In some embodiments, Ring D in formulae D-ii to D-v is substituted withone or two substituents selected from the group consisting of C₁₋₃aliphatic, —CO₂R⁵, —C(O)N(R⁴)₂, —OR⁵, —N(R⁴)₂, and -T⁵-R^(m), where T⁵is a C₁₋₃ alkylene chain and R^(m) is —OR⁵, —N(R⁴)₂, —CO₂R⁵, or—C(O)N(R⁴)₂.

In certain embodiments, at least one substituent on Ring C is selectedfrom the group consisting of:

-   -   where X is O or NH.

In certain other embodiments, at least one substituent on Ring C isselected from the group consisting of:

-   -   where X is O or NH, and each R^(4z) independently is hydrogen or        —CH₃.

In certain other embodiments, at least one substituent on Ring C isselected from the group consisting of:

-   -   where X is O or NH, and each R^(4z) independently is hydrogen or        —CH₃.

In some embodiments, Ring C is substituted with at least one —C(O)N(R⁴)₂or —C(═NH)N(R⁴)₂, where one R⁴ is hydrogen or C₁₋₃ alkyl, and the otherR⁴ is an optionally substituted heterocyclyl or heterocyclylalkyl. Insome such embodiments, Ring C is substituted with at least onesubstituent selected from the group consisting of:

-   -   where X is O or NH.

In some other such embodiments, Ring C is substituted with at least onesubstituent selected from the group consisting of:

-   -   where X is O or NH, and each R^(4z) independently is H or CH₃.

In some embodiments, Ring C is a bicyclic aryl group, which issubstituted with 0-2 independently selected R^(d) and 0-3 independentlyselected R^(2d) or C₁₋₆ aliphatic groups. In some such embodiments, RingC is a phenyl ring fused to a 5- or 6-membered carbocyclic, heteroaryl,or heterocyclyl ring, wherein each ring independently is substituted orunsubstituted. In certain such embodiments, Ring C is an optionallysubstituted benzodioxanyl or benzodioxolyl ring. In certain other suchembodiments, Ring C is an optionally substituted benzimidazolyl,benzthiazolyl, benzoxazolyl, or phthalimidyl ring, wherein Ring C isattached to the rest of formula (A), (A-1), or (B) at the benzo ring ofthe bicyclic Ring C moiety.

In some other embodiments, Ring C is a monocyclic 5- or 6-membered arylor heteroaryl ring, which is substituted with 0-2 independently selectedsubstituents R^(d) and 0-2 independently selected R^(2d) or C₁₋₆aliphatic groups. In some such embodiments, Ring C is an optionallysubstituted heteroaryl ring selected from the group consisting ofpyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, andoxazolyl. In some other embodiments, Ring C is a substituted orunsubstituted phenyl ring. In some embodiments, Ring C is a monocyclic5- or 6-membered aryl or heteroaryl ring, which is substituted with 0,1, or 2 substituents R^(d), as defined above.

In yet other embodiments, Ring C is a monocyclic 5- or 6-memberedheterocyclyl or cycloaliphatic ring, which is substituted with 0-2independently selected substituents R^(d) and 0-2 independently selectedR^(2d) or C₁₋₆ aliphatic groups.

Some embodiments of the invention relate to a subgenus of formula (A)defined by formula (I):

-   -   or a pharmaceutically acceptable salt thereof, wherein Ring A,        Ring B, Ring C, and each of the variables R^(a), R^(b), R^(e),        R^(f1), and R^(f2) have the values described below.    -   Ring A is substituted with 0-3 R^(b).    -   Ring B is a substituted or unsubstituted aryl or heteroaryl        ring.    -   Ring C is a substituted or unsubstituted aryl or heteroaryl        ring. Additionally, Ring C can be a heterocyclyl, or        cycloaliphatic ring.    -   R^(a) is hydrogen, —C(O)R¹, —CO₂R¹, —SO₂R¹, or a C₁₋₃ aliphatic        having 0-2 substituents independently selected from R³ or R⁷.        -   R¹ is an optionally substituted C₁₋₆ aliphatic or an            optionally substituted aryl, heteroaryl, or heterocyclyl            group.    -   Each R^(b) independently is R^(2b), an optionally substituted        aliphatic, or an optionally substituted aryl, heteroaryl, or        heterocyclyl group. In some embodiments each R^(b) independently        is selected from the group consisting of C₁₋₆ aliphatic, R^(2b),        R^(7b), -T¹-R^(2b), and -T¹-R^(7b). In some embodiments, two        adjacent R^(b), taken together with the intervening carbon        atoms, form an optionally substituted fused 4- to 8-membered        aromatic or non-aromatic ring having 0-3 ring heteroatoms        selected from the group consisting of O, N, and S.        -   T¹ is a C₁₋₆ alkylene chain optionally substituted with R³            or R^(3b), wherein T¹ or a portion thereof optionally forms            part of a 3- to 7-membered ring.        -   Each R^(2b) independently is -halo, —NO₂, —CN,            —C(R⁵)═C(R⁵)₂, —C(R⁵)═C(R⁵)(R¹⁰), —C≡C—R⁵, —C≡C—R¹⁰, —OR⁵,            —SR⁶, —S(O)R⁶, —SO₂R⁶, —SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵,            —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵, —OC(O)N(R⁴)₂,            —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,            —C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂,            —N(R⁴)C(═NR⁴)—N(R⁴)₂, —N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂,            —P(O)(R⁵)₂, or —P(O)(OR⁵)₂.        -   Each R^(3b) independently is a C₁₋₃ aliphatic optionally            substituted with R³ or R⁷, or two substituents R^(3b) on the            same carbon atom, taken together with the carbon atom to            which they are attached, form a 3- to 6-membered carbocyclic            ring.        -   Each R^(7b) independently is an optionally substituted aryl,            heterocyclyl, or heteroaryl group.    -   R^(e) is hydrogen or a C₁₋₃ aliphatic optionally substituted        with R³ or R⁷.    -   R^(f1) and R^(f2) each are hydrogen, or R^(f1) and R^(f2)        together form a bond.    -   Each R³ independently is selected from the group consisting of        -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl),        —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl).    -   Each R⁴ independently is hydrogen or an optionally substituted        aliphatic, aryl, heteroaryl, or heterocyclyl group; or two R⁴ on        the same nitrogen atom, taken together with the nitrogen atom,        form an optionally substituted 4- to 8-membered or 5- to        8-membered heteroaryl or heterocyclyl ring having, in addition        to the nitrogen atom, 0-2 ring heteroatoms selected from N, O,        and S.    -   Each R⁵ independently is hydrogen or an optionally substituted        aliphatic, aryl, heteroaryl, or heterocyclyl group.    -   Each R⁶ independently is an optionally substituted aliphatic or        aryl group.    -   Each R⁷ independently is an optionally substituted aryl,        heterocyclyl, or heteroaryl group.    -   Each R¹⁰ independently is —CO₂R⁵ or —C(O)N(R⁴)₂.

In some embodiments, the compound of formula (I) is characterized by atleast one, two, or three of the following features (a)-(f):

-   -   (a) R^(a) is hydrogen or C₁₋₃ alkyl;    -   (b) R^(f1) and R^(f2) together form a bond;    -   (c) Ring A is substituted with 0-2 R^(b), where each R^(b)        independently is selected from the group consisting of C₁₋₃        aliphatic, R^(2b), R^(7b), -T¹-R^(2b), and -T¹-R^(7b), where T¹        is a C₁₋₃ alkylene chain;    -   (d) Ring B is a monocyclic 5- or 6-membered aryl or heteroaryl        ring, which is substituted with 0-2 R^(c), where each R^(c)        independently is selected from the group consisting of C₁₋₃        aliphatic, R^(2c), R^(7c), -T¹-R^(2c), and -T¹-R^(7c), where T¹        is a C₁₋₃ alkylene chain;    -   (e) Ring C is a mono- or bicyclic aryl or heteroaryl ring, which        is substituted with 0-2 independently selected R^(d) and 0-2        independently selected R^(2d) or C₁₋₆ aliphatic groups; and    -   (f) R^(e) is hydrogen.

In some embodiments, the compound of formula (I) is characterized by allsix of the features (a)-(f) above.

Some embodiments of the invention relate to a subgenus of formula (A)defined by formula (B) or (II):

-   -   wherein each of R^(e), R^(x), R^(y), and Rings A, B, and C have        the values and preferred values described above for formulae (B)        and (I). In some such embodiments, Ring B is a mono- or bicyclic        aryl or heteroaryl ring, which is substituted with 0-2        independently selected R^(c) and 0-2 independently selected        R^(2c) or C₁₋₆ aliphatic groups, and Ring C as a mono- or        bicyclic aryl, heteroaryl, heterocyclyl or cycloaliphatic ring,        which is substituted with 0-2 independently selected R^(d) and        0-2 independently selected R^(2d) or C₁₋₆ aliphatic groups.

In some embodiments, the compound of formula (II) is defined by formula

-   -   wherein Ring A is substituted with 0-2 independently selected        R^(b), and Ring B is substituted with 0-2 independently selected        R^(c). In some embodiments, the compound of formula (IIa) is        characterized by at least one of the following features (a)-(c):    -   (a) each R^(b) independently is selected from the group        consisting of C₁₋₃ aliphatic, R^(2b), R^(7b), -T¹-R^(2b), and        -T¹-R⁷, where T¹ is a C₁₋₃ alkylene chain optionally substituted        with fluoro, and each R^(2b) independently is selected from the        group consisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵,        and —N(R⁴)₂;    -   (b) each R^(c) independently is selected from the group        consisting of C₁₋₃ aliphatic, R^(2c), R^(7c), -T¹-R^(2c), and        -T¹-R^(7c), where T¹ is a C₁₋₃ alkylene chain optionally        substituted with fluoro, and each R^(2c) independently is        selected from the group consisting of -halo, —NO₂,        —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and —N(R⁴)₂; and    -   (c) R^(e) is hydrogen.

Some embodiments of the invention relate to a subgenus of the compoundsof formula (IIa) defined by formula (III):

-   -   wherein each of R^(b), R^(c), R^(e), and Ring C have the values        or preferred values described above for any preceding formula.

Some embodiment of the invention relate to a subgenus of the compoundsof formula (IIa) defined by formula (IIa):

-   -   wherein: each of R^(b2) and R^(b3) independently is hydrogen or        R^(b); each of R^(c1) and R^(c5) independently is hydrogen or        R^(c); and each of Ring C, R^(b), R^(c), and R^(e) have the        values and preferred values described above for any preceding        formula.

In some embodiments, each R^(b) in formula (III) or (IIa) is selectedfrom the group consisting of C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, andR^(2b); and each R^(c) is selected from the group consisting of C₁₋₃aliphatic, C₁₋₃ fluoroaliphatic, and R^(2c). In certain suchembodiments, each of R^(2b) and R^(2c) independently is selected fromthe group consisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and—N(R⁴)₂.

In some embodiments, the invention relates to a compound of formula(IIa), wherein R^(e) is hydrogen; each of R^(b2) and R^(b3)independently is selected from the group consisting of hydrogen, -halo,C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and —OR⁵, where R⁵ is hydrogen orC₁₋₃ aliphatic; and each of R^(c1) and R^(c5) independently is selectedfrom the group consisting of hydrogen, -halo, C₁₋₃ aliphatic, C₁₋₃fluoroaliphatic, and —OR⁵, where R⁵ is hydrogen or C₁₋₃ aliphatic. Insome embodiments, each of R^(b3) and R^(c1) independently is selectedfrom the group consisting of -halo, C₁₋₃aliphatic, C₁₋₃ fluoroaliphatic,and —OR⁵, where R⁵ hydrogen or C₁₋₃ aliphatic. In certain suchembodiments, R^(b2) is hydrogen, R^(c5) is selected from the groupconsisting of hydrogen, -halo, C₁₋₃aliphatic, C₁₋₃ fluoroaliphatic, and—OR⁵, and each of R^(b3) and R^(c1) independently is selected from thegroup consisting of -halo, C₁₋₃aliphatic, C₁₋₃ fluoroaliphatic, and—OR⁵, where R⁵ hydrogen or C₁₋₃ aliphatic. In certain embodiments,R^(b2) is hydrogen, R^(c2) is hydrogen, chloro, fluoro, bromo, methyl,trifluoromethyl, or methoxy, and each of R^(b3) and R^(c1) independentlyis chloro, fluoro, bromo, methyl, trifluoromethyl, or methoxy.

Some embodiments of the invention relate to a subgenus of the compoundsof formula (A) defined by formula (IV):

-   -   wherein:    -   Ring A is substituted with 0-2 R^(b);    -   Ring B is a mono- or bicyclic aryl or heteroaryl ring, which        optionally is substituted with 0-2 independently selected R^(c)        and 0-3 independently selected R^(2c) or C₁₋₆ aliphatic groups;    -   R^(e) is hydrogen or a C₁₋₃ aliphatic optionally substituted        with R³ or R⁷;    -   R^(g) is selected from the group consisting of hydrogen, C₁₋₆        aliphatic, and R^(2d); and each of R^(h) and R^(k) independently        is hydrogen or R^(d).

In some such embodiments, the invention relates to a compound of formula(IV), wherein:

-   -   each R⁴ in R^(d) or R^(2d) is hydrogen, C₁₋₃ alkyl, or a 5- or        6-membered aryl or heteroaryl ring; or two R⁴ on the same        nitrogen atom, taken together with the nitrogen atom, form an        optionally substituted 5- to 6-membered heteroaryl or 4- to        8-membered heterocyclyl ring having, in addition to the nitrogen        atom, 0-2 ring heteroatoms selected from N, O, and S; and    -   each R⁵ in R^(d) or R^(2d) is hydrogen, C₁₋₃ alkyl, or a 5- or        6-membered aryl or heteroaryl ring.

In some such embodiments, two R⁴ on the same nitrogen atom in R^(d) orR^(2d), taken together with the nitrogen atom, form an optionallysubstituted piperidinyl, piperazinyl, or morpholinyl ring.

In some embodiments, the invention relates to a compound of formula (IV)wherein:

-   -   Ring A is substituted with 0-2 R^(b), where each R^(b)        independently is selected from the group consisting of C₁₋₃        aliphatic, R^(2b), R^(7b), -T¹-R^(2b), and -T¹-R^(7b), where T¹        is a C₁₋₃ alkylene chain;    -   Ring B is a monocyclic 5- or 6-membered aryl or heteroaryl ring,        which is substituted with 0-2 independently selected R^(c),        where each R^(c) independently is selected from the group        consisting of C₁₋₃ aliphatic, R^(2c), R^(7c), -T¹-R^(2c), and        -T¹-R^(7c), where T¹ is a C₁₋₃ alkylene chain; and    -   R^(e) is hydrogen.

In some such embodiments, each R^(b) independently is selected from thegroup consisting of C₁₋₃ aliphatic, R^(2b), and -T¹-R^(2b), and eachR^(c) independently is selected from the group consisting of C₁₋₃aliphatic, R^(2c), and -T¹-R^(2c). In some embodiments, each R^(2b)independently is selected from the group consisting of -halo, —NO₂,—C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, and —N(R⁴)₂, and each R^(2c) independentlyis selected from the group consisting of -halo, —NO₂, —C(R⁵)═C(R⁵)₂,—C≡C—R⁵, —OR⁵, and —N(R⁴)₂.

In some embodiments, the invention is directed to the compound offormula (IV), wherein one of R^(h) and R^(k) is R^(7d). In some suchembodiments, R^(g) is hydrogen, and R^(7d) is tetrazolyl.

In some embodiments, the invention relates to a compound of formula(IV), wherein R^(g) is hydrogen, one of R^(h) and R^(k) has the formula-T²-R^(2d) or -T²-R^(7d), and the other of R^(h) and R^(k) is selectedfrom the group consisting of hydrogen, -halo, C₁₋₃ aliphatic, and —OR⁵,where R⁵ is hydrogen or C₁₋₃ aliphatic. In some embodiments, T² is aC₁₋₆ alkylene chain, which optionally is interrupted by —C(O)N(R⁴)— or—N(R⁴)C(O)—.

In some embodiments, the invention is directed to a compound of formula(IV) wherein R^(g) is hydrogen, one of R^(h) and R^(k) has the formula—V-T³-R^(2d), and the other of R^(h) and R^(k) is selected from thegroup consisting of hydrogen, -halo, C₁₋₃ aliphatic, and —OR⁵, where R⁵is hydrogen or C₁₋₃ aliphatic. In some such embodiments, V is—C(O)N(R⁴)—, T³ is a C₂₋₄ alkylene chain, and R^(2d) is —N(R⁴)₂, whereeach R⁴ independently is hydrogen or C₁₋₃ aliphatic, or —N(R⁴)₂ is anoptionally substituted 5- to 6-membered heteroaryl or 4- to 8-memberedheterocyclyl ring having, in addition to the nitrogen, 0-2 ringheteroatoms selected from N, O, and S. In certain such embodiments,—N(R⁴)₂ is an optionally substituted heterocyclyl selected from thegroup consisting of piperidinyl, piperazinyl, and morpholinyl. Incertain other such embodiments, —N(R⁴)₂ is an optionally substitutedheterocyclyl selected from pyrrolidinyl and azetidinyl.

In some other embodiments, the invention relates to a compound offormula (IV), wherein R^(g) is hydrogen, one of R^(h) and R^(k) has theformula —V-T³-R^(7d), and the other of R^(h) and R^(k) is selected fromthe group consisting of hydrogen, -halo, C₁₋₃ aliphatic, and —OR⁵, whereR⁵ is hydrogen or C₁₋₃ aliphatic. In certain such embodiments, V is—C(O)N(R⁴)—, T³ is a C₂₋₄ alkylene chain, and R^(7d) is an optionallysubstituted 4- to 8-membered heterocyclyl or an optionally substituted5- to 6-membered heteroaryl. In certain such embodiments, R^(7d) is anoptionally substituted heteroaryl selected from the group consisting ofpyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, oxazolyl,imidazolyl, and pyrazolyl. In certain other such embodiments, R^(7d) isa 6- to 8-membered bridged bicyclic heterocyclyl.

In some embodiments, the invention is directed to a compound of formula(IV) wherein R^(g) is hydrogen, and at least one of R^(h) and R^(k) isselected from the group consisting of —CO₂R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)N(R⁴)₂, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵, or—NR⁴C(O)R⁵. In some such embodiments, at least one of R^(h) and R^(k) is—CO₂R⁵, where R⁵ is hydrogen or C₁₋₆ aliphatic. In some embodiments,each of R^(g) and R^(k) is hydrogen, and R^(h) is —CO₂R⁵.

In some embodiments, R^(g) is hydrogen, and one of R^(h) and R^(k) is—C(O)—N(R⁴)₂ or —C(═NR⁴)N(R⁴)₂, where —N(R⁴)₂ is an optionallysubstituted heterocyclyl selected from the group consisting ofpiperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, and azetidinyl. Insome such embodiments, one of R^(h) and R^(k) has one of the formulaeD-i to D-v, as defined above. In certain such embodiments, one of R^(h)or R^(k) has one of the formulae D-1 to D-51, or has the formulaembodied at the relevant position of any of the compounds depicted inTable 3 below.

Some embodiment of the invention relate to a subgenus of the compoundsof formula (A) defined by formula (C):

-   -   wherein:    -   Ring A is a substituted or unsubstituted 5- or 6-membered aryl,        heteroaryl, cycloaliphatic, or heterocyclyl ring;    -   Ring B is substituted with 0-2 independently selected R^(c) and        0-3 independently selected R^(2c) or C₁₋₆ aliphatic groups;    -   Ring C is substituted 0-2 independently selected R^(d) and 0-3        independently selected R^(2d) or C₁₋₆ aliphatic groups; and    -   each of R^(e), R^(x), and R^(y) has the values and preferred        values described above.

In some embodiments, the invention relates to a subgenus of formula (C)defined by formula (V):

-   -   wherein:    -   R^(e) is hydrogen or a C₁₋₃ aliphatic optionally substituted        with R³ or R⁷;    -   Ring A is substituted with 0-3 R^(b);    -   Ring B is substituted with 0-2 independently selected R^(c) and        0-2 independently selected R^(2c) or C₁₋₆ aliphatic groups; and    -   Ring C is substituted or unsubstituted.

In some embodiments, the compound of formula (V) is defined by formula(Va):

-   -   wherein:    -   R^(e) is hydrogen;    -   each of R^(b2) and R^(b3) independently is selected from the        group consisting of hydrogen, -halo, C₁₋₃ aliphatic, C₁₋₃        fluoroaliphatic, and —OR⁵, where R⁵ is hydrogen or C₁₋₃        aliphatic;    -   each of R^(c1) and R^(c5) independently is selected from the        group consisting of hydrogen, -halo, C₁₋₃ aliphatic, C₁₋₃        fluoroaliphatic, and —OR⁵, where R⁵ is hydrogen or C₁₋₃        aliphatic;    -   R^(g) is selected from the group consisting of hydrogen, C₁₋₆        aliphatic, and R^(2d); and    -   each of R^(h) and R^(k) independently is hydrogen or R^(d).

In some embodiments, the invention relates to a compound of formula (Va)wherein at least one of R^(h) and R^(k) has the formula —V-T³-R^(2d) or—V-T³-R^(7d), where:

-   -   V is —C(O)N(R⁴)—;    -   T³ is a C₂₋₄ alkylene chain;    -   R^(2d) is —N(R⁴)₂, where R⁴ is hydrogen or C₁₋₃ aliphatic, or        two R⁴ on the same nitrogen atom, taken together with the        nitrogen atom, form an optionally substituted 4- to 8-membered        heterocyclyl or an optionally substituted 5- to 6-membered        heteroaryl ring having, in addition to the nitrogen, 0-2 ring        heteroatoms selected from N, O, and S; and    -   R^(7d) is an optionally substituted 4- to 8-membered        heterocyclyl or an optionally substituted 5- to 6-membered        heteroaryl.

In some other embodiments, the invention relates to a compound offormula (Va), wherein R^(g) is hydrogen, and at least one of R^(h) andR^(k) is selected from the group consisting of —CO₂R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)N(R⁴)₂, —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵, or—NR⁴C(O)R⁵.

In a particular embodiment, the invention relates to a compound offormula (Va), wherein:

-   -   R^(e), R^(b2), R^(g), and R^(k) are each hydrogen;    -   R^(b3) and R^(c1) are each independently selected from the group        consisting of -halo, C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and        —OR⁵, where R⁵ is hydrogen or C₁₋₃ aliphatic;    -   R^(c5) is selected from the group consisting of hydrogen, -halo,        C₁₋₃ aliphatic, C₁₋₃ fluoroaliphatic, and —OR⁵, where R⁵ is        hydrogen or C₁₋₃ aliphatic; and    -   R^(h) is —CO₂H, —C(O)N(R⁴)₂, —C(═NR⁴)N(R⁴)₂,        —C(O)N(R⁴)C(═NR⁴)—N(R⁴)₂, or —N(R⁴)C(═NR⁴)—N(R⁴)—C(O)R⁵, where        R⁵ is an optionally substituted 4- to 8-membered        nitrogen-containing heterocyclyl ring, and —N(R⁴)₂ is an        optionally substituted 4- to 8-membered heterocyclyl ring having        in addition to the nitrogen atom 0-2 heteroatoms selected from        N, O, and S.

Compounds embodying any combination of the preferred values for thevariables described herein are considered to be within the scope of thepresent invention.

Table 3 shows specific examples of compounds of formula (V).

TABLE 3 Aurora Kinase Inhibitors

I-1

I-2

I-3

I-4

I-5

I-6

I-7

I-8

I-9

I-10

I-11

I-12

I-13

I-14

I-15

I-16

I-17

I-18

I-19

I-20

I-21

I-22

I-23

I-24

I-25

I-26

I-27

I-28

I-29

I-30

I-31

I-32

I-33

I-34

I-35

I-36

I-37

I-38

I-39

I-40

I-41

I-42

I-43

I-44

I-45

I-46

I-47

I-48

I-49

I-50

I-51

I-52

I-53

I-54

I-55

I-56

I-57

I-58

I-59

I-60

I-61

I-62

I-63

I-64

I-65

I-66

I-67

I-68

I-69

I-70

I-71

I-72

I-73

I-74

I-75

I-76

I-77

I-78

I-79

I-80

I-81

I-82

I-83

I-84

I-85

I-86

I-87

I-88

I-89

I-90

I-91

I-92

I-93

I-94

I-95

I-96

I-97

I-98

I-99

I-100

I-101

I-102

I-103

I-104

I-105

I-106

I-107

I-108

I-109

I-110

I-111

I-112

I-113

I-114

I-115

I-116

I-117

I-118

I-119

I-120

I-121

I-122

I-123

I-124

I-125

I-126

I-127

I-128

I-129

I-130

I-131

I-132

I-133

I-134

I-135

I-136

I-137

I-138

I-139

I-140

I-141

I-142

I-143

I-144

I-145

I-146

I-147

I-148

I-149

I-150

I-151

I-152

I-153

I-154

I-155

I-156

I-157

I-158

I-159

I-160

I-161

I-162

I-163

I-164

I-165

I-166

I-167

I-168

I-169

I-170

I-171

I-172

I-173

I-174

I-175

I-176

I-177

I-178

I-179

I-180

I-181

I-182

I-183

I-184

I-185

I-186

I-187

I-188

I-189

I-190

I-191

I-192

I-193

I-194

I-195

I-196

I-197

I-198

I-199

I-200

I-201

I-202

I-203

I-204

I-205

I-206

I-207

I-208

I-209

I-210

I-211

I-212

I-213

I-214

I-215

I-216

I-217

I-218

I-219

I-220

I-221

I-222

I-223

I-224

I-225

I-226

I-227

I-228

I-229

I-230

I-231

I-232

I-233

I-234

I-235

I-236

I-237

I-238

I-239

I-240

I-241

I-242

I-243

I-244

I-245

I-246

I-247

I-248

I-249

I-250

I-251

I-252

I-253

I-254

I-255

I-256

I-257

I-258

I-259

I-260

I-261

I-262

I-263

I-264

I-265

I-266

I-267

I-268

I-269

I-270

I-271

I-272

I-273

I-274

I-275

I-276

I-277

I-278

I-279

I-280

I-281

I-282

I-283

I-284

I-285

I-286

I-287

I-288

I-289

I-290

I-291

I-292

I-293

I-294

I-295

I-296

I-297

I-298

I-299

I-300

I-301

I-302

I-303

I-304

I-305

I-306

I-307

I-308

I-309

I-310

I-311

I-312

I-313

I-314

I-315

I-316

I-317

I-318

I-319

I-320

I-321

I-322

I-323

I-324

I-325

I-326

I-327

I-328

I-329

I-330

I-331

I-332

I-333

I-334

I-335

I-336

I-337

I-338

I-339

I-340

I-341

I-342

I-343

I-344

I-345

I-346

I-347

I-348

I-349

I-350

I-351

I-352

I-353

I-354

I-355

I-356

I-357

I-358

I-359

I-360

I-361

I-362

I-363

I-364

I-365

I-366

I-367

I-368

I-369

I-370

I-371

I-372

I-373

I-374

I-375

I-376

I-377

I-378

I-379

I-380

I-381

I-382

I-383

I-384

I-385

I-386

I-387

I-388

I-389

I-390

I-391

I-392

I-393

I-394

I-395

I-396

I-397

I-398

I-399

I-400

I-401

I-402

I-403

I-404

I-405

I-406

I-407

I-408

I-409

I-410

I-411

I-412

I-413

I-414

I-415

I-416

I-417

I-418

I-419

I-420

I-421

I-422

I-423

I-424

I-425

I-426

I-427

I-428

I-429

I-430

I-431

I-432

I-433

I-434

I-435

I-436

I-437

I-438

I-439

I-440

I-441

I-442

I-443

I-444

I-445

I-446

I-447

I-448

I-449

I-450

I-451

I-452

I-453

I-454

I-455

I-456

I-457

I-458

I-459

I-460

I-461

I-462

I-463

I-464

I-465

I-466

I-467

I-468

I-469

I-470

I-471

I-472

I-473

I-474

I-475

I-476

I-477

I-478

I-479

I-480

I-481

I-482

I-483

I-484

I-485

I-486

I-487

I-488

I-489

I-490

I-491

I-492

I-493

I-494

I-495

I-496

I-497

I-498

I-499

I-500

I-501

I-502

I-503

I-504

I-505

I-506

I-507

I-508

I-509

I-510

I-511

I-512

I-513

I-514

I-515

I-516

I-517

I-518

I-519

I-520

I-521

I-522

I-523

I-524

I-525

I-526

I-527

I-528

I-529

I-530

I-531

I-532

I-533

I-534

I-535

The compounds in Table 3 above also may be identified by the followingchemical names:

-   I-1:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-methylamino-ethyl)-benzamide-   I-2:    N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-N-methyl-benzamide-   I-3:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(2-methylamino-ethyl)-benzamide-   I-4:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-dimethylamino-ethyl)-benzamide-   I-5:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-dimethylamino-ethyl)-N-methyl-benzamide-   I-6:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(3-dimethylamino-propyl)-benzamide-   I-7:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(3-dimethylamino-propyl)-N-methyl-benzamide-   I-8:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-piperazin-1-yl-methanone-   I-9:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-10:    {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-11:    [4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone-   I-12:    {4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-13:    {4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-14:    {4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-15:    2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone-   I-16:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-piperidin-4-yl-benzamide-   I-17:    (4-Amino-piperidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-18:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone-   I-19:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-20:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-21:    4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-22:    4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-23:    4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-24:    4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-25:    2-{3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-N-[3-(4-methyl-piperazin-1-yl)-propyl]-acetamide-   I-26:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-morpholin-4-yl-methanone-   I-27:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N,N-bis-(2-hydroxy-ethyl)-benzamide-   I-28:    {4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-morpholin-4-yl-methanone-   I-29:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-30:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-31:    4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-32:    4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(3-morpholin-4-yl-propyl)-benzamide-   I-33:    4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-34:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-hydroxy-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-35:    [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-pyridin-2-yl-amine-   I-36:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5-dichloro-phenyl)-amine-   I-37:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-methoxy-phenyl)-amine-   I-38:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-ethoxy-phenyl)-amine-   I-39:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3-methoxy-phenyl)-amine-   I-40:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2-methoxy-phenyl)-amine-   I-41:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-chloro-phenyl)-amine-   I-42:    [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-chloro-phenyl)-amine-   I-43:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3-chloro-phenyl)-amine-   I-44:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2-chloro-phenyl)-amine-   I-45:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenol-   I-46:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-morpholin-4-yl-phenyl)-amine-   I-47:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine-   I-48:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-pyridin-4-ylmethyl-phenyl)-amine-   I-49:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzonitrile-   I-50:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-nitro-phenyl)-amine-   I-51:    4-[7-(2-Fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-52:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-53:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-54:    4-(9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic    acid-   I-55:    4-[9-Chloro-7-(2-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-56:    4-[9-Chloro-7-(4-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-57:    4-[9-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-58:    4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-59:    4-[10-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-60:    4-[10-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-61:    4-[10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-62:    4-[7-(2-Fluoro-phenyl)-10-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-63:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide-   I-64:    3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide-   I-65:    {3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-acetic    acid-   I-66:    2-{3-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-acetamide-   I-67:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzenesulfonic    acid-   I-68:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzenesulfonamide-   I-69:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide-   I-70:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine-   I-71:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-72:    [9-Chloro-7-(2-fluoro-phenyl)-6,7-dihydro-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-73:    [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-74:    (9-Chloro-7-o-tolyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4-dimethoxy-phenyl)-amine-   I-75:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-76:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-isopropyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-77:    (3,4-Dimethoxy-phenyl)-[10-fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-78:    [10-Bromo-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-79:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-trifluoromethyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-80:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-81:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-10-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-82:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-11-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-83:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-amine-   I-84:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-fluoro-3-methoxy-phenyl)-amine-   I-85:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-hydroxy-benzoic    acid-   I-86:    4-[9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-hydroxy-benzoic    acid-   I-87:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dichloro-phenyl)-amine-   I-88:    [9-Chloro-7-(2-chloro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5-dimethoxy-phenyl)-amine-   I-89:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,5-dimethyl-phenyl)-amine-   I-90:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-phenyl-amine-   I-91:    4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-92:    4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-93:    (3-Dimethylamino-pyrrolidin-1-yl)-{4-[7-(2-fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-94:    4-[9-Chloro-7-(2,5-dimethoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-95:    4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N,N-bis-(2-hydroxy-ethyl)-benzamide-   I-96:    4-[9-Chloro-7-(2,4-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-97:    4-[9-Chloro-7-(2,4-difluoro-phenyl)-7H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-98:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-dimethylamino-azetidin-1-yl)-methanone-   I-99:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(1-methyl-pyrrolidin-3-yl)-benzamide-   I-100:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-dimethylamino-pyrrolidin-1-yl)-methanone-   I-101:    4-[9-Chloro-7-(2,4-dimethoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-102:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone-   I-103:    (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-104:    4-[9-Chloro-7-(2,3-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid methyl ester-   I-105:    4-[9-Chloro-7-(2,5-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid methyl ester-   I-106:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-phosphonic    acid-   I-107:    N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanesulfonamide-   I-108:    N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-N-methyl-acetamide-   I-109:    2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoylamino}-succinic    acid-   I-110:    [9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-111:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3,5-dimethyl-piperazin-1-yl)-methanone-   I-112:    1-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoyl}-pyrrolidine-2-carboxylic    acid-   I-113:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methyl-piperazin-1-yl)-methanone-   I-114:    [9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-[4-(2H-tetrazol-5-yl)-phenyl]-amine-   I-115:    N-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-acetamide-   I-116:    5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-fluoro-benzoic    acid-   I-117:    N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-benzamide-   I-118:    2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoylamino}-propionic    acid-   I-119:    5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-pyridine-2-carboxylic    acid-   I-120:    2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-N-(2-morpholin-4-yl-ethyl)-acetamide-   I-121:    5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-methoxy-benzoic    acid-   I-122:    5-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-methyl-benzoic    acid-   I-123:    6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-nicotinic    acid-   I-124:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide-   I-125:    2-Chloro-5-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-126:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-acetic    acid-   I-127:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-trifluoromethyl-benzoic    acid-   I-128:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(1-methyl-piperidin-4-yl)-benzamide-   I-129:    N-(3-Amino-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide-   I-130:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(3-methylamino-propyl)-benzamide-   I-131:    N-(2-Amino-2-methyl-propyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzamide-   I-132:    2-(3,4-Dimethoxy-phenylamino)-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepine-10-carboxylic    acid-   I-133:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-methyl-benzoic    acid-   I-134:    2-Chloro-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-135:    4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-136:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-fluoro-benzoic    acid-   I-137:    4-[7-(2-Fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-138:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-9-methoxy-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-amine-   I-139:    [9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-140:    4-[9,10-Dichloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-141:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-2-methoxy-benzoic    acid-   I-142:    N-(2-Amino-ethyl)-4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzamide-   I-143:    4-(9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic    acid-   I-144:    [7-(2-Bromo-phenyl)-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine-   I-145:    2-{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-1-(4-methyl-piperazin-1-yl)-ethanone-   I-146:    3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-147:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[2-(l    H-imidazol-4-yl)-ethyl]-benzamide-   I-148:    4-[7-(2-Fluoro-phenyl)-9-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-149:    {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-acetic    acid-   I-150:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-pyridin-4-yl-ethyl)-benzamide-   I-151:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-pyridin-3-yl-ethyl)-benzamide-   I-152:    (9-Chloro-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)-(3,4-dimethoxy-phenyl)-amine-   I-153:    4-[7-(2-Fluoro-phenyl)-10-methyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-154:    (3,4-Dimethoxy-phenyl)-[7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-yl]-amine-   I-155:    4-[9-Chloro-7-(4-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-156:    4-[9-Chloro-7-(3-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-157:    4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[3-(4-methyl-piperazin-1-yl)-propyl]-benzamide-   I-158:    4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-morpholin-4-yl-ethyl)-benzamide-   I-159:    {4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-160:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(2-pyridin-2-yl-ethyl)-benzamide-   I-161:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(2-pyridin-2-yl-ethyl)-benzamide-   I-162:    4-[9-Chloro-7-(3-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-163:    {3-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-164:    9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-165:    9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-morpholin-4-yl-2-oxoethyl)piperazin-1-yl]carbonyl}phenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-amine-   I-166:    9-Chloro-7-(2-fluorophenyl-N-(4-{[4-(2-furoyl)piperazin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-167:    Benzyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-1-carboxylate-   I-168:    Ethyl-4-(4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-1-carboxylate-   I-169:    2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazin-1-yl]benzoic    acid-   I-170:    2-[4-(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)    piperazin-1-yl]-N-isopropylacetamide-   I-171:    9-Chloro-7-(2-fluorophenyl)-N-(4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-172:    N-[2-(aminocarbonyl)phenyl]-4-{[9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide-   I-173:    9-Chloro-7-(2-fluorophenyl)-N-{4-[(4-pyrimidin-2-ylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-174:    4-{[9-Chloro-7-(2-chloro-6-fluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-175:    9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-176:    9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-177:    9-Chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-178:    9-Chloro-N-(4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-179:    9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-180:    9-Chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-181:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-[4-(3-piperidin-1-yl-propyl)-piperazin-1-yl]-methanone-   I-182:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-[4-(2-piperidin-1-yl-ethyl)-piperazin-1-yl]-methanone-   I-183:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone-   I-184:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-185:    4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-(3-dimethylamino-propyl)-N-methyl-benzamide-   I-186:    {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone-   I-187:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-[4-(2-dipropylamino-ethyl)-piperazin-1-yl]-methanone-   I-188:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-[4-(3-pyrrolidin-1-yl-propyl)-piperazin-1-yl]-methanone-   I-189:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-[4-(2-morpholin-4-yl-ethyl)-piperazin-1-yl]-methanone-   I-190:    4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-191:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3(S)-methyl-piperazin-1-yl)-methanone-   I-192:    (3-Amino-azetidin-1-yl)-{4-[9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-193:    {4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-dimethylaminomethyl-azetidin-1-yl)-methanone-   I-194:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3(R)-methyl-piperazin-1-yl)-methanone-   I-195:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-piperazin-1-yl-methanone-   I-196:    (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-197:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone-   I-198:    4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(3-methylamino-propyl)-benzamide-   I-199:    {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone-   I-200:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-cyclohexanecarboxylic    acid-   I-201:    9-chloro-N-(4-{[4-(2-ethoxyphenyl)piperazin-1-yl]carbonyl}phenyl)-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-202:    N-[amino(imino)methyl]-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide-   I-203:    3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-204:    9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-205: 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[4-(dimethylamino)    piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-206: 9-chloro-7-(2,6-difluorophenyl)-N-(3-{[3-(dimethylamino)    pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-207:    N-[2-(aminomethyl)-1,3-benzoxazol-5-yl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-208:    9-chloro-N-[4-({4-[3-(diethylamino)propyl]piperazin-1-yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-209:    9-chloro-N-[4-({4-[2-(diethylamino)ethyl]piperazin-1-yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-210:    9-chloro-N-[4-({4-[3-(dimethylamino)propyl]piperazin-1-yl}carbonyl)phenyl]-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-211:    9-chloro-7-(2-fluorophenyl)-N-[4-({4-[(1-methylpiperidin-3-yl)methyl]piperazin-1-yl}carbonyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-212:    9-chloro-7-(2,6-difluorophenyl)-N-(4-nitrophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-213:    9-chloro-N-(3-chloro-4-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]carbonyl}phenyl)-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-214: 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)    carbonyl]phenyl}-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-215:    9-chloro-N-(3-chloro-4-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-216: 9-chloro-N-{3-chloro-4-[(3-methylpiperazin-1-yl)    carbonyl]phenyl}-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-217:    N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]benzene-1,4-diamine-   I-218: methyl    2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoate-   I-219:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxylic    acid-   I-220:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-221:    N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-222:    9-chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-223:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[4-(dimethylamino)piperidin-1-yl](imino)methyl]benzamide-   I-224:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide-   I-225:    4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[3-(dimethylamino)propyl]-N-methylbenzamide-   I-226:    3-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[3-(dimethylamino)propyl]-N-methylbenzamide-   I-227:    9-chloro-N-(3-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-228:    9-chloro-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-229:    9-chloro-N-(3-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-230:    N-(4-{[3-(aminomethyl)azetidin-1-yl]carbonyl}phenyl)-9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-231:    9-chloro-N-(3-{[3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-232:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-233:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-234: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)    azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-235:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-236:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzonitrile-   I-237:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]benzamide-   I-238:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide-   I-239:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-240:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-241:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-242:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-243:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-[4-(piperazin-1-ylcarbonyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-244:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[[4-(dimethylamino)piperidin-1-yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-245:    N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)guanidine-   I-246:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide-   I-247:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide-   I-248: methyl    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxylate-   I-249:    2-[(4-carboxyphenyl)amino]-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepine-9-carboxylic    acid-   I-250:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-251:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)    (imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-252:    N-(2-aminoethyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-253:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-254:    4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide-   I-255:    4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[2-(dimethylamino)ethyl]-N-methylbenzamide-   I-256:    7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxylic    acid-   I-257:    N-(3-aminopropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-258:    2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-259:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide-   I-260:    N-(2-amino-2-methylpropyl)-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide-   I-261:    4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methyl-N-[3-(methylamino)propyl]benzamide-   I-262:    N-{4-[(3-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-263:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-264:    N-(3-aminopropyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-265:    N-(2-aminoethyl)-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-266:    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxylic    acid-   I-267:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-268: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{imino[3-(methylamino)    pyrrolidin-1-yl]methyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-269:    9-chloro-N-(4-chloro-3-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-270:    9-chloro-7-(2,6-difluorophenyl)-N-[4-(5,5-dimethyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-271:    N-[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]-N′-pyrimidin-2-ylbenzene-1,4-diamine-   I-272:    4-{[9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-273:    9-bromo-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-274:    4-{[9-bromo-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-275:    7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-9-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-276:    9-(3-aminoprop-1-yn-1-yl)-7-(2,6-difluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-277:    4-({9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-yl}amino)benzoic    acid-   I-278:    N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-279:    4-[(9-chloro-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic    acid-   I-280:    N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-4-methylpiperazine-1-carboxamide-   I-281:    9-chloro-N-(4-chloro-3-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-282:    9-chloro-N-(4-chloro-3-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-283:    2-chloro-5-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methyl-N-[2-(methylamino)ethyl]benzamide-   I-284:    N-{4-[(3-aminopyrrolidin-1-yl)(imino)methyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-285:    2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-1,4,5,6-tetrahydropyrimidin-5-ol-   I-286:    N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-287:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-288:    9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-289:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-290:    9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-291:    9-chloro-N-(4-chloro-3-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-292:    N-{3-[(4-aminopiperidin-1-yl)carbonyl]-4-chlorophenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-293: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)    piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-294: methyl    4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylate-   I-295:    4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxylic    acid-   I-296:    N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-297:    9-chloro-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-7-[2-(trifluoromethyl)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-298:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-299:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-300: ethyl    2-amino-4-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate-   I-301:    4-{[9-chloro-7-(3-fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-302:    9-{[3-(dimethylamino)azetidin-1-yl]carbonyl}-7-(2-fluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-303:    7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[3-(methylamino)propyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide-   I-304:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3-fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-305:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(3-fluoropyridin-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-306:    2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5-carboxylic    acid-   I-307:    N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-2-(dimethylamino)acetamide-   I-308:    2-amino-N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-2-methylpropanamide-   I-309: ethyl    (2R)-4-amino-2-[(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)amino]butanoate-   I-310:    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide-   I-311:    7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-(3-morpholin-4-ylpropyl)-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide-   I-312:    9-[(3,5-dimethylpiperazin-1-yl)carbonyl]-7-(2-fluorophenyl)-N-(3-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-313:    9-chloro-N-(3-chloro-4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-314: ethyl    2-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-4,5-dihydro-1H-imidazole-5-carboxylate-   I-315:    9-chloro-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-316:    9-chloro-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-pyridin-2-yl-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-317:    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperazine-2-carboxamide-   I-318:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]-3-chlorophenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-319:    N-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)piperidine-4-carboxamide-   I-320:    4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-321:    9-chloro-7-(2,4-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-322:    9-chloro-7-(2,4-dimethoxyphenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-323:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-324:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-325:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-326:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-327:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-328:    9-chloro-N-(3,4-dimethoxyphenyl)-7-{2-[(dimethylamino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-329:    9-chloro-7-(2-methoxyphenyl)-N-{4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-330:    9-chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-331:    9-chloro-7-(2-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-332:    9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-333:    9-chloro-7-(2-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-334:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-335:    4-{[9-chloro-7-(2-fluoro-6-{methyl[3-(methylamino)propyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-336:    4-{[9-chloro-7-(2-fluoro-6-{methyl[3-(methylamino)propyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-337:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)    ethanone-   I-338:    N-[3-(3-aminoprop-1-yn-1-yl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-339:    4-[(9-chloro-7-{2-fluoro-6-[(2-hydroxyethyl)amino]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide-   I-340:    4-[(7-{2-[(2-aminoethyl)amino]-6-fluorophenyl}-9-chloro-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide-   I-341:    4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide-   I-342:    4-[(9-chloro-7-{2-[4-(dimethylamino)piperidin-1-yl]-6-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide-   I-343:    9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)prop-1-yn-1-yl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-344:    9-chloro-7-(2,6-difluorophenyl)-N-(3-iodophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-345:    4-{[9-chloro-7-(2-{[2-(dimethylamino)ethyl]amino}-6-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-346:    4-[(9-chloro-7-{2-[[2-(dimethylamino)ethyl](methyl)amino]-6-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide-   I-347:    4-{[9-chloro-7-(2-fluoro-6-{methyl[2-(methylamino)ethyl]amino}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-348:    4-({7-[2-(4-aminopiperidin-1-yl)-6-fluorophenyl]-9-chloro-5H-pyrimido[5,4-d][2]benzazepin-2-yl}amino)-N-methylbenzamide-   I-349:    7-(2-fluorophenyl)-2-[(3-methoxyphenyl)amino]-N-methyl-N-[2-(methylamino)ethyl]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide-   I-350:    4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)piperidine-4-carboxamide-   I-351:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-352:    9-chloro-7-(2,6-difluorophenyl)-N-(4-methyl-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-353:    7-(2,6-difluorophenyl)-2-[(3-methoxyphenyl)amino]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxylic    acid-   I-354:    4-({9-chloro-7-[2-fluoro-6-(methylamino)phenyl]-5H-pyrimido[5,4-d][2]benzazepin-2-yl}amino)-N-methylbenzamide-   I-355:    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methyl-1,3-thiazole-4-carboxamide-   I-356:    N-1H-benzimidazol-2-yl-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-357:    7-(2,6-difluorophenyl)-2-[(4-methyl-1,3-thiazol-2-yl)amino]-5H-pyrimido[5,4-d][2]benzazepine-9-carboxylic    acid-   I-358:    3-amino-1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)propan-1-one-   I-359:    1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-3-(dimethylamino)propan-1-one-   I-360:    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-1,3-thiazole-4-carboxylic    acid-   I-361: ethyl    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-1,3-thiazole-4-carboxylate-   I-362:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]-1,3-thiazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-363: ethyl    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-1,3-oxazole-5-carboxylate-   I-364:    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-1,3-oxazole-5-carboxylic    acid-   I-365:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(3R)-3-methylpiperazin-1-yl]carbonyl}-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-366:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[(2R)-2-methylpiperazin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-367:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}-1,3-thiazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-368:    2-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-1,3-oxazole-4-carboxylic    acid-   I-369:    9-chloro-7-(2,6-difluorophenyl)-N-{5-[(3,5-dimethylpiperazin-1-yl)carbonyl]-1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-370:    9-chloro-7-(2,6-difluorophenyl)-N-(5-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-371:    4-{[9-chloro-7-(2,6-difluorophenyl)-5-methyl-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-372:    9-chloro-7-(2,6-difluorophenyl)-N-{3-[3-(dimethylamino)propyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-373:    N-[3-(3-aminopropyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-374:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]-1,3-oxazol-2-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-375:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}-1,3-oxazol-2-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-376:    7-(2,6-difluorophenyl)-2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-N-methyl-5H-pyrimido[5,4-d][2]benzazepine-9-carboxamide-   I-377:    2-{[4-(aminocarbonyl)phenyl]amino}-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepine-9-carboxylic    acid-   I-378:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4d][2]benzazepin-2-yl]amino}benzoyl)-N-methyl-4-(methylamino)    piperidine-4-carboxamide-   I-379:    N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-380:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-381:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-4-(methylamino)piperidine-4-carboxamide-   I-382:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3,5-trimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-383:    N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-384:    N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzamide-   I-385:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-hydroxybenzamide-   I-386:    N-{4-[(aminooxy)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-387:    4-{[9-chloro-7-(2,6-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-388:    4-{[9-chloro-7-(2,3-difluorophenyl)-7H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-389:    3-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpyrrolidine-3-carboxamide-   I-390:    3-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)pyrrolidine-3-carboxamide-   I-391:    9-chloro-7-(2,6-difluorophenyl)-N-{4-[(3,3-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-392:    4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)benzamide-   I-393:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)-3-methylpyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-394:    9-chloro-7-(2,6-difluorophenyl)-N-(3-methyl-1H-pyrazol-5-yl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-395:    2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-396:    4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide-   I-397:    4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N,N-dimethylpiperidine-4-carboxamide-   I-398:    4-[(9-methoxy-7-oxo-6,7-dihydro-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]benzoic    acid-   I-399:    2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-9-methoxy-5,6-dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one-   I-400:    9-methoxy-2-[(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)amino]-5,6-dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one-   I-401: 4-[(8-methyl-7-oxo-5,6,    7,8-tetrahydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2-yl)amino]benzoic    acid-   I-402:    2-({4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}amino)-8-methyl-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-7(6H)-one-   I-403:    2-[(3-methoxyphenyl)amino]-8-methyl-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-7(6H)-one-   I-404:    9-chloro-2-[(3,4-dimethoxyphenyl)amino]-5,6-dihydro-7H-pyrimido[5,4-d][2]benzazepin-7-one-   I-405:    4-{[4-amino-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-406:    9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-407:    9-chloro-N-(3-chloro-4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-408:    4-{[9-chloro-7-(2-fluoro-6-hydroxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-409:    9-chloro-N-[4-(1,7-diazaspiro[4.4]non-7-ylcarbonyl)phenyl]-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-410:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[2-(methylamino)-7-azabicyclo[2.2.1]hept-7-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-411:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methyl-3-(methylamino)pyrrolidine-3-carboxamide-   I-412:    1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-3-(methylamino)pyrrolidine-3-carboxamide-   I-413:    1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methyl-3-(methylamino)piperidine-3-carboxamide-   I-414:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-415:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-methyl-3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-416:    {2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methyl-3-methylamino-piperidin-1-yl)-methanone-   I-417:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-methyl-4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-418:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(dimethylamino)-4-methylpiperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-419:    N-{4-[(4-amino-4-methylpiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-420:    9-chloro-N-(3-chloro-4-{[4-methyl-4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-421:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-methyl-4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-422:    2-Chloro-4-[9-chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-4-methylamino-piperidin-1-yl)-methanone-   I-423:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(3-fluoro-4-{[4-methyl-4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-424:    9-chloro-N-{3-chloro-4-[(3,3,5,5-tetramethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-425:    N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-fluoro-N-methylbenzamide-   I-426:    N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-427:    N-8-azabicyclo[3.2.1]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-428:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)-8-azabicyclo[3.2.1]oct-8-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-429:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)-8-azabicyclo[3.2.1]oct-8-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-430:    4-{[7-(2,6-difluorophenyl)-9-methyl-5H-pyrimido[5,4-c]thieno[2,3-e]azepin-2-yl]amino}benzoic    acid-   I-431:    7-(2,6-difluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-c]thieno[2,3-e]azepin-2-amine-   I-432:    N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2,6-difluorophenyl)-10-methyl-5,10-dihydropyrimido[5,4-c]pyrrolo[2,3-e]azepin-2-amine-   I-433:    7-(2,6-difluorophenyl)-9-methyl-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-furo[2,3-c]pyrimido[4,5-e]azepin-2-amine-   I-434:    4-(2,6-difluorophenyl)-2-methyl-N-(4-{[3-methyl-3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-6H-pyrimido[5,4-c][1,3]thiazolo[4,5-e]azepin-9-amine-   I-435:    N-{4-[(3-amino-3-methylpyrrolidin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5,9-dihydropyrimido[5,4-c]pyrrolo[3,4-e]azepin-2-amine-   I-436:    4-{[4-(2,6-difluorophenyl)-1-methyl-1,6-dihydropyrazolo[4,3-c]pyrimido[4,5-e]azepin-9-yl]amino}benzoic    acid-   I-437:    1-{4-[4-(2,6-Difluoro-phenyl)-2-methyl-6H-3-thia-5,8,10-triaza-benzo    [e]azulen-9-ylamino]-benzoyl}-4-dimethylamino-piperidine-4-carboxylic    acid methylamide-   I-438:    4-(4-{[7-(2,6-difluorophenyl)-5H-furo[3,2-c]pyrimido[4,5-e]azepin-2-yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide-   I-439:    4-(4-{[4-(2,6-difluorophenyl)-6H-isoxazolo[4,5-c]pyrimido[4,5-e]azepin-9-yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide-   I-440:    4-(2,6-difluorophenyl)-9-[(4-{[3-methyl-3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)amino]-3,6-dihydroimidazo[4,5-c]pyrimido[4,5-e]azepin-2(1H)-one-   I-441:    2-amino-N-(3-{[7-(2,6-difluorophenyl)-8,10-dimethyl-5H-pyrimido[5,4-c]thieno[3,4-e]azepin-2-yl]amino}phenyl)-N,2-dimethylpropanamide-   I-442:    9-chloro-7-(2,6-difluorophenyl)-N-{3-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-443:    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-N-methyl-1-(methylamino)cyclohexanecarboxamide-   I-444:    7-(3-{[7-(2-fluoro-6-methoxyphenyl)-9-methoxy-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-1,7-diazaspiro[4.4]nonan-6-one-   I-445:    9-chloro-N-[4-(3,8-diazabicyclo[3.2.1]oct-3-ylcarbonyl)phenyl]-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-446:    1-(3-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-3,5,5-trimethylpiperazin-2-one-   I-447:    9-chloro-N-[4-(2,6-dimethylpiperidin-4-yl)phenyl]-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-448:    N-[4-(1-amino-1-methylethyl)phenyl]-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-449:    N-[4-(2,5-diazaspiro[3.4]oct-2-ylcarbonyl)phenyl]-7-(2,6-difluorophenyl)-10-methyl-5H-isothiazolo[5,4-c]pyrimido[4,5-e]azepin-2-amine-   I-450:    4-(2,6-difluorophenyl)-1-methyl-9-[(4-{[4-methyl-4-(methylamino)piperidin-1-yl]carbonyl}phenyl)amino]-1,6-dihydro-2-pyrimido[5,4-c][1,3]thiazolo[4,5-e]azepin-2-one-   I-451:    4-(2,6-difluorophenyl)-N-[4-(1H-imidazol-2-yl)phenyl]-1-methyl-1,6-dihydroimidazo[4,5-c]pyrimido[4,5-e]azepin-9-amine-   I-452:    4-{[7-(2,6-difluorophenyl)-5H-[1]benzofuro[2,3-c]pyrimido[4,5-e]azepin-2-yl]amino}benzoic    acid-   I-453:    7-(2-fluorophenyl)-N-{4-[(3,3,5,5-tetramethylpiperazin-1-yl)carbonyl]phenyl}-8,9,10,11-tetrahydro-5H-pyrido[4′,3′:4,5]thieno[3,2-c]pyrimido[4,5-e]azepin-2-amine-   I-454:    9-bromo-7-(2-fluorophenyl)-N-(4-{[3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2-amine-   I-455:    7-(2-fluorophenyl)-N-(3-methyl-1H-indazol-6-yl)-5,12-dihydropyrimido[4′,5′:5,6]azepino[4,3-b]indol-2-amine-   I-456:    1-(4-{[7-(2,6-difluorophenyl)-9,10-dimethyl-5,8-dihydropyrimido[5,4-c]pyrrolo[3,2-e]azepin-2-yl]amino}benzoyl)-3-(methylamino)pyrrolidine-3-carboxamide-   I-457:    {3-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-458:    [9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(2-methylaminomethyl-benzothiazol-6-yl)-amine-   I-459:    4-[9-Chloro-7-(2-isopropoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-460:    4-[9-Chloro-7-(2-fluoro-6-isopropoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-461:    4-[9-Chloro-7-(2-ethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-462:    4-[9-Chloro-7-(2-ethoxy-6-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-463:    4-[9-Chloro-7-(2-fluoro-6-methyl-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-464:    4-[9-Chloro-7-(2-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-465:    4-[9-Chloro-7-(2-fluoro-6-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-466:    4-[9-Chloro-7-(3-fluoro-2-trifluoromethoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-467:    4-[9-Chloro-7-(2,3-dimethoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-468:    4-[9-Chloro-7-(2-isobutyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-469:    4-(7-Benzofuran-2-yl-9-chloro-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic    acid-   I-470:    4-[9-Chloro-7-(1-methyl-1H-pyrrol-2-yl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-471:    4-[9-Chloro-7-(1-methyl-1H-imidazol-2-yl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-472:    4-(9-Chloro-7-thiophen-2-yl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic    acid-   I-473:    4-[9-Chloro-7-(2H-pyrazol-3-yl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-474:    4-[9-Chloro-7-(2-ethynyl-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-475:    4-[7-(2-Aminomethyl-phenyl)-9-chloro-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-476:    4-[9-Chloro-7-(5-fluoro-2-methoxy-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-477:    4-[9-Chloro-7-(3-methoxy-pyridin-2-yl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-478:    4-[8-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-479:    4-[8-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-480:    4-[11-Fluoro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-481:    4-[11-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-482:    6-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-pyridazine-3-carboxylic    acid-   I-483:    2-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-1H-imidazole-4-carboxylic    acid-   I-484:    4-[9-Chloro-7-(2-fluoro-phenyl)-4-methyl-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-485:    4-[4-Aminomethyl-9-chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido-[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-486:    4-(9-Aminomethyl-7-phenyl-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino)-benzoic    acid-   I-487:    9-Chloro-7-(2-fluorophenyl)-N-{4-[(2-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-488:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[{3-[(dimethylamino)methyl]azetidin-1-yl}(imino)methyl]benzamide-   I-489:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[imino(piperazin-1-yl)methyl]benzamide-   I-490:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[imino(3-methylpiperazin-1-yl)methyl]benzamide-   I-491:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]benzamide-   I-492:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[imino(4-methylpiperazin-1-yl)methyl]benzamide-   I-493:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide-   I-494:    1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)amino](imino)methyl]pyrrolidine-3-carboxamide-   I-495:    1-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)amino](imino)methyl]piperidine-3-carboxamide-   I-496:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[{4-[(cyclopropylcarbonyl)amino]piperidin-1-yl}(imino)methyl]benzamide-   I-497:    4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[(dimethylamino)(imino)methyl]benzamide-   I-498:    N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]cyclopropanecarboxamide-   I-499:    N-[[(4-{[9-Chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]-3-(dimethylamino)cyclopentanecarboxamide-   I-500:    4-({9-Chloro-7-[2-fluoro-6-(trifluoromethyl)phenyl]-5H-pyrimido-[5,4-d][2]benzazepin-2-yl}amino)benzoic    acid-   I-501:    4-{[9-Chloro-7-(2,6-dichlorophenyl)-5H>-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-502:    4-{[9-Chloro-7-(2-fluoro-6-methylphenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-503:    4-{[7-(2-Bromo-6-chlorophenyl)-9-chloro-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-504:    9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]-3-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-505:    4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)    (imino)methyl]-N-methylbenzamide-   I-506:    4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)    azetidin-1-yl](imino)methyl]-N-methylbenzamide-   I-507:    3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]benzamide-   I-508:    3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)    pyrrolidin-1-yl](imino)methyl]benzamide-   I-509:    9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1-yl)carbonyl]-4-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-510:    N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]-3-(dimethylamino)cyclopentanecarboxamide-   I-511:    N-[[(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}-2-fluorophenyl)amino](imino)methyl]-3-(dimethylamino)cyclopentanecarboxamide-   I-512:    N-[[(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}-2-fluorophenyl)amino](imino)methyl]-3-(dimethylamino)cyclopentanecarboxamide-   I-513:    N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-3,5-dimethylpiperazine-1-carboximidamide-   I-514:    4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)pyrrolidin-1-yl](imino)methyl]-N-methylbenzamide-   I-515:    N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5<i>H</i>-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}phenyl)-3,5-dimethylpiperazine-1-carboximidamide-   I-516:    N-(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide-   I-517:    3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-[[3-(dimethylamino)azetidin-1-yl](imino)methyl]benzamide-   I-518:    N-(5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-fluorophenyl)-N,3,5-trimethylpiperazine-1-carboximidamide-   I-519:    N-[[(3-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}phenyl)amino](imino)methyl]-3-(dimethylamino)cyclopentanecarboxamide-   I-520:    9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-521:    N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}phenyl)-N,3,5-trimethylpiperazine-1-carboximidamide-   I-522:    N-(4-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-fluorophenyl)-3,5-dimethylpiperazine-1-carboximidamide-   I-523:    9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]-3-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-524:    5-{[9-Chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-(2,6-dimethylpiperidin-4-yl)-1H-isoindole-1,3(2H)-dione-   I-525:    N-[2-(Aminomethyl)-1H-benzimidazol-6-yl]-9-chloro-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-526:    9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1H-benzimidazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-527:    9-Chloro-N-{2-[(dimethylamino)methyl]-1H-benzimidazol-6-yl}-7-(2-fluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-528:    9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzothiazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-529:    9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1H-benzimidazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-530:    9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzoxazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-531:    9-Chloro-7-(2-fluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzoxazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-532:    9-Chloro-7-(2,6-difluorophenyl)-N-{3-[(3,5-dimethylpiperazin-1-yl)(imino)methyl]-4-fluorophenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-533:    9-Chloro-7-(2,6-difluorophenyl)-N-{2-[(methylamino)methyl]-1,3-benzothiazol-6-yl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-534:    {3-[9-Chloro-7-(2,6-difluorophenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone-   I-535:    3-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-methyl-N-(4-methyl-pentyl)-benzamide

In one embodiment, the invention relates to a compound selected from thegroup consisting of:

-   I-52:    4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-135:    4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-174:    4-{[9-Chloro-7-(2-chloro-6-fluorophenyl)-5H-pyrimido-[5,4-d][2]benzazepin-2-yl]amino}benzoic    acid-   I-175:    9-Chloro-7-(2,6-difluorophenyl)-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-177:    9-Chloro-N-{4-[(3,5-dimethylpiperazin-1-yl)carbonyl]phenyl}-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-179:    9-Chloro-N-(4-{[3-(dimethylamino)azetidin-1-yl]carbonyl}phenyl)-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-183:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-dimethylamino-piperidin-1-yl)-methanone-   I-190:    4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoic    acid-   I-191:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3(S)-methyl-piperazin-1-yl)-methanone-   I-196:    (3-Amino-pyrrolidin-1-yl)-{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-methanone-   I-197:    {4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone-   I-199:    {4-[9-Chloro-7-(2-fluoro-6-methoxy-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(3-methylamino-pyrrolidin-1-yl)-methanone-   I-220:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-232:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-{4-[(3-methylpiperazin-1-yl)carbonyl]phenyl}-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-234: 9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(methylamino)    azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-235:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)azetidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-240:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-241:    N-{4-[(4-aminopiperidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-242:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[4-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-263:    9-chloro-7-(2-fluoro-6-methoxyphenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-286:    N-{4-[(3-aminoazetidin-1-yl)carbonyl]phenyl}-9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-293:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-310:    4-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperazine-2-carboxamide-   I-318:    N-{4-[(3-aminopyrrolidin-1-yl)carbonyl]-3-chlorophenyl}-9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-326:    9-chloro-7-(2-chloro-6-fluorophenyl)-N-(4-{[3-(methylamino)piperidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-341:    4-amino-1-(4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide-   I-383:    N-1-azabicyclo[2.2.2]oct-3-yl-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-N-methylbenzamide-   I-380:    9-chloro-7-(2,6-difluorophenyl)-N-(4-{[3-methyl-3-(methylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-amine-   I-396:    4-amino-1-(2-chloro-4-{[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}benzoyl)-N-methylpiperidine-4-carboxamide

The compounds of the present invention can be prepared by methods knownto one of ordinary skill in the art and/or by reference to the syntheticroutes set forth in Schemes 1, 2, and 3 below. One of ordinary skill inthe art will recognize that variations in reaction conditions, includingvariations in solvent, reagents, catalysts, and reaction temperature,may be possible for each of the reactions described below. Alternatesynthetic routes also are possible.

Scheme 1 depicts a general synthetic route for preparation of compoundsof formula (I) wherein each of rings A and B is an optionallysubstituted phenyl ring. One of ordinary skill in the art willappreciate that certain compounds of formula (I) wherein one or both ofrings A and B is other than phenyl can be prepared by a route analogousto that outlined in Scheme 1, by appropriate selection of the ketonestarting material in Method G.

Methods for the synthesis ofdimethylaminomethylene-benzo[c]azepin-5-ones of the formula v (seeScheme 1) have been described in U.S. Pat. Nos. 3,947,585, 4,022,801 and4,028,381. Methods for the conversion of compounds of formula v topyrimido[5,4-d][2]benzazepines lacking a Ring C substituent also areknown and have been described, e.g., in U.S. Pat. Nos. 4,318,854 and4,547,581. Compounds of the present invention (formula IIa), whichinclude Ring C, can be prepared by the reaction of compounds of formulav with aryl or heteroaryl guanidines, as illustrated in Scheme 1.

Methods for the synthesis of amino-substituted diaryl ketones of formula(i) are known, and exemplary synthetic procedures are described in theExamples. Conversion of (i) to the iodo-substituted diaryl ketone offormula (ii) can be accomplished by diazotization of the amine andiodide displacement, as exemplified in Method G. Compound (iii) can beprepared from (ii) by cross-coupling of the aryl iodide with a protectedpropargyl amine, according to Method I. In Scheme 1, an iodo-substituteddiaryl ketone is coupled with N-Boc-propargylamine, but those ofordinary skill in the art will recognize that other halogen-substituteddiaryl ketones and other protected propargylamines may be used.Additionally, a variety of catalysts, bases, solvents and temperaturesmay be employed for the cross-coupling reaction. For compounds whereinRing B is other than phenyl, the preparation of (iii) may alternativelybe accomplished by Method J, in which the Weinreb amide of a2-iodobenzoic acid is coupled with N-Boc-propargylamine, followed by alithiated Ring B.

Stepwise conversion of (iii) to (iv) can be effected by sequentialtreatment with mercury (II) sulfate, HCl/dioxane, andN,N-diisopropylethylamine, according to Method K. Alternatively, (iii)can be converted to (iv) by sequential treatment with aqueousHCl/dioxane and sodium carbonate, according to Method L. Those ofordinary skill in the art will recognize that aryl alkynes can behydrated with a variety of other strong acids, such as trifluoroaceticacid and sulfuric acid. Additionally, a variety of basic conditions canpromote the azepine imine bond formation.

Treatment of (iv) with N,N-dimethylformamide dimethyl acetal in varioussolvents and at various temperatures affords (v). Example 11 illustratesthe conversion of (iv) to (v) in toluene at 80° C. The conversion of (v)to the pyrimido compound (IIa) is accomplished by treatment with an arylor heteroaryl guanidine. The reaction may be performed by submitting areaction mixture containing (v), an aryl or heteroaryl guanidine, andN,N-diisopropylethylamine in DMF to microwave irradiation, according toMethod Q. Alternatively, the latter reaction may be performed in thepresence of potassium carbonate in refluxing ethanol, according toMethod R.

In some embodiments, preparation of (IIa) may alternatively beaccomplished by Method S, in which (v) is first treated with guanidinehydrochloride to form a 5H-benzo[c]pyrimido[4,5-e]azepin-2-yl amine.Conversion of the amine to the corresponding iodide, followed bycross-coupling with a heteroaryl amine then affords compound (Ha), inwhich Ring C is heteroaryl.

Scheme 2 depicts a general synthetic route for preparation of compoundsof formula (A-1) wherein Ring A is an optionally substituted 5- or6-membered aryl, heteroaryl, or heterocyclyl ring, Ring B is anoptionally substituted aryl, heterocyclyl, cycloaliphatic, or heteroarylring, and Ring C is a substituted or unsubstituted aryl, heteroaryl,heterocyclyl, or cycloaliphatic ring.

Methods for the synthesis of heterocyclic-substituted β-ketonitriles offormula (vi) are known and described in the literature e.g., Katritzkyet al, JOC (2003), 68(12), 4932-4934 and Bergman et al, Synthesis(2004), 16, 2760-2765. Treatment of compounds (vi) withN,N-dimethylformamide dimethyl acetal in various solvents and at varioustemperatures affords intermediate enaminone (vii). Methods for thesynthesis of intermediate enaminones of formula (vii) have been furtherdescribed in PCT Int. Appl. WO 00/78731.

The preparation of cyanopyrimidine (viii) may be accomplished bytreatment of enaminone (vii) with a mono-substituted guanidine, as shownin Step 2. The reaction may be performed by refluxing a reaction mixturecontaining (vii) and a guanidine in ethanol in the presence of potassiumcarbonate. Methods for the synthesis of intermediate pyrimidines offormula (viii) have been further described in PCT Int. Appl. WO00/78731.

As shown in Step 3, compound (viii) may be reduced to amine (ix) byhydrogenation in the presence of a metal catalyst, for example Raneynickel, as described by Price et al, J. Am. Chem. Soc. 68:766-9 (1946).Alternatively, the reduction may be carried out with a reducing agentsuch as LiAlH₄ as described by Thurkauf et al, Bioorg. & Med. Chem.Letters 13(17):2921-2924, (2003).

Conversion of amine (ix) to amide (x) can be accomplished by reaction of(ix) with an acid chloride in the presence of a base, or alternatively,with a carboxylic acid in the presence of a coupling reagent. Amide (x)may then be converted to the desired compound of formula (A-1) byheating with a cyclodehydration reagent such as polyphosphoric acid,phosphorus pentoxide/methanesulfonic acid, phosphorus oxychloride, orphosphorus oxychloride/tin(IV) chloride.

Scheme 3 depicts another general synthetic route for preparation ofcompounds of formula (A-1) wherein Ring A is an optionally substituted5- or 6-membered aryl, heteroaryl, or heterocyclyl ring, Ring B is anoptionally substituted aryl, heterocyclyl, cycloaliphatic, or heteroarylring, and Ring C is a substituted or unsubstituted aryl, heteroaryl,heterocyclyl, or cycloaliphatic ring.

Methods for the synthesis of heterocyclic-substituted carboxylic acidsof formula (xii) are well-known and are widely described in theliterature. Condensation of compound (xii) with a β-alanine esteraffords amide (xiii). Methods for the synthesis of intermediate amidesof formula (xiii) have been further described in the literature, e.g.,Portevin et al, Tetrahedron Letters, 44(52):9263-9265 (2003) andEl-Naggar et al, J. Indian Chem. Soc., 59(6):783-6 (1982).

The preparation of acid (xiv) may be accomplished by treatment of ester(xiii) with a dilute aqueous solution of an alkali-metal hydroxide,e.g., sodium or lithium hydroxide. Examples of this transformation havebeen described by Portevin et al, Tetrahedron Letters, 44(52):9263-9265(2003)

Compound (xiv) may be cyclized to azepinedione (xv) by treatment with acyclodehydration reagent, for example polyphosphoric acid (PPA), asdescribed by Annoura et al, Tetrahedron Letters 36(3):413-16 (1995).

The preparation of enaminones (xvi) may be accomplished by treatment ofcompounds (xv) with N,N-dimethylformamide dimethyl acetal. The reactionmay be performed in various solvents and at various temperatures.

The preparation of pyrimidinoazepinone (xvii) may be accomplished bytreatment of enaminone (xvi) with a mono-substituted guanidine. Thereaction may be performed by refluxing a reaction mixture containing(xvi) and a guanidine in an alcoholic solvent in the presence ofpotassium carbonate.

Conversion of pyrimidinoazepinone (xvii) to imidoyl chloride (xviii) maybe accomplished by reaction of (xvii) with a chlorinating reagent,typically POCl₃ or SOCl₂. Compound (xviii) may then be cross-coupledwith an organoboronic acid using palladium catalysis to yield azepine(xi), following the method of Nadin et al, J. Org. Chem., 68(7),2844-2852 (2003).

The compounds of this invention are inhibitors of Aurora kinase. Thecompounds can be assayed in vitro or in vivo for their ability to bindto and/or inhibit an Aurora kinase. In vitro assays include assays todetermine inhibition of the ability of an Aurora kinase to phosphorylatea substrate protein or peptide. Alternate in vitro assays quantitate theability of the compound to bind to an Aurora kinase. Inhibitor bindingmay be measured by radiolabelling the inhibitor prior to binding,isolating the inhibitor/Aurora kinase complex and determining the amountof radiolabel bound. Alternatively, inhibitor binding may be determinedby running a competition experiment in which new inhibitors areincubated with Aurora kinase bound to a known radioligand. The compoundsalso can be assayed for their ability to affect cellular orphysiological functions mediated by Aurora kinase activity. Assays foreach of these activities are described in the Examples and/or are knownin the art.

In another aspect, therefore, the invention provides a method forinhibiting Aurora kinase activity in a cell, comprising contacting acell in which inhibition of Aurora kinase is desired with an Aurorakinase inhibitor of formula (I). In some embodiments, the Aurora kinaseinhibitor interacts with and reduces the activity of all enzymes of theAurora kinase family in the cell. In some other embodiments, the Aurorakinase inhibitor interacts with and reduces the activity of fewer thanall Aurora kinase enzymes in the cell. In certain preferred embodiments,the Aurora kinase inhibitor selectively inhibits one Aurora kinaseenzyme in the cell.

Preferably, the method according to this aspect of the invention causesan inhibition of cell proliferation of the contacted cells. The phrase“inhibiting cell proliferation” is used to denote an ability of aninhibitor of Aurora kinase to inhibit cell number or cell growth incontacted cells as compared to cells not contacted with the inhibitor.An assessment of cell proliferation can be made by counting cells usinga cell counter or by an assay of cell viability, e.g., an MTT, XTT, orWST assay. Where the cells are in a solid growth (e.g., a solid tumor ororgan), such an assessment of cell proliferation can be made bymeasuring the growth, e.g., with calipers, and comparing the size of thegrowth of contacted cells with non-contacted cells.

Preferably, the growth of cells contacted with the inhibitor is retardedby at least about 50% as compared to growth of non-contacted cells. Invarious embodiments, cell proliferation of contacted cells is inhibitedby at least about 75%, at least about 90%, or at least about 95% ascompared to non-contacted cells. In some embodiments, the phrase“inhibiting cell proliferation” includes a reduction in the number ofcontacted cells, as compare to non-contacted cells. Thus, an inhibitorof Aurora kinase that inhibits cell proliferation in a contacted cellmay induce the contacted cell to undergo growth retardation, to undergogrowth arrest, to undergo programmed cell death (i.e., apoptosis), or toundergo necrotic cell death.

In another aspect, the invention provides a pharmaceutical compositioncomprising a compound of formula (I) as defined above, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier.

If pharmaceutically acceptable salts of the compounds of the inventionare utilized in these compositions, the salts preferably are derivedfrom inorganic or organic acids and bases. For reviews of suitablesalts, see, e.g., Berge et al, J. Pharm. Sci. 66:1-19 (1977) andRemington: The Science and Practice of Pharmacy, 20th Ed., ed. A.Gennaro, Lippincott Williams & Wilkins, 2000.

Nonlimiting examples of suitable acid addition salts include thefollowing: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate,hexanoate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate,2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate,persulfate, 3-phenyl-propionate, picrate, pivalate, propionate,succinate, tartrate, thiocyanate, tosylate and undecanoate.

Suitable base addition salts include, without limitation, ammoniumsalts, alkali metal salts, such as sodium and potassium salts, alkalineearth metal salts, such as calcium and magnesium salts, salts withorganic bases, such as dicyclohexylamine, N-methyl-D-glucamine,t-butylamine, ethylene diamine, ethanolamine, and choline, and saltswith amino acids such as arginine, lysine, and so forth. For example,compounds of formula (V), wherein Ring C is substituted with —CO₂H maybe formulated as the corresponding sodium salts.

Also, basic nitrogen-containing groups may be quaternized with suchagents as lower alkyl halides, such as methyl, ethyl, propyl, and butylchloride, bromides and iodides; dialkyl sulfates, such as dimethyl,diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl,lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkylhalides, such as benzyl and phenethyl bromides and others. Water oroil-soluble or dispersible products are thereby obtained.

The term “pharmaceutically acceptable carrier” is used herein to referto a material that is compatible with a recipient subject, preferably amammal, more preferably a human, and is suitable for delivering anactive agent to the target site without terminating the activity of theagent. The toxicity or adverse effects, if any, associated with thecarrier preferably are commensurate with a reasonable risk/benefit ratiofor the intended use of the active agent.

The pharmaceutical compositions of the invention can be manufactured bymethods well known in the art such as conventional granulating, mixing,dissolving, encapsulating, lyophilizing, or emulsifying processes, amongothers. Compositions may be produced in various forms, includinggranules, precipitates, or particulates, powders, including freezedried, rotary dried or spray dried powders, amorphous powders, tablets,capsules, syrup, suppositories, injections, emulsions, elixirs,suspensions or solutions. Formulations may optionally containstabilizers, pH modifiers, surfactants, bioavailability modifiers andcombinations of these.

Pharmaceutical formulations may be prepared as liquid suspensions orsolutions using a liquid, such as, but not limited to, an oil, water, analcohol, and combinations of these. Pharmaceutically suitablesurfactants, suspending agents, or emulsifying agents, may be added fororal or parenteral administration. Suspensions may include oils, such asbut not limited to, peanut oil, sesame oil, cottonseed oil, corn oil andolive oil. Suspension preparation may also contain esters of fatty acidssuch as ethyl oleate, isopropyl myristate, fatty acid glycerides andacetylated fatty acid glycerides. Suspension formulations may includealcohols, such as, but not limited to, ethanol, isopropyl alcohol,hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as butnot limited to, poly(ethyleneglycol), petroleum hydrocarbons such asmineral oil and petrolatum; and water may also be used in suspensionformulations.

Pharmaceutically acceptable carriers that may be used in thesecompositions include, but are not limited to, ion exchangers, alumina,aluminum stearate, lecithin, serum proteins, such as human serumalbumin, buffer substances such as phosphates, glycine, sorbic acid,potassium sorbate, partial glyceride mixtures of saturated vegetablefatty acids, water, salts or electrolytes, such as protamine sulfate,disodium hydrogen phosphate, potassium hydrogen phosphate, sodiumchloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodiumcarboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

According to a preferred embodiment, the compositions of this inventionare formulated for pharmaceutical administration to a mammal, preferablya human being. Such pharmaceutical compositions of the present inventionmay be administered orally, parenterally, by inhalation spray,topically, rectally, nasally, buccally, vaginally or via an implantedreservoir. The term “parenteral” as used herein includes subcutaneous,intravenous, intramuscular, intra-articular, intra-synovial,intrasternal, intrathecal, intrahepatic, intralesional and intracranialinjection or infusion techniques. Preferably, the compositions areadministered orally, intravenously, or subcutaneously. The formulationsof the invention may be designed to be short-acting, fast-releasing, orlong-acting. Still further, compounds can be administered in a localrather than systemic means, such as administration (e.g., by injection)at a tumor site.

Sterile injectable forms of the compositions of this invention may beaqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally acceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilmay be employed including synthetic mono- or di-glycerides. Fatty acids,such as oleic acid and its glyceride derivatives are useful in thepreparation of injectables, as are natural pharmaceutically-acceptableoils, such as olive oil or castor oil, especially in theirpolyoxyethylated versions. These oil solutions or suspensions may alsocontain a long-chain alcohol diluent or dispersant, such ascarboxymethyl cellulose or similar dispersing agents which are commonlyused in the formulation of pharmaceutically acceptable dosage formsincluding emulsions and suspensions. Other commonly used surfactants,such as Tweens, Spans and other emulsifying agents or bioavailabilityenhancers which are commonly used in the manufacture of pharmaceuticallyacceptable solid, liquid, or other dosage forms may also be used for thepurposes of formulation. Compounds may be formulated for parenteraladministration by injection such as by bolus injection or continuousinfusion. A unit dosage form for injection may be in ampoules or inmulti-dose containers.

The pharmaceutical compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers that are commonly used includelactose and corn starch. Lubricating agents, such as magnesium stearate,are also typically added. For oral administration in a capsule form,useful diluents include lactose and dried cornstarch. When aqueoussuspensions are required for oral use, the active ingredient is combinedwith emulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions of this invention may beadministered in the form of suppositories for rectal administration.These may be prepared by mixing the agent with a suitable non-irritatingexcipient which is solid at room temperature but liquid at rectaltemperature and therefore will melt in the rectum to release the drug.Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also beadministered topically, especially when the target of treatment includesareas or organs readily accessible by topical application, includingdiseases of the eye, the skin, or the lower intestinal tract. Suitabletopical formulations are readily prepared for each of these areas ororgans.

Topical application for the lower intestinal tract may be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-transdermal patches may also be used. For topicalapplications, the pharmaceutical compositions may be formulated in asuitable ointment containing the active component suspended or dissolvedin one or more carriers. Carriers for topical administration of thecompounds of this invention include, but are not limited to, mineraloil, liquid petrolatum, white petrolatum, propylene glycol,polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.Alternatively, the pharmaceutical compositions may be formulated in asuitable lotion or cream containing the active components suspended ordissolved in one or more pharmaceutically acceptable carriers. Suitablecarriers include, but are not limited to, mineral oil, sorbitanmonostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol,2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated asmicronized suspensions in isotonic, pH adjusted sterile saline, or,preferably, as solutions in isotonic, pH adjusted sterile saline, eitherwith our without a preservative such as benzylalkonium chloride.Alternatively, for ophthalmic uses, the pharmaceutical compositions maybe formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also beadministered by nasal aerosol or inhalation. Such compositions areprepared according to techniques well known in the art of pharmaceuticalformulation and may be prepared as solutions in saline, employing benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, fluorocarbons, and/or other conventional solubilizingor dispersing agents.

The pharmaceutical compositions of this invention are particularlyuseful in therapeutic applications relating to an Aurora kinase-mediateddisorder. As used herein, the term “Aurora kinase-mediated disorder”includes any disorder, disease or condition which is caused orcharacterized by an increase in Aurora kinase expression or activity, orwhich requires Aurora kinase activity. The term “Aurora kinase-mediateddisorder” also includes any disorder, disease or condition in whichinhibition of Aurora kinase activity is beneficial. Aurorakinase-mediated disorders include proliferative disorders. Non-limitingexamples of proliferative disorders include chronic inflammatoryproliferative disorders, e.g., psoriasis and rheumatoid arthritis;proliferative ocular disorders, e.g., diabetic retinopathy; benignproliferative disorders, e.g., hemangiomas; and cancer.

Preferably, the composition is formulated for administration to apatient having or at risk of developing or experiencing a recurrence ofan Aurora kinase-mediated disorder. The term “patient”, as used herein,means an animal, preferably a mammal, more preferably a human. Preferredpharmaceutical compositions of the invention are those formulated fororal, intravenous, or subcutaneous administration. However, any of theabove dosage forms containing a therapeutically effective amount of acompound of the invention are well within the bounds of routineexperimentation and therefore, well within the scope of the instantinvention. In some embodiments, the pharmaceutical composition of theinvention may further comprise another therapeutic agent. Preferably,such other therapeutic agent is one normally administered to patientswith the disease or condition being treated.

By “therapeutically effective amount” is meant an amount sufficient tocause a detectable decrease in Aurora kinase activity or the severity ofan Aurora kinase-mediated disorder. The amount of Aurora kinaseinhibitor needed will depend on the effectiveness of the inhibitor forthe given cell type and the length of time required to treat thedisorder. It should also be understood that a specific dosage andtreatment regimen for any particular patient will depend upon a varietyof factors, including the activity of the specific compound employed,the age, body weight, general health, sex, and diet of the patient, timeof administration, rate of excretion, drug combinations, the judgment ofthe treating physician, and the severity of the particular disease beingtreated. The amount of additional therapeutic agent present in acomposition of this invention typically will be no more than the amountthat would normally be administered in a composition comprising thattherapeutic agent as the only active agent. Preferably, the amount ofadditional therapeutic agent will range from about 50% to about 100% ofthe amount normally present in a composition comprising that agent asthe only therapeutically active agent.

In another aspect, the invention provides a method for treating apatient having or at risk of developing or experiencing a recurrence ofan Aurora kinase-mediated disorder. The method comprises the step ofadministering to the patient a compound or pharmaceutical compositionaccording to the invention. The compounds and pharmaceuticalcompositions of the invention can be used to achieve a beneficialtherapeutic or prophylactic effect, for example, in a patient with aproliferative disorder, as discussed above. The compounds andpharmaceutical compositions of the invention are particularly useful forthe treatment of cancer.

As used herein, the term “cancer” refers to a cellular disordercharacterized by uncontrolled or disregulated cell proliferation,decreased cellular differentiation, inappropriate ability to invadesurrounding tissue, and/or ability to establish new growth at ectopicsites. The term “cancer” includes, but is not limited to, solid tumorsand bloodborne tumors. The term “cancer” encompasses diseases of skin,tissues, organs, bone, cartilage, blood, and vessels. The term “cancer”further encompasses primary and metastatic cancers.

Non-limiting examples of solid tumors that can be treated by the methodsof the invention include pancreatic cancer; bladder cancer; colorectalcancer; breast cancer, including metastatic breast cancer; prostatecancer, including androgen-dependent and androgen-independent prostatecancer; renal cancer, including, e.g., metastatic renal cell carcinoma;hepatocellular cancer; lung cancer, including, e.g., non-small cell lungcancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinomaof the lung; ovarian cancer, including, e.g., progressive epithelial orprimary peritoneal cancer; cervical cancer; gastric cancer; esophagealcancer; head and neck cancer, including, e.g., squamous cell carcinomaof the head and neck; melanoma; neuroendocrine cancer, includingmetastatic neuroendocrine tumors; brain tumors, including, e.g., glioma,anaplastic oligodendroglioma, adult glioblastoma multiforme, and adultanaplastic astrocytoma; bone cancer; and soft tissue sarcoma.

In some other embodiments, the cancer is a hematologic malignancy.Non-limiting examples of hematologic malignancy include acute myeloidleukemia (AML); chronic myelogenous leukemia (CML), includingaccelerated CML and CML blast phase (CML-BP); acute lymphoblasticleukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's disease(HD); non-Hodgkin's lymphoma (NHL), including follicular lymphoma andmantle cell lymphoma; B-cell lymphoma; T-cell lymphoma; multiple myeloma(MM); Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS),including refractory anemia (RA), refractory anemia with ringedsiderblasts (RARS), (refractory anemia with excess blasts (RAEB), andRAEB in transformation (RAEB-T); and myeloproliferative syndromes.

In some embodiments, the compound or composition of the invention isused to treat a cancer in which the activity of an Aurora kinase isamplified. In some embodiments, the compound or composition of theinvention is used to treat a patient having or at risk of developing orexperiencing a recurrence in a cancer selected from the group consistingof colorectal cancer, ovarian cancer, breast cancer, gastric cancer,prostate cancer, and pancreatic cancer. In certain embodiments, thecancer is selected from the group consisting of breast cancer,colorectal cancer, and pancreatic cancer.

In some embodiments, the Aurora kinase inhibitor of the invention isadministered in conjunction with another therapeutic agent. The othertherapeutic agent may also inhibit Aurora kinase or may operate by adifferent mechanism. In some embodiments, the other therapeutic agent isone that is normally administered to patients with the disease orcondition being treated. The Aurora kinase inhibitor of the inventionmay be administered with the other therapeutic agent in a single dosageform or as a separate dosage form. When administered as a separatedosage form, the other therapeutic agent may be administered prior to,at the same time as, or following administration of the Aurora kinaseinhibitor of the invention.

In some embodiments, the Aurora kinase inhibitor of the invention isadministered in conjunction with a therapeutic agent selected from thegroup consisting of cytotoxic agents, radiotherapy, and immunotherapy.Non-limiting examples of cytotoxic agents suitable for use incombination with the Aurora kinase inhibitors of the invention include:antimetabolites, including, e.g., capecitibine, gemcitabine,5-fluorouracil or 5-fluorouracil/leucovorin, fludarabine, cytarabine,mercaptopurine, thioguanine, pentostatin, and methotrexate;topoisomerase inhibitors, including, e.g., etoposide, teniposide,camptothecin, topotecan, irinotecan, doxorubicin, and daunorubicin;vinca alkaloids, including, e.g., vincristine and vinblastin; taxanes,including, e.g., paclitaxel and docetaxel; platinum agents, including,e.g., cisplatin, carboplatin, and oxaliplatin; antibiotics, including,e.g., actinomycin D, bleomycin, mitomycin C, adriamycin, daunorubicin,idarubicin, doxorubicin and pegylated liposomal doxorubicin; alkylatingagents such as melphalan, chlorambucil, busulfan, thiotepa, ifosfamide,carmustine, lomustine, semustine, streptozocin, decarbazine, andcyclophosphamide; thalidomide and related analogs, including, e.g.,CC-5013 and CC-4047; protein tyrosine kinase inhibitors, including,e.g., imatinib mesylate and gefitinib; antibodies, including, e.g.,trastuzumab, rituximab, cetuximab, and bevacizumab; mitoxantrone;dexamethasone; prednisone; and temozolomide.

In order that this invention be more fully understood, the followingpreparative and testing examples are set forth. These examplesillustrate how to make or test specific compounds, and are not to beconstrued as limiting the scope of the invention in any way.

EXAMPLES

Definitions AcOH acetic acid ATP adenosine triphosphate BSA bovine serumalbumin Boc tert-butoxycarbonyl DMF N,N-dimethylformamide DTTdithiothreitol EDTA ethylenediaminetetraacetic acid EtOAc ethyl acetateEt₂O diethyl ether MeOH methanol MTT methylthiazoletetrazolium XTT2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- carboxanilideinner salt WST(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3- benzenedisulfonate sodium salt PKA cAMP-dependent protein kinase PPApolyphosphoric acid TBTUO-Benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate THFtetrahydrofuran h hours min minutes m/z mass to charge MS mass spectrumHRMS high resolution mass spectrum

Example 1: Method a for the Synthesis of Compounds of Formula (i) (SeeScheme 1)

(2-Amino-4-methoxy-phenyl)-(2-fluoro-phenyl)-methanone (1h)

3-Anisidine (1.0 g, 8.0 mmol) was added dropwise to a stirred solutionof BCl₃ (1M in CH₂Cl₂, 8.8 mL, 8.8 mmol) in anhydrous CH₂Cl₂ (20 mL) at0° C. AlCl₃ (1.15 g, 8.8 mmol) was added in one portion followed by2-fluorobenzonitrile (1.6 mL, 16.0 mmol). The mixture was refluxed for16 h and then cooled to 0° C. HCl (2N, 30 mL) was added and the mixturewas heated to 80° C. and stirred vigorously for 30 min. Upon cooling toroom temperature, the mixture was extracted with CH₂Cl₂ (3×50 mL). Thecombined organic portions were washed with brine, dried over MgSO₄,filtered and evaporated in vacuo. The resulting brown oil was purifiedby column chromatography (silica gel, Hexanes:EtOAc, 4:1) to provide 1h(1.1 g, 56%), MS m/z=246 (M+H).

(2-Amino-3-methyl-phenyl)-(2-fluoro-phenyl)-methanone (1b)

In a manner similar to that described above for compound 1h,o-tolylamine and 2-fluorobenzonitrile were converted to 1b (20% yield)MS m/z=230 (M+H).

(2-Amino-4-fluoro-phenyl)-(2-fluoro-phenyl)-methanone (1c)

In a manner similar to that described above for compound 1h,3-fluoro-phenylamine and 2-fluorobenzonitrile were converted to 1c (25%yield) MS m/z=234 (M+H).

(2-Amino-4-bromo-phenyl)-(2-fluoro-phenyl)-methanone (1e)

In a manner similar to that described above for compound 1h,3-bromo-phenylamine and 2-fluorobenzonitrile were converted to 1e (15%yield) MS m/z=294/296 (M+H).

(2-Amino-4-methyl-phenyl)-(2-fluoro-phenyl)-methanone (1g)

In a manner similar to that described above for compound 1h,m-tolylamine and 2-fluorobenzonitrile were converted to 1g (44% yield)MS m/z=230 (M+H).

(2-Amino-4,5-dichloro-phenyl)-(2-fluoro-phenyl)-methanone (1ad)

In a manner similar to that described above for compound 1h,3,4-dichloroaniline and 2-fluorobenzonitrile were converted to 1ad (17%yield) MS m/z=284 (M+H).

(2-Amino-5-isopropyl-phenyl)-(2-fluoro-phenyl)-methanone (1ag)

In a manner similar to that described above for compound 1h,4-isopropylaniline and 2-fluorobenzonitrile were converted to 1ag (22%yield) MS m/z=258 (M+H).

Example 2: Method B for the Synthesis of Compounds of Formula (i)

(2-Amino-5-methyl-phenyl)-(2-fluoro-phenyl)-methanone (1af)

2-Iodofluorobenzene (2.0 mL, 17 mmol) was dissolved in anhydrous THF (20mL) under an argon atmosphere and cooled to −20° C. A solution ofisopropyl magnesium chloride (8.5 mL, 17.0 mmol) was slowly added, andthe solution was stirred for 20 min. 2-Nitro-5-methylbenzaldehyde (2.7g, 16.5 mmol) in THF (20 mL) was then added, and the mixture was stirredfor 20 min at −20° C. and then quenched with saturated aqueous NH₄Cl.The mixture was partitioned between EtOAc (100 mL) and H₂O (100 mL). Theorganic portion was collected, dried over MgSO₄, filtered and evaporatedin vacuo. This material was dissolved in anhydrous CH₂Cl₂ (80 mL).Silica gel (20.3 g) and pyridinium chlorochromate (5.4 g, 25 mmol) werethen added and the suspension was stirred at room temperature for 3 h.The mixture was then filtered through silica gel. The filtrate wasconcentrated in vacuo and the resulting residue was purified by columnchromatography (silica gel, hexanes:EtOAc, 3:2) to provide the2-nitro-benzophenone (3.7 g, 14 mmol). The benzophenone was dissolved inglacial acetic acid (50 mL), MeOH (50 mL) and deionized H₂O (10 mL).Iron powder (<10 micron, 1.0 g) was added with vigorous stirring and thesuspension heated to 60° C. After 20 min, additional iron powder (2.0 g)was added and the mixture was stirred at 60° C. for 3 h. After cooling,silica gel (12.5 g) was added and the volatile components were removedin vacuo. The resulting powder was suspended in EtOAc (100 mL) andcarefully treated with 1N NaOH until basic to litmus. The suspension wasfiltered and the organic portion was separated, washed with brine, driedover MgSO₄, filtered and evaporated in vacuo. The resulting residue waspurified by column chromatography (silica gel, hexanes:EtOAc, 1:3) toprovide 1af (3.1 g, 94%) MS m/z=230 (M+H).

(2-Amino-4-trifluoromethyl-phenyl)-(2-fluoro-phenyl)-methanone (1f)

In a manner similar to that described above for compound 1af,2-nitro-4-trifluoromethyl-benzaldehyde was converted to 1f (46% yield)MS m/z=230 (M+H).

(2-Amino-5-fluoro-phenyl)-(2-fluoro-phenyl)-methanone (1j)

In a manner similar to that described above for compound 1af,5-Fluoro-2-nitro-benzaldehyde was converted to 1j (60% yield) MS m/z=234(M+H).

(2-Amino-5-methoxy-phenyl)-(2-fluoro-phenyl)-methanone (1ah)

In a manner similar to that described above for compound 1af,5-methoxy-2-nitro-benzaldehyde was converted to 1ah (62% yield) MSm/z=246 (M+H).

Example 3: Method C for the Synthesis of Compounds of the Formula (i)

(2-Amino-5-chloro-phenyl)-(2-methyl-phenyl)-methanone (1m)

Benzoyl chloride (5.3 mL, 45 mmol) was added dropwise to a suspension ofNa₂CO₃ (3.8 g, 36 mmol) and 2-amino-5-chloro-benzoic acid (3.1 g, 18mmol) in THF (60 mL). The mixture was allowed to stir for 16 h and thenH₂O (200 mL) was added. The resulting precipitate was collected byfiltration, washed with MeOH/H₂O (1/1, 100 mL) and then dried in vacuoto provide 6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one (4.3 g, 92%). Toa suspension of the benzoxazinone (5.0 g, 19 mmol) in CH₂Cl₂ (100 mL) at−78° C. was added o-tolylmagnesium chloride (2 M in THF, 48 mmol)dropwise. The mixture was allowed to warm to −30° C. and stir for 1 h.1N HCl (100 mL) was then added. The organic phase was collected and theaqueous phase was washed with CH₂Cl₂ (2×50 mL). The combined organicportions were washed with 0.1N NaOH (2×50 mL), dried over MgSO₄,filtered and concentrated in vacuo to provideN-[4-chloro-2-(2-methyl-benzoyl)-phenyl]-benzamide (6.3 g, 93%). Theacylated amino-benzophenone (3.5 g, 10 mmol) was dissolved in MeOH (50mL) containing KOH (3 M, 30 mmol) and was refluxed for 16 h. Thesolution was then cooled to room temperature and diluted with H₂O (50mL) and EtOAc (100 mL). The organic phase was collected, washed with H₂O(3×50 mL), dried over MgSO₄, filtered and evaporated to dryness in vacuoto provide 1m (2.4 g, 98%) MS m/z=246 (M+H).

(2-Amino-5-chloro-phenyl)-(2-methoxy-phenyl)-methanone (1n)

In a manner similar to that described above for compound 1m,6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one was converted to 1n (84%yield) MS m/z=262 (M+H).

(2-Amino-5-chloro-phenyl)-(2-dimethylaminomethyl-phenyl)-methanone (1q)

To a solution of N-[4-chloro-2-(2-methyl-benzoyl)-phenyl]-benzamide (5.1g, 14.6 mmol) and N-bromosuccinimide (2.85 g, 16 mmol) in CCl₄ (150 mL)was added 2,2′-azobisisobutrylnitrile (0.2 g, 1.5 mmol). The solutionwas refluxed for 4 h. The solution was then cooled to room temperature,diluted with CH₂Cl₂ (150 mL) and washed with H₂O (3×50 mL). The organicportion was dried over Na₂SO₄ and evaporated to dryness in vacuo toprovide N-[2-(2-bromomethyl-benzoyl)-4-chloro-phenyl]-benzamide (4.6 g,74%). A solution of the benzamide (2.3 g, 5.4 mmol) in CH₂Cl₂ (50 mL)was saturated with dimethylamine, stirred for 16 h and evaporated todryness in vacuo. The resulting residue was dissolved in MeOH (50 mL)and KOH (0.9 g, 16 mmol) in H₂O (5 mL) was added. The solution wasrefluxed for 24 h. The solution was concentrated in vacuo and thendiluted with EtOAc (150 mL) and H₂O (50 mL). The organic portion waswashed with H₂O (3×50 mL), dried over Na₂SO₄ and purified by columnchromatography (silica gel, 18:80:2 MeOH:CH₂Cl₂:NHOH) to provide 1q(0.9g, 53% yield) MS m/z=289 (M+H).

(2-Amino-5-chloro-phenyl)-(3-fluoro-phenyl)-methanone (1r)

In a manner similar to that described above for compound 1m,6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one was converted to 1r (36%yield) MS m/z=250 (M+H).

(2-Amino-5-chloro-phenyl)-(3-methoxy-phenyl)-methanone (1s)

In a manner similar to that described above for compound 1m,6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one was converted to 1s (64%yield) MS m/z=262 (M+H).

(2-Amino-5-chloro-phenyl)-(2,4-dimethoxy-phenyl)-methanone (1x)

In a manner similar to that described above for compound 1m,6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one was converted to 1x (63%yield) MS m/z=292 (M+H).

(2-Amino-5-chloro-phenyl)-(2,5-dimethoxy-phenyl)-methanone (1z)

In a manner similar to that described above for compound 1m,6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one was converted to 1z (62%yield) MS m/z=292 (M+H).

Example 4: Method D for the Synthesis of Compounds of the Formula (i)

(2-Amino-5-chloro-phenyl)-(2-fluoro-6-methoxy-phenyl)-methanone (1ac)

To a solution of 1-fluoro-3-methoxy-benzene (19.6 g, 155 mmol) in THF(180 mL), at −78° C., was added dropwise 2.5 M n-butyllithium in hexanes(62 mL, 155 mmol). The solution was stirred at −78° C. for 3 h and thenadded to a suspension of 6-chloro-2-phenyl-benzo[d][1,3]oxazin-4-one(38.8 g, 150 mmol) in THF (280 mL) at −20° C. The mixture was allowed togradually warm until the solution became homogenous. 1N HCl (150 mL)followed by EtOAc (250 mL) were then added and the solution allowed towarm to room temperature. The organic portion was collected and washedwith H₂O (250 mL), saturated NaHCO₃ (2×250 mL) and H₂O (250 mL). Theorganic portion was then dried over Na₂SO₄ and evaporated to dryness, invacuo, to provide theN-[4-Chloro-2-(2-fluoro-6-methoxy-benzoyl)-phenyl]-benzamide as anorange solid (42.7 g). To a solution ofN-[4-Chloro-2-(2-fluoro-6-methoxy-benzoyl)-phenyl]-benzamide (42.7 g,110 mmol) in MeOH (540 mL) was added KOH (56.4 g, 1 mole) in H₂O (100mL). The solution was allowed to reflux for 16 h. The solution was thenallowed to cool to room temperature and the resulting precipitateremoved by filtration. The filtrate was concentrated in vacuo, dilutedwith EtOAc (250 mL) and washed with H₂O (3×100 mL). The organic portionwas then dried over Na₂SO₄, concentrated in vacuo and then purified bycolumn chromatography (silica gel, 0 to 15% EtOAc/hexanes) to provide1ac (19.6 g, 47%) MS m/z=280 (M+H).

Example 5: Method E for the Synthesis of Compounds of the Formula (i)

(2-Amino-5-chloro-phenyl)-(4-fluoro-phenyl)-methanone (1t)

To p-fluorobenzoyl chloride (49.7 g, 314 mmol), heated to 120° C., wasadded p-chloroaniline (17.8 g, 139 mmol) over 10 min. The mixture wasthen heated to 180° C. and ZnCl₂ (23.8 g, 174 mmol) was added over 10min. The resulting mixture was heated at 205° C. for 2 h. After coolingto 120° C., 3N HCl (125 mL) was added cautiously and the mixture wasmaintained at 120° C. for 1 h. The hot aqueous portion was then decantedand the remaining residue was washed with hot 3N HCl (2×125 mL). Theresidue was poured onto ice and extracted with CH₂Cl₂ (3×100 mL). Thecombined organic portions were washed with 3N HCl (2×50 mL), 5N NaOH(2×50 mL) and H₂O (3×50 mL) and were then dried over MgSO₄, filtered andconcentrated in vacuo to provide 15 g (29%) of theN-[4-chloro-2-(4-fluoro-benzoyl)-phenyl]-4-fluoro-benzamide as a darkyellow powder. To a flask containing the acylated amino-benzophenone(6.7 g, 18 mmol) was added 1:1 conc. HCl:AcOH (700 mL) and the resultingmixture was heated to 105° C. and stirred for 16 h. The mixture wascooled to room temperature and concentrated in vacuo. The residue waspoured onto ice and extracted with CH₂Cl₂ (3×100 mL). The combinedorganic portions were washed with 5N NaOH (2×50 mL) and H₂O (3×50 mL)and then dried over MgSO₄, filtered and evaporated in vacuo. Theresulting residue was purified by column chromatography (silica gel, 5to 25% EtOAc/hexanes) and recrystallized from hexanes to provide 1t (3.4g, 76%) MS m/z=250 (M+H).

(2-Amino-5-chloro-phenyl)-(4-methoxy-phenyl)-methanone (1u)

To a solution ofN-[4-chloro-2-(4-fluoro-benzoyl)-phenyl]-4-fluoro-benzamide (6.0 g, 16mmol), prepared as described above for compound is, in MeOH (400 mL) wasadded 5N NaOH (50 mL) and the resulting solution was allowed to refluxfor 16 h. The solution was cooled to room temperature and concentratedin vacuo. The aqueous portion was extracted with CH₂Cl₂ (2×100 mL). Thecombined organic portions were washed with H₂O (3×50 mL), dried overMgSO₄, filtered and evaporated in vacuo. The resulting residue waspurified by column chromatography (silica gel, 5 to 25% EtOAc/hexanes)and recrystallized from MeOH to provide 1u (3.5 g, 83%) as a lightyellow powder MS m/z=262 (M+H).

(2-Amino-5-methyl-phenyl)-(2,6-difluoro-phenyl)-methanone (1aj)

In a manner similar to that described above for compound it, p-toluidineand 2,6-difluorobenzoyl chloride were converted to 1aj (16% yield) MSm/z=248 (M+H).

Example 6: Method F for the Synthesis of Compounds of Formula (i)

(2-Amino-5-chloro-phenyl)-(2,6-difluoro-phenyl)-methanone (1aa)

4-Chloro-N-Boc-aniline (3.4 g, 15 mmol) was dissolved in dryinhibitor-free THF (40 mL) under argon and cooled to −78° C. t-BuLi (1.7M in pentane, 20 mL, 34 mmol) was cooled in a dry ice/acetone bath andadded to the Boc-aniline solution, via a cannula, over 20 min. Theyellow solution was stirred at −78° C. for 30 min, warmed to −30° C. foran additional 2.5 h, and then cooled to −78° C. 2,6-Difluorobenzoylchloride (2.8 g, 16 mmol) was dissolved in dry THF (30 mL) and cooled to−78° C. under argon. The o-lithiated aniline was added, via a cannula,to the acid chloride solution over 30 min. The solution was stirred foran additional 20 min before quenching with 1N HCl (50 mL). The solutionwas diluted with EtOAc and the organic portion was separated, dried overMgSO₄ and concentrated to dryness in vacuo. The resulting orange oil waspurified by column chromatography (silica gel, Hexanes:EtOAc 4:1) toprovide the Boc protected amino-benzophenone (3.3 g, 60%). TheN-Boc-aminobenzophenone was dissolved in dry CH₂Cl₂ (50 mL) andtrifluoroacetic acid (50 mL) was added. After stirring for 1 h, thesolution was evaporated to dryness in vacuo. The resulting residue wasdissolved in EtOAc (100 mL) and water (100 mL) containing NaHCO₃. Theorganic portion was washed with a saturated aqueous NaHCO₃ solution,dried over MgSO₄, and concentrated to dryness in vacuo to provide,quantitatively, 1aa MS m/z=268 (M+H).

(2-Amino-5-chloro-phenyl)-(2,3-difluoro-phenyl)-methanone (1v)

In a manner similar to that described above for compound 1aa,4-Chloro-N-Boc-aniline and 2,3-difluoro-benzoyl chloride were convertedto 1v (14% yield) MS m/z=268 (M+H).

(2-Amino-5-chloro-phenyl)-(2,4-difluoro-phenyl)-methanone (1w)

In a manner similar to that described above for compound 1aa,4-Chloro-N-Boc-aniline and 2,4-difluoro-benzoyl chloride were convertedto 1w (20% yield) MS m/z=268 (M+H).

(2-Amino-5-chloro-phenyl)-(2,5-difluoro-phenyl)-methanone (1y)

In a manner similar to that described above for compound 1aa,4-Chloro-N-Boc-aniline and 2,4-difluoro-benzoyl chloride were convertedto 1y (10% yield) MS m/z=268 (M+H).

(2-Amino-5-chloro-phenyl)-(2-chloro-6-fluoro-phenyl)-methanone (1ab)

In a manner similar to that described above for compound 1aa,4-Chloro-N-Boc-aniline and 2-chloro-6-fluoro-benzoyl chloride wereconverted to 1ab (42% yield) MS m/z=284 (M+H).

(2-amino-5-chlorophenyl)-(2-(trifluoromethyl)phenyl)methanone (1o)

In a manner similar to that described above for compound 1aa,4-Chloro-N-Boc-aniline and 2-(trifluoromethyl)benzoyl chloride wereconverted to 1o (% yield) MS m/z=(M+H).

Example 7: Method G and Method H for the Synthesis of Compounds ofFormula ii (See Scheme 1)

(5-Chloro-2-iodo-phenyl)-(2,6-difluoro-phenyl)-methanone (2aa)

Method G:

(2-Amino-5-chloro-phenyl)-(2,6-difluoro-phenyl)-methanone (1aa) (2.6 g,9.7 mmol) was dissolved in acetic acid (10 mL) and concentrated HCl (4mL) and the solution was cooled to 0° C. A solution of NaNO₂ (0.7 g,10.7 mmol) in H₂O (6 mL) was added dropwise so as to maintain atemperature of between 0-5° C. Following this addition, the reactionmixture was stirred at 0° C. for 30 min. Cold EtOAc (20 mL) was addeddropwise and the solution was stirred for 20 min. Iodine (1.5 g, 5.8mmol) and potassium iodide (1.9 g, 11.6 mmol) in H₂O (10 mL) were addeddropwise and the mixture was warmed to room temperature and stirred for1 h. The reaction mixture was diluted with EtOAc (200 mL) and washedwith saturated aqueous sodium thiosulfate (4×100 mL). The combinedaqueous portions were extracted with EtOAc (3×50 mL). The combinedorganic portions were then washed with a saturated aqueous NaHCO₃solution (3×50 mL), H₂O (2×50 mL), dried over Na₂SO₄, filtered andevaporated in vacuo to afford 2aa (3.3 g, 90%) as a light yellow solid.

4-(2-Fluoro-benzoyl)-3-iodo-benzoic acid methyl ester (2i)

Method H:

To a solution of 2g (1 g, 3 mmol) in t-butanol (25 mL) and H₂O (25 mL)was added KMnO₄ (3.8 g, 24 mmol). The solution was refluxed for 18 h.THF (50 mL) was added and the solution was refluxed for 30 min, cooledto room temperature and filtered. The filtrate was concentrated invacuo, diluted with MeOH (20 mL) and acidified with concentrated HCl.The solution was diluted with H₂O (10 mL) and the resulting precipitatewas collected to provide 4-(2-fluoro-benzoyl)-3-iodo-benzoic acid (1 g,92%) as a white solid. The 4-(2-fluoro-benzoyl)-3-iodo-benzoic acid (0.5g, 1.4 mmol) in MeOH (6 mL) containing concentrated HCl (100 μL) wassubmitted to microwave irradiation (300 W) for 30 min at 140° C. Theresulting precipitate was collected to provide 2i (0.4 g, 79%) as awhite solid MS m/z=385 (M+H).

2-(5-Chloro-2-iodo-benzoyl)-benzoic acid methyl ester (2p)

In a manner similar to that described above for compound 2i, 2m wasconverted to 2p (81% yield) MS m/z=401 (M+H).

3-(2-Fluorobenzoyl)-4-iodobenzoic acid methyl ester (2ai)

In a manner similar to that described above for compound 2i, 2af wasconverted to 2ai (60% yield) MS m/z=385 (M+H).

3-(2,6-Difluorobenzoyl)-4-iodobenzoic acid methyl ester (2ak)

In a manner similar to that described above for compound 2i, 2aj wasconverted to 2ak (58% yield) MS m/z=403 (M+H).

The illustrative compounds of the formula 2, set forth in Table 4 below,were prepared in a similar manner to that illustrated by Method G orMethod H, as described above for compounds 2aa and 2i.

TABLE 4 Illustrative Examples of Compounds of Formulae 1-5 SubstituentMass Spectra (M + H) 1-5 R^(b1) R^(b2) R^(b3) R^(c1) R^(c2) R^(c3)R^(c4) R^(c5) 2 3 4 5 a H H H H H H H H 309 336 236 291 b Me H H F H H HH 341 368 268 323 c H F H F H H H H 345 372 272 327 d H Cl H F H H H H361 388 288 343 e H Br H F H H H H 405/407 432/434 332/334 387/389 f HCF₃ H F H H H H 395 422 322 377 g H Me H F H H H H 341 368 268 323 h HOMe H F H H H H 357 384 284 339 i H CO₂Me H F H H H H 385 412 312 367 jH H F F H H H H 345 372 272 327 k H H Cl F H H H H 361 388 288 343 l H HCl Cl H H H H 377 404 304 359 m H H Cl Me H H H H 357 384 284 339 n H HCl OMe H H H H 373 400 300 355 o H H Cl CF₃ H H H H 411 438 338 393 p HH Cl CO₂Me H H H H 401 428 328 383 q H H Cl CH₂N(Me)₂ H H H H 400 427327 382 r H H Cl H F H H H 361 388 288 343 s H H Cl H OMe H H H 373 400300 355 t H H Cl H H F H H 361 388 288 343 u H H Cl H H OMe H H 373 400300 355 v H H Cl F F H H H — 406 306 361 w H H Cl F H F H H — 406 306361 x H H Cl OMe H OMe H H 403 430 330 385 y H H Cl F H H F H — 406 306361 z H H Cl OMe H H OMe H 403 430 330 385 aa H H Cl F H H H F — 406 306361 ab H H Cl F H H H Cl — 422 322 377 ac H H Cl F H H H OMe — 418 318373 ad H Cl Cl F H H H H 395 422 322 377 ae H H H F H H H H — 354 254309 af H H Me F H H H H 341 368 268 323 ag H H iPr F H H H H 369 — — —ah H H OMe F H H H H 357 384 284 339 ai H H CO₂Me F H H H H 385 412 312367 aj H H CH₃ F H H H F 359 — — — ak H H CO₂Me F H H H F 403 430 330385 al H H Cl -(pyridyl) H H H H — 371 271 326 am H H Cl -(pyridyl) H HH F — 389 289 344

Example 8: Method I for the Synthesis of Compounds of Formula iii (SeeScheme 1)

{3-[4-Chloro-2-(2,6-difluoro-benzoyl)-phenyl]-prop-2-ynyl}-carbamic acidtert-butyl ester (3aa)

(5-Chloro-2-iodo-phenyl)-(2,6-difluoro-phenyl)-methanone (2aa) (5.5g,14.5 mmol), prop-2-ynyl-carbamic acid tert-butyl ester (2.5 g, 16 mmol),PdCl₂(PPh₃)₂ (0.6 g, 0.9 mmol) and Cu(I)I (0.2 g, 0.9 mmol) weresuspended in anhydrous CH₂Cl₂ (50 mL) and the mixture was sparged withnitrogen for 30 min. Diethylamine (8 mL) was added and the solution wasstirred at room temperature for 16 h. The solution was concentrated invacuo and the resulting residue purified by column chromatography(silica gel, 0 to 15% EtOAc/hexanes) to afford 3aa (3.6 g, 61%) as awhite solid, MS m/z=406 (M+H).

The illustrative compounds of the formula 3, set forth in Table 4, wereprepared in a similar manner to that illustrated by Method I, asdescribed above for compounds 3aa.

Example 9: Method J for the Synthesis of Compounds of Formula iii (SeeScheme 1)

tert-Butyl 3-(4-chloro-2-picolinoylphenyl)prop-2-ynylcarbamate (3al)

5-Chloro-2-iodobenzoic acid (2.8 g, 10 mmol) was taken up in drymethylene chloride (80 mL) and DMF (50 μL, cat.) followed by thionylchloride (2.4 g, 20 mmol) were added. The mixture was stirred at refluxfor 12 h, cooled to room temperature and evaporated in vacuo. Theresidue was azeotroped with toluene (2×10 mL) and used without furtherpurification. The 5-chloro-2-iodobenzoyl chloride (10 mmol) was taken upin dry methylene chloride (50 mL) and N,O-dimethylhydroxylaminehydrochloride (1.1 g, 11 mmol) was added. The mixture was cooled to 0°C., and pyridine (2.4 g, 30 mmol) was added. The mixture was allowed towarm to room temperature, stir for 12 h, and was then quenched withsaturated brine (20 mL). The organic phase was separated and the waterphase was extracted with methylene chloride (2×10 mL). The combinedorganic extracts were dried with anhydrous MgSO₄, filtered andevaporated in vacuo. The residue was purified using flash chromatographyon silica gel (50 g) using methylene chloride as eluent to provide5-chloro-2-iodo-N-methoxy-N-methylbenzamide (3.1 g, 95%) MS m/z=326(M+H).

The Weinreb amide (3.1 g, 9.5 mmol) and prop-2-ynyl-carbamic acidtert-butyl ester (2.9 g, 19 mmol) were coupled according to method H toprovide3-(4-chloro-2-(methoxy(methyl)carbamoyl)phenyl)prop-2-ynylcarbamic acidtert-butyl ester (2.7 g, 80%), MS m/z=353 (M+H). To this product,dissolved in dry THF (40 mL) and cooled to −78° C., was added lithiatedpyridine, prepared from 2-bromopyridine (4.2 g, 26.6 mmol) andn-butyllithium (14.3 mL of 1.6 M solution in hexanes, 22.8 mmol) in dryTHF (40 mL) under argon atmosphere at −78° C. The resulting mixture wasgradually warmed to −40° C. over 1 h and then quenched with brine (20mL). After warming to room temperature, the mixture was extracted withethyl acetate (3×20 mL). The organic extracts were dried with MgSO₄,filtered and evaporated. The residue was purified using flashchromatography on silica gel (100 g) using methylene chloride to 10%ethyl acetate in methylene chloride as eluent to give 3al (2.14 g, 76%):MS m/z=371 (M+H).

tert-Butyl 3-(4-chloro-2-(3-fluoropicolinoyl)phenyl)prop-2-ynylcarbamate(3am)

In a manner similar to that described above for compound 3al,3-(4-chloro-2-(methoxy(methyl)carbamoyl)phenyl)prop-2-ynylcarbamic acidtert-butyl ester and 2-bromo-3-fluoropyridine were converted to 3am (45%yield): MS m/z=389 (M+H).

The illustrative compounds of the formula 3, set forth in Table 4, wereprepared in a similar manner to that illustrated by Method J, asdescribed above for compounds 3al and 3am.

Example 10: Method K and Method L for the Synthesis of Compounds ofFormula iv (See Scheme 1)

8-Chloro-l-(2-fluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one (4k)

Method K:

A solution of{3-[4-chloro-2-(2-fluoro-benzoyl)-phenyl]-prop-2-ynyl}-carbamic acidtert-butyl ester (9.2 g, 23 mmol) in CH₂Cl₂ (100 mL) containing formicacid (9.18 mL) was cooled to 0° C. Mercury(II) sulphate (2.1 g, 7.1mmol) was added and the reaction stirred for 2 h at 0° C. The mixturewas diluted with H₂O (20 mL) and NH₄OH (20 mL). The organic phase wascollected and the aqueous phase was extracted with EtOAc (3×100 mL). Thecombined organic portions were washed with H₂O, dried over MgSO₄,filtered and the solvents evaporated in vacuo to afford[3-[4-chloro-2-(2-fluorobenzoyl)-phenyl]-3-oxopropyl]-carbamic acidtert-butyl ester 8.9 g (95%) as a brown solid. This material (8.9 g, 22mmol) was dissolved in HCl (4N in dioxane, 185 mL) and stirred at roomtemperature for 30 min. The solution was then evaporated in vacuo. Theresidue was dissolved in CH₂Cl₂ (250 mL) and diisopropylethylamine amine(18 mL) was added. The solution was stirred at room temperature for 2 h.The solution was evaporated in vacuo and the residue purified by columnchromatography (silica gel, 10 to 50% EtOAc/hexanes) to provide 4k (2.9g, 46%) as a brown solid MS m/z=288 (M+H).

8-Chloro-1-(2,6-difluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one (4aa)

Method L:

A solution of{3-[4-chloro-2-(2,6-difluoro-benzoyl)-phenyl]-prop-2-ynyl}-carbamic acidtert-butyl ester (5.6 g, 15 mmol) was dissolved in dioxane (200 mL). 5NHCl (aq) (200 mL) was added and the solution was stirred at roomtemperature for 14 h and then at 60° C. for 2 h. The solution wasdiluted with CH₂Cl₂ (200 mL) and Na₂CO₃ was added until the solution pHwas basic to litmus. The mixture was allowed to stir for 2 h. Theorganic portion was separated and the aqueous portion was extracted withCH₂Cl₂ (2×100 mL). The combined organic portions were washed with H₂O(3×50 mL), dried over Na₂SO₄, filtered and evaporated in vacuo toprovide 4aa (4.2 g, 100%) MS m/z=306 (M+H).

The illustrative compounds of formula 4, set forth in Table 4, wereprepared in a similar manner to that illustrated by Method K and MethodL, as described above for compounds 4k and 4aa.

Example 11: Method M for the Synthesis of Compounds of the Formula v(See Scheme 1)

8-Chloro-4-dimethylaminomethylene-1-(2,6-difluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one(5aa)

8-Chloro-1-(2,6-difluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one (4aa)(4.2 g, 15 mmol) was dissolved in toluene (100 mL) andN,N-dimethylformamide dimethyl acetal (19 mL) and heated at 80° C. for 2h. The solution was evaporated in vacuo and the resulting residue waspurified by column chromatography (silica gel, 0 to 75% EtOAc/hexanes)to afford 5aa (2.6 g, 78%) as a pale brown solid MS m/z=361 (M+H).

The illustrative compounds of formula 5, set forth in Table 4, wereprepared in a similar manner to that illustrated by Method M, asdescribed above for 5aa.

Example 12: Preparation of Aryl or Heteroaryl Guanidines by Methods N, Oor P

N-(3,4-Dimethoxy-phenyl)-guanidine

Method N:

To a vigorously stirred solution of 3,4-dimethoxyaniline (15.3 g, 0.1mol) in EtOH (60 mL) at 0° C. was added nitric acid (69%, 9.0 mL, 0.1mol) dropwise. A solution of cyanamide (4.6 g, 0.1 mol) in H₂O (8.5 mL)was added and the solution was heated at reflux for 3 h. The mixture wasthen diluted with EtOH (50 mL), chilled to 4° C. and the resultinggolden needles were collected and dried in vacuo to provideN-(3,4-dimethoxy-phenyl)-guanidine as the nitric acid salt (14.7 g, 57%)MS m/z=196 (M+H).

N-Pyridin-3-yl-guanidine

Method O:

To a mixture of 3-aminopyridine (1.0 g, 10.6 mmol),1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (4.0 g, 13.8mmol) and Et₃N (15 mL) in CH₂Cl₂ (100 mL) was added mercuric chloride(4.0 g, 14.8 mmol). The resulting mixture was stirred under a nitrogenatmosphere at room temperature for 16 h, during which time a dense whiteprecipitate formed. The mixture was filtered through Celite®, and washedwith Et₂O. The combined filtrates were evaporated to dryness in vacuoand the resulting white solid purified by column chromatography (silicagel, 15% EtOAc/hexanes) to yield the bis-Boc protected guanidine (3.1 g,88%). To a solution of this material (3.1 g, 9.3 mmol) in MeOH (2 mL)was added HCl (4N in dioxane, 60 mmol). The resulting solution wasrefluxed for 16 h, cooled to room temperature and triturated with Et₂Oto provide the N-pyridin-3-yl-guanidine as the hydrochloride salt (1.2g, 74%) MS m/z=173 (M+H).

t-Butyl Guanidinobenzoate, HCl Salt

Method P:

To a solution of t-butyl 4-aminobenzoate (2.0 g, 10.3 mmol) in CH₂Cl₂(20 mL) was added 1,3-bis(benzyloxycarbonyl)-2-methyl-2-thiopseudourea(5.6 g, 15.5 mmol), Et₃N (5.0 mL, 36 mmol), and mercuric chloride (3.37g, 12.4 mmol). The reaction mixture was stirred overnight at roomtemperature. The reaction mixture was filtered through Celite®, and thefiltrates were concentrated in vacuo and purified by columnchromatography (1:1 CH₂Cl₂/hexanes to 100% CH₂Cl₂, and then 10%EtOAc/CH₂Cl₂) to provide tert-butyl4-(2,3-bis(benzyloxycarbonyl)guanidino)benzoate (3.9 g, 75%). To apressure bottle was charged 20% palladium hydroxide on carbon (2 g)followed by a solution of t-butyl4-(2,3-bis(benzyloxycarbonyl)guanidine)benzoate (3.9 g, 7.7 mmol) inEtOAc (80 mL). The mixture was stirred under hydrogen at 50 psi at roomtemperature overnight. The solution was filtered through Celite® and thefiltrate evaporated in vacuo to provide t-butyl guanidinobenzoate (1.8g, 100%). To the guanidine (855 mg, 3.6 mmol) in EtOAc (50 mL) was add2M HCl in Et₂O (1.9 mL, 3.8 mM). The solution was concentrated and theprecipitate was collected by filtration, washed with Et₂O and dried invacuo to yield (840 mg, 85%) of the HCl salt.

Example 13: Method Q, Method R and Method S for the Synthesis ofCompounds of Formula (I)

4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoicacid (I-52)

Method Q:

A solution of8-chloro-4-dimethylaminomethylene-1-(2-fluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one(5k) (0.22 g, 0.64 mmol), 4-guanidino-benzoic acid hydrochloride (0.15g, 0.70 mmol) and diisopropylethylamine (i-Pr₂EtN) (0.23 mL, 1.32 mmol)in DMF (2.5 mL) was submitted to microwave irradiation (300 W) for 300sec at 250° C. The mixture was cooled and then poured into H₂O (100 mL).While stirring, 1N HCl was added dropwise to pH=3 followed by EtOAc (50mL). The resulting precipitate was collected by filtration and driedunder vacuum to yield I-52 as a tan solid (0.13 g, 47%).

4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoicacid (I-135)

Method R:

8-Chloro-4-dimethylaminomethylene-1-(2,6-difluoro-phenyl)-3,4-dihydro-benzo[c]azepin-5-one(5aa) (2.6 g, 7.1 mmol), 4-guanidino-benzoic acid hydrochloride (1.7 g,7.8 mmol) and K₂CO₃-1.5H₂O (2.6 g, 15.6 mmol) in EtOH (50 mL) wererefluxed for 14 h. The mixture was cooled and then poured into H₂O (400mL). While stirring, 1N HCl was added dropwise to pH=3. EtOAc (400 mL)was then added and the organic portion was washed with H₂O (2×100 mL),dried over Na₂SO₄ and concentrated to dryness in vacuo. The residue wassuspended in CH₂Cl₂ and filtered. The solids were dissolved in EtOAc,filtered through silica gel, concentrated to dryness in vacuo and driedunder vacuum to yield I-135 as a white solid (1.4 g, 42%).

4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoicacid (I-135) (1.5 g, 2.95 mol) was added to a solution of ethanol (8.86mL) and water (1.2 mL), and the mixture was heated to 50° C. An aqueousNaOH solution (0.02458 g/mL) was added to a target solution pH of 11.6.Additional water was added to a total of 4.26 mL/g of free acid. Theresultant slurry was heated to 70° C. and rapidly filtered, maintaininga solution temperature of 65-70° C. Warm ethanol (9.15 mL, 7.21 g) wasadded, and the solution cooled to 65° C. Seed crystals of the sodiumsalt of I-135 (7.1 mg, 0.014 mol) were added as a slurry in 10% (wt)solution of 75:25 ethanol:water. The mixture was maintained at 65° C.for one hour, and then was cooled to 35° C. at a rate of 12° C./hour. At35° C., a second addition of ethanol (4.72 g, 5.98 mL) was performed.The mixture was cooled to 0° C. at a rate of 12° C./hour, and then heldat 0° C. for one hour. The resultant thick slurry was filtered, and thewet filter cake was rinsed with cold ethanol (5.52 g, 7 mL) to afford a72% yield of the sodium salt of I-135, as a hydrate.

2-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-oxazole-5-carboxylicacid (I-364)

Method S:

8-Chloro-4-dimethylaminomethylene-1-(2,6-difluorophenyl)-3,4-dihydrobenzo[c]azepin-5-one(5aa) (3.6 g, 10 mmol), guanidine hydrochloride (1.06 g, 11 mmol),potassium carbonate (4.6 g, 33 mmol), and ethanol (100 mL) were combinedin a 100-mL round-bottomed flask and stirred at reflux for 3 hours. Thereaction mixture was poured into 500 mL water with stirring. The mixturewas extracted with ethyl acetate (4×200 mL). The organic extracts werecombined, washed with saline, dried (Na₂SO₄), filtered, and evaporatedto leave a brown solid. The solid was stirred with diethyl ether,filtered, washed with ether, then dried in vacuo to provide9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamine (3.16 g, 89%) as a light brown solid MS m/z=357 (M+H). The amine(2.0 g, 5.6 mmol), diiodomethane (7.7 g, 28.6 mmol), copper (I) iodide(1.1 g, 5.6 mmol), dry tetrahydrofuran (40 mL), and isoamyl nitrite (2.0g, 16.8 mmol) were combined in a round-bottomed flask and stirred atreflux for 1 hour. The dark purple solution was cooled to roomtemperature and then transferred to a separatory funnel containing 1NHCl (250 mL) and ethyl acetate (150 mL). The organic layer was separatedand the aqueous layer was extracted with ethyl acetate (100 mL). Theorganic extracts were combined, washed with ammonium hydroxide (3%),saturated ammonium chloride, and saturated saline, and then dried(Na₂SO₄), filtered, and concentrated to leave a dark oil. Purificationby column chromatography (silica gel, CH₂Cl₂ to 10% ethyl acetate inCH₂Cl₂) afforded9-Chloro-7-(2,6-difluoro-phenyl)-2-iodo-5H-benzo[c]pyrimido[4,5-e]azepineas a pale yellow solid (1.3g, 50%) MS m/z=468 (M+H).

A mixture of9-Chloro-7-(2,6-difluoro-phenyl)-2-iodo-5H-benzo[c]pyrimido[4,5-e]azepine(200 mg, 0.43 mmol), ethyl 2-aminooxazole-5-carboxylate (81.2 mg, 0.52mmol), tris(dibenzylideneacetone)dipalladium(0) (Pd₂(dba)₃) (935 mg,0.034 mmol), Xantphos (30 mg, 0.052 mmol), powdered K₃PO₄ (183 mg, 0.86mmol), and degassed toluene were submitted to microwave irradiation (300W) for 20 minutes at 145° C. The mixture was cooled to room temperatureand then evaporated to leave a brown solid which was purified by columnchromatography (silica gel, CH₂Cl₂ to 50% diethyl ether in CH₂Cl₂) toyield2-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-oxazole-5-carboxylicacid ethyl ester as a yellow powder (103 mg, 48%) MS m/z=496 (M+H).2-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-oxazole-5-carboxylicacid ethyl ester (91 mg, 0.18 mmol), methanol (1 mL), tetrahydrofuran (3mL), and 1N LiOH (3.7 mL, 3.7 mmol) were stirred at room temperature for3 hours. Water (50 mL) was added with stirring, and the resulting clearyellow solution was acidified by slowly adding 1N HCl. A yellowprecipitate formed. Diethyl ether (10 mL) was added and the precipitatewas collected by filtration, washed with water, diethyl ether and thendried in vacuo to yield I-364 as a yellow powder (78 mg, 93% yield) MSm/z=468 (M+H).

Example 14: Method T for the Synthesis of Compounds of Formula (I)

{4-[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone(I-9)

1-Methyl-piperazine (0.03 mL, 0.3 mmole) was added to a solution of I-52(0.1 g, 0.2 mmole), TBTU (0.08 g, 0.2 mmole) and Et₃N (0.06 mL, 0.4mmole) in DMF (5 mL). The solution was allowed to stir for 30 min andthen diluted with 0.1N NaOH (50 mL) and EtOAc (50 mL). The organicportion was separated, dried over Na₂SO₄ and concentrated in vacuo. Theresulting residue was purified by column chromatography (Silica Gel,CH₂Cl₂:MeOH:NH₄OH, 94:5:1) to yield I-9 (0.07 g, 47%).

Example 15: Method U for the Synthesis of Compounds of Formula (I)

4-[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-N-[(3-dimethylamino-pyrrolidin-1-yl)-imino-methyl]-benzamide(I-237)

A mixture of I-135 (4.8 g, 10 mmol) and DMF (100 mL) was stirred andfluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate (2.9 g, 11mmol) was added in one portion, followed by diisopropylethylamine (3.9g,30 mmol). The mixture was stirred at room temperature for 10 minutes.2-Methyl-2-thiopseudourea sulfate (3.2g, 11 mmol) was then added as asolid and the reaction mixture was stirred at room temperatureovernight. The reaction was quenched into saline (500 mL) and theoff-white precipitate was collected by filtration, washed with water,and dried in vacuo to yield1-{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoyl}-2-methyl-isothioureaas a pale yellow solid (5.81 g, 100%) MS m/z=549 (M+H).

A solution of the benzoyl-methylisothiourea (250 mg, 0.5 mmol),3-dimethylaminopyrrolidine (58 mg, 0.5 mmol), triethylamine (50 mg, 0.5mmol), and toluene (10 mL) was stirred at reflux for 8 hours. Thevolatiles were then removed in vacuo and the brown residue was purifiedby column chromatography (silica gel, 1% 7N NH₃ in MeOH/CH₂Cl₂ to 5% NH₃in MeOH/CH₂Cl₂) to yield I -237 as a yellow solid (154 mg, 54%) MSm/z=615 (M+H).

Example 16: Method V for the Synthesis of Compounds of Formula (I)

[9-Chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-{4-[(3,5-dimethyl-piperazin-1-yl)-imino-methyl]-phenyl}-amine(I-251)

Anhydrous HCl gas was added to a stirred suspension of I-236 (1.9g, 4.4mmol) in absolute ethanol (75 mL) at 0° C. until a homogeneous solutionresulted. The solution was allowed to warm to room temperature and sitfor three days. Diethyl ether (100 mL) was added and the resultingprecipitate collected by filtration, washed with diethyl ether, anddried in vacuo to yield4-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzimidicacid ethyl ester HCl salt as a bright yellow powder (2.4 g, 94%) MSm/z=504 (M+H).

A mixture of the ethyl benzimidate (100 mg, 0.17 mmol),2,6-dimethylpiperazine (200 mg, 8.8 mmol), and absolute ethanol (1 mL)was submitted to microwave irradiation (300 W) for 7.5 minutes at 120°C. The reaction solution was cooled to room temperature and slowlypoured into a stirring saline solution (10 mL). The resultingprecipitate was collected and purified by column chromatography (silicagel, 0.25% NH₄OH/2% MeOH/97.75% CH₂Cl₂ to 2.5% NH₄OH/20% MeOH/77.5%CH₂Cl₂) to yield I-251 as a pale yellow solid (30 mg, 30%).

Example 17: Method W for the Synthesis of Compounds of Formula (I)

4-Methyl-piperazine-1-carboxylic acid{4-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-phenyl}-amide(I-280)

A mixture of[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(4-nitro-phenyl)-amine(I-212, 500 mg, 1.05 mmol), stannous chloride dihydrate (1.42 g, 6.3mmol) and ethyl acetate (15 mL) was refluxed for 28 hours, then cooledto room temperature and allowed to sit overnight. The mustard-yellowreaction mixture was poured onto 50g cracked ice with stirring, and sat.NaHCO₃ solution was added to adjust the pH to 8. The mixture wasextracted with ethyl acetate (3×100 mL). The extracts were combined,dried (Na₂SO₄), filtered and evaporated in vacuo to provideN-[9-chloro-7-(2,6-difluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-benzene-1,4-diamineas an orange/yellow solid (500 mg, 100%) MS m/z=448 (M+H). A solution ofthis product (50 mg, 0.1 mmol), 4-methylpiperazine-1-carbonylchloride(89 mg, 0.6 mmol), diisopropylethylamine (142 mg, 1.1 mmol), in dioxane(0.5 mL) was submitted to microwave irradiation (300 W) for 60 minutesat 160° C. The reaction solution was cooled to room temperature andslowly poured into a stirring saline solution (10 mL). The resultingprecipitate was collected by filtration, washed with water and purifiedby RP-HPLC (C₁₈, 0 to 100% CH₃CN in 0.1% aqueous HCO₂H) to yield I-280as a pale yellow solid (6 mg, 10%) MS m/z=574 (M+H).

Example 18: Method X for the Synthesis of Compounds of Formula (I)

4-[(7-{2-[(2-aminoethyl)amino]-6-fluorophenyl}-9-chloro-5H-pyrimido[5,4-d][2]benzazepin-2-yl)amino]-N-methylbenzamide(I-340)

A solution of I-334 (49 mg, 0.1 mmol) in ethylene diamine (200 μL) wassubmitted to microwave irradiation (300 W) for 20 minutes at 140° C. Thereaction solution was cooled to room temperature and slowly poured intoa stirring saline solution (10 mL). The resulting precipitate wascollected by filtration, washed with water and purified by columnchromatography (silica gel, 1% NH₄OH/2% MeOH/97% CH₂Cl₂ to 2.5%NH₄OH/20% MeOH/77.5% CH₂Cl₂) to yield I-340 as a pale yellow solid (46mg, 87%) MS m/z=530 (M+H).

Certain exemplary compounds of the invention were prepared by methods Qthrough X, employing procedures analogous to those described above forI-52, I-135, I-236, I-237, I-280, and I-340. HRMS data were collected ona Sciex Qstar® time of flight mass spectrometer coupled to an AgilentHPLC. Experimentally determined (M+H)⁺ for certain exemplary compoundsare presented in Table 5, and were within 10 ppm error of calculated(M+H)⁺.

Example 19: Method Y for the Synthesis of Compounds of the Formula (I)

[9-Chloro-7-(2-fluoro-phenyl)-6,7-dihydro-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine(I-72)

[9-Chloro-7-(2-fluoro-phenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine(I-71, 49 mg, 0.10 mmol) was dissolved in dichloromethane (1.8 mL).Acetic acid (0.43 mL) was added and the solution was stirred and cooledto 0° C. Zinc dust (20 mg, 0.31 mmol) was then added and the mixture wasstirred at 0° C. for 1 hour and then allowed to warm to room temperatureand stir for 4 hours. Additional zinc dust (10 mg, 0.15 mmol) and aceticacid (0.22 mL) was added and the mixture was stirred at room temperaturefor 20 hours. The reaction mixture was diluted with dichloromethane. Theorganic layer was separated and washed with 1N NaOH, brine and thendried over magnesium sulfate, filtered and concentrated in vacuo. Theyellow powder was purified by column chromatography (silica gel, ethylacetate) to afford[9-Chloro-7-(2-fluoro-phenyl)-6,7-dihydro-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl]-(3,4-dimethoxy-phenyl)-amine(I-72) as an orange solid (32 mg, 65%): MS m/z=477.

Example 20: Method Z for the Synthesis of Compounds of the Formula (I)

4-[9-Chloro-7-(2,6-difluoro-phenyl)-7H-benzo[c]pyrimido[4,5-e]azepin-2-ylamino]-benzoicacid (I-387). To a solution of 1-135 (1.0 g, 2.1 mmol) in THF (20 mL)was added potassium tert-butoxide (1M in THF, 21 mmol). The solution wasallowed to stir for 1 hr and then the pH was adjusted to 3 with 1N HCl.The solution was then diluted with water (100 mL) and extracted withEtOAc (3×50 mL). The organic portion was dried (Na₂SO₄), concentrated invacuo and the resulting brown oil purified by RP-HPLC (C18, 0 to 100%CH₃CN in water containing 0.1% formic acid) to provide, afterlyophilization, I-387 (0.3 g, 30%).

TABLE 5 High Resolution Mass Spectra of Exemplary Compounds of Formula(A) Com- Com- Com- pound HRMS pound HRMS pound HRMS I-1: 515.1739 I-128:569.221 I-254: 559.2009 I-2: 515.1775 I-129: 515.1759 I-255: 573.2187I-3: 529.1881 I-130: 529.1927 I-256: 455.1499 I-4: 529.1889 I-131:529.1929 I-257: 547.1803 I-5: 543.2054 I-132: 485.1637 I-258: 511.0542I-6: 543.2066 I-134: 493.0633 I-259: 601.2042 I-7: 557.2233 I-135:477.0955 I-260: 547.1813 I-8: 527.1769 I-136: 477.0929 I-261: 573.2173I-9: 541.1910 I-137: 455.1529 I-262: 571.2009 I-10: 557.1613 I-138:471.1842 I-263: 585.2164 I-11: 537.2175 I-139: 509.0987 I-264: 559.2041I-12: 553.2114 I-140: 493.0648 I-265: 545.1858 I-13: 541.1881 I-141:489.1129 I-266: 589.1555 I-14: 521.2463 I-142: 501.1594 I-267: 558.1969I-15: 555.2072 I-143: 441.1137 I-268: 558.1982 I-16: 541.1897 I-144:535.0517 I-269: 621.1760 I-17: 541.1908 I-145: 554.2076 I-270: 529.1733I-18: 569.2207 I-146: 459.1021 I-271: 526.1345 I-19: 598.2473 I-147:552.1697 I-272: 496.1588 I-20: 614.2190 I-148: 551.2548 I-273: 507.0622I-21: 594.2742 I-150: 563.1742 I-274: 521.0448 I-22: 610.2708 I-151:563.175 I-275: 536.2267 I-23: 598.2503 I-152: 457.1424 I-276: 482.1776I-24: 578.3039 I-153: 439.1575 I-277: 509.0967 I-25: 612.2655 I-154:441.1735 I-278: 531.1524 I-26: 528.1619 I-155: 471.1229 I-279: 442.1091I-27: 546.1722 I-156: 471.1243 I-280: 574.1943 I-28: 544.1313 I-157:598.2497 I-281: 593.1419 I-29: 571.2018 I-158: 571.2015 I-282: 607.1584I-30: 587.1709 I-159: 541.1905 I-283: 581.1453 I-31: 567.2256 I-160:577.1898 I-284: 544.1826 I-32: 597.2367 I-161: 563.1744 I-285: 531.1529I-33: 571.2046 I-162: 459.1019 I-286: 543.1704 I-34: 603.1674 I-163:541.1911 I-287: 591.1867 I-35: 432.0783 I-164: 604.2055 I-288: 605.2016I-36: 483.0332 I-165: 654.2409 I-289: 577.1710 I-37: 445.1213 I-166:621.1838 I-290: 591.1900 I-38: 459.1367 I-167: 661.2162 I-291: 579.1263I-39: 445.1213 I-168: 599.2003 I-292: 593.1439 I-40: 445.1215 I-169:647.1998 I-293: 587.2139 I-41: 449.0731 I-170: 626.2448 I-294: 617.1853I-42: 465.0443 I-171: 624.2685 I-295: 603.1746 I-43: 449.0728 I-172:577.1576 I-296: 563.1593 I-44: 449.0727 I-173: 605.2002 I-297: 577.1714I-45: 447.0789 I-174: 493.0656 I-298: 524.1949 I-46: 500.1630 I-175:573.1983 I-299: 510.1813 I-47: 513.1947 I-176: 573.1986 I-300: 605.1879I-48: 506.1558 I-177: 585.2192 I-301: 460.0978 I-49: 440.1073 I-178:585.2203 I-302: 537.2438 I-50: 460.0966 I-179: 571.2037 I-303: 539.2562I-51: 425.1431 I-180: 559.1851 I-304: 542.1863 I-52: 459.1014 I-181:652.2994 I-305: 528.1737 I-53: 475.0752 I-182: 638.2822 I-306: 545.1308I-54: 455.1261 I-183: 587.2117 I-307: 533.1642 I-55: 471.1210 I-184:559.1845 I-308: 533.1680 I-56: 459.1027 I-185: 575.2131 I-309: 605.1894I-57: 443.1332 I-186: 599.2348 I-310: 602.1863 I-58: 439.1550 I-187:654.3136 I-311: 581.2652 I-59: 443.1286 I-188: 638.2832 I-312: 551.2576I-60: 459.1016 I-189: 640.2628 I-313: 621.1731 I-61: 503.0516 I-190:489.1142 I-314: 573.1610 I-62: 455.1496 I-191: 559.1845 I-315: 524.1979I-63: 474.0871 I-192: 513.1625 I-316: 538.2110 I-64: 474.0879 I-193:555.2103 I-317: 588.1727 I-65: 489.0889 I-194: 559.1843 I-318: 579.1300I-66: 488.1034 I-195: 545.1683 I-319: 559.1850 I-67: 495.0690 I-196:545.1693 I-320: 545.1876 I-68: 494.0832 I-197: 559.1814 I-321: 573.1971I-69: 591.0810 I-198: 561.2004 I-322: 597.2403 I-70: 547.0605 I-199:571.2047 I-323: 575.1523 I-71: 475.1339 I-200: 465.1514 I-324: 589.1704I-72: 477.1491 I-201: 647.2340 I-325: 589.1678 I-73: 491.1031 I-202:518.1331 I-326: 589.1680 I-74: 471.1579 I-203: 477.0943 I-327: 575.1517I-75: 455.1873 I-204: 559.1814 I-328: 514.1995 I-76: 483.2202 I-205:587.2156 I-329: 553.2092 I-77: 459.1602 I-206: 573.2001 I-330: 567.2287I-78: 519.0851 I-207: 503.1197 I-331: 567.2301 I-79: 509.1604 I-208:640.2953 I-332: 553.2124 I-80: 455.1873 I-209: 626.2832 I-333: 567.2288I-81: 471.1830 I-210: 612.2649 I-334: 490.1270 I-82: 455.1872 I-211:638.2782 I-335: 559.2007 I-83: 473.1168 I-212: 478.0905 I-336: 572.2352I-84: 463.1152 I-213: 658.2264 I-337: 475.1144 I-85: 475.1000 I-214:575.1556 I-338: 486.1287 I-86: 491.0677 I-215: 607.1598 I-339: 531.1727I-87: 483.0331 I-216: 593.1427 I-340: 530.1895 I-88: 491.1035 I-217:448.1154 I-341: 616.2019 I-89: 443.1442 I-218: 525.0715 I-342: 598.2501I-90: 477.093 I-219: 589.1588 I-343: 514.1631 I-91: 477.0928 I-220:573.1994 I-344: 558.9984 I-92: 551.2557 I-221: 559.1807 I-345: 558.2185I-93: 501.1302 I-222: 573.1989 I-346: 572.2341 I-94: 542.2212 I-223:629.2331 I-347: 558.2203 I-95: 477.0929 I-224: 587.1893 I-348: 570.2169I-96: 477.0931 I-225: 587.2358 I-349: 525.2404 I-97: 541.1928 I-226:587.2364 I-350: 602.1911 I-98: 555.2058 I-227: 571.2031 I-351: 561.1395I-99: 555.208 I-228: 585.2198 I-352: 454.0727 I-100: 501.134 I-229:599.2352 I-353: 473.1430 I-101: 541.1905 I-230: 527.1765 I-354: 501.1626I-102: 527.1755 I-231: 585.2195 I-355: 497.0780 I-103: 491.1094 I-232:571.2033 I-356: 473.1106 I-104: 477.1084 I-233: 571.2028 I-357: 464.1012I-105: 495.0789 I-234: 545.1676 I-358: 504.1412 I-106: 508.105 I-235:557.1849 I-359: 532.1712 I-107: 486.1508 I-236: 458.0994 I-360: 484.0467I-108: 574.1296 I-237: 615.2217 I-361: 512.0783 I-109: 489.1484 I-238:615.2214 I-362: 580.1487 I-110: 555.2063 I-239: 559.1851 I-363: 496.0996I-111: 556.1545 I-240: 557.1880 I-364: 468.0686 I-112: 541.1925 I-241:571.2035 I-365: 566.1355 I-113: 483.1249 I-242: 585.2169 I-366: 559.1852I-114: 472.1352 I-243: 557.1893 I-367: 566.1333 I-115: 477.0961 I-244:586.2295 I-368: 468.0684 I-116: 529.1913 I-245: 490.1365 I-369: 564.1728I-117: 530.1387 I-246: 547.1831 I-370: 550.1549 I-118: 585.217 I-247:561.2004 I-371: 491.1096 I-119: 489.1156 I-248: 603.1714 I-372: 518.1921I-120: 473.1179 I-249: 469.1317 I-373: 490.1603 I-121: 460.0964 I-250:572.2137 I-374: 564.1736 I-122: 607.1699 I-251: 572.2140 I-375: 550.1579I-123: 493.0631 I-252: 533.1689 I-376: 596.2613 I-124: 473.1161 I-253:573.1966 I-377: 486.1401 I-378: 630.2207 I-385: 492.106 I-392: 599.2152I-379: 559.1829 I-386: 492.1055 I-393: 587.2156 I-380: 573.1978 I-387:477.095 I-394: 437.1107 I-381: 616.2039 I-388: 477.0948 I-395: 511.0564I-382: 587.2132 I-389: 602.1900 I-396: 650.1655 I-383: 599.2158 I-390:588.1738 I-397: 664.1835 I-384: 585.1999 I-301: 573.1996

Example 21: Expression and Purification of Aurora Kinase Enzymes Auroraa Enzyme Expression and Purification

Recombinant mouse Aurora A with an amino-terminus hexahistidine tag(His-Aurora A) was expressed using a standard baculovirus vector andinsect cell expression system (Bac-to-Bac®, Invitrogen).

Soluble, recombinant mouse Aurora A was purified from insect cells usingNi-NTA agarose (Qiagen) as described by the manufacturer and furtherpurified over an S75 size exclusion column (Amersham Pharmacia Biotech).

Aurora B Enzyme Expression and Purification

Recombinant mouse Aurora B with an amino-terminus hexahistidine tag(His-Aurora B) was expressed using a standard baculovirus vector andinsect cell expression system (Bac-to-Bac®, Invitrogen).

Soluble, recombinant mouse Aurora B was purified from insect cells usingNi-NTA agarose (Qiagen) as described by the manufacturer.

Example 22: Aurora Kinase Enzyme Assays Aurora a DELFIA® Kinase Assay

The mouse Aurora A enzymatic reaction totaled 25 μL and contained 25 mMTris-HCl (pH 8.5), 2.5 mM MgCl₂, 0.05% Surfact-AMPS-20, 5 mM SodiumFluoride, 5 mM DTT, 250 μM ATP, 10 μM peptide substrate(Biotin-β-Ala-QTRRKSTGGKAPR-NH₂), and 500 μM recombinant murine Aurora Aenzyme. The enzymatic reaction mixture, with and without Aurorainhibitors, was incubated for 15 minutes at room temperature beforetermination with 100 μL of stop buffer (1% BSA, 0.05% Surfact-AMPS-20,and 100 mM EDTA). A total of 100 μL of the enzyme reaction mixture wastransferred to wells of a Neutravidin-coated 96-well plate (Pierce) andincubated at room temperature for 30 minutes. The wells were washed withwash buffer (25 mM Tris, 150 mM sodium chloride, and 0.1% Tween 20) andincubated for 1 hour with 100 μL of antibody reaction mixture containing1% BSA, 0.05% Surfact-AMPS-20, anti-phospho-PKA rabbit polyclonalantibody (1:2000, New England Biolabs), and europium labeled anti-rabbitIgG (1:2000, Perkin Elmer). The wells were washed and then the boundeuropium was liberated using 100 μL of Enhancement Solution (PerkinElmer). Quantification of europium was done using a Wallac™ EnVision(Perkin Elmer).

Compounds I-1 to I-12, I-14 to I-32, I-34, I-37, I-39, I-45, I-52 toI-55, I-57 to I-59, I-63 to I-69, I-73 to I-75, I-80, I-85, I-86, I-91,I-93 to I-96, I-98 to I-103, I-109, I-111 to I-113, I-117, I-118, I-120,I-126, I-128 to I-131, I-134 to I-138, I-142, I-145, I-147 to I-151,I-157, I-160 to I-163, I-165, I-166, I-168 to I-171, I-173 to I-199,I-202 to I-211, I-213 to I-217, I-219 to I-235, I-237 to I-301, I-304 toI-310, I-313 to I-327, I-329 to I-335, I-337 to I-341, I-343, I-350 toI-355, I-357 to I-360, and I-362 to I-376 exhibited IC₅₀ values lessthan or equal to 1.0 μM in this assay.

Compounds I-1 to I-12, I-14 to I-22, I-24 to I-32, I-52 to I-55, I-57,I-58, I-63, I-65 to I-67, I-69, I-73, I-86, I-93, I-98 to I-100, I-102,I-103, I-111 to I-113, I-117, I-128, I-130, I-135, I-145, I-147, I-148,I-160, I-161, I-163, I-171, I-174 to I-199, I-204 to I-206, I-208 toI-211, I-213 to I-217, I-219 to I-229, I-231 to I-235, I-237 to I-244,I-246 to I-257, I-259 to I-270, I-272, I-274, I-277, I-278, I-280 toI-301, I-304 to I-310, I-313 to I-319, I-321, I-323 to I-327, I-329 toI-334, I-337, I-338, I-341, I-343, I-350, I-351, I-353, I-355, I-357,I-359, I-362, I-365 to I-368, and I-371 to I-376 exhibited IC₅₀ valuesless than or equal to 100 nM in this assay.

Aurora B DELFIA® Kinase Assay

The mouse Aurora B enzymatic reaction totaling 25 μL contained 25 mMTris-HCl (pH 8.5), 2.5 mM MgCl₂, 0.025% Surfact-AMPS-20 (Pierce), 1%Glycerol, 1 mM DTT, 1 mM ATP, 3 μM peptide substrate(Biotin-β-Ala-QTRRKSTGGKAPR-NH₂), and 20 nM recombinant murine Aurora Benzyme. The enzymatic reaction mixture, with or without Aurorainhibitors, was incubated for 3 hours at room temperature beforetermination with 100 μL of stop buffer (1% BSA, 0.05% Surfact-AMPS-20,and 100 mM EDTA). A total of 100 L of the enzyme reaction mixture wastransferred to wells of a Neutravidin-coated 96-well plate (Pierce) andincubated at room temperature for 30 minutes. The wells were washed withwash buffer (25 mM Tris, 150 mM sodium chloride, and 0.1% Tween 20) andincubated for 1 hour with 100 μL of antibody reaction mix containing 1%BSA, 0.05% Surfact-AMPS-20, anti-phospho-PKA rabbit polyclonal antibody(1:2000, New England Biolabs), and europium labeled anti-rabbit IgG(1:2000, Perkin Elmer). The wells were washed and then the boundeuropium was liberated using 100 μL of Enhancement Solution (PerkinElmer). Quantification of europium was done using a Wallac™ EnVision(Perkin Elmer).

Example 23: Cellular Assay Aurora Phosphorylation Assays

Inhibition of Aurora A or Aurora B activity in whole cell systems can beassessed by determination of decreased phosphorylation of Aurorasubstrates. For example, determining decreased phosphorylation ofhistone H3 on Serine 10, an Aurora B substrate can be used to measureinhibition of Aurora B activity in a whole cell system. Alternatively,any known Aurora B substrate can be used in similar assay methods toassess inhibition of Aurora B activity. Similarly, Aurora A inhibitioncan be determined using analogous methods and known Aurora A substratesfor detection.

In a specific example, HeLa cells were seeded in a 96-well cell cultureplate (10×10³ cells/well) and incubated overnight at 37° C. Cells wereincubated with Aurora inhibitors for 1 hour at 37° C., fixed with 4%paraformaldehyde for 10 minutes and then permeabilized with 0.5%TritonX-100 in PBS. Cells were incubated with mouse anti-pHisH3 (1:120,Cell Signaling Technologies) and rabbit anti-mitotic marker (1:120,Millennium Pharmaceuticals Inc.) antibodies for 1 hour at roomtemperature. After washing with PBS the cells were stained withanti-rabbit IgG Alexa 488 (1:180, Molecular Probes) and anti-mouse IgGAlexa 594 (1:180) for 1 hour at room temperature. DNA was then stainedwith Hoechst solution (2 μg/ml). The percentage of pHisH3 andanti-mitotic positive cells were quantified using Discovery I andMetaMorph (Universal Imaging Corp.). Aurora B inhibition was determinedby calculating the decrease of pHisH3 positive cells.

Anti-Proliferation Assays

HCT-116 (1000) or other tumor cells in 100 μL of appropriate cellculture medium (McCoy's 5A for HCT-116, Invitrogen) supplemented with10% fetal bovine serum (Invitrogen) was seeded in wells of a 96-wellcell culture plate and incubated overnight at 37° C. Aurora inhibitorswere added to the wells and the plates were incubated for 96 hours at37° C. MTT or WST reagent (10 μL, Roche) was added to each well andincubated for 4 hours at 37° C. as described by the manufacturer. ForMTT the metabolized dye was solublized overnight according tomanufacturer's instructions (Roche). The optical density for each wellwas read at 595 nm (primary) and 690 nm (reference) for the MTT and 450nm for the WST using a spectrophotometer (Molecular Devices). For theMTT the reference optical density values were subtracted from the valuesof the primary wavelength. Percent inhibition was calculated using thevalues from a DMSO control set to 100%.

Example 24: In Vivo Assays In Vivo Tumor Efficacy Model

HCT-116 (1×10⁶) or other tumor cells in 100 μL of phosphate bufferedsaline were aseptically injected into the subcutaneous space in theright dorsal flank of female CD-1 nude mice (age 5-8 weeks, CharlesRiver) using a 23-ga needle. Beginning at day 7 after inoculation tumorswere measured twice weekly using a vernier caliper. Tumor volumes werecalculated using standard procedures (0.5×(length×width²)). When thetumors reached a volume of approximately 200 mm³ mice were injected i.v.in the tail vein with Aurora inhibitors (100 μL) at various doses andschedules. All control groups received vehicle alone. Tumor size andbody weight was measure twice a week and the study was terminated whenthe control tumors reached approximately 2000 mm³.

While the foregoing invention has been described in some detail forpurposes of clarity and understanding, these particular embodiments areto be considered as illustrative and not restrictive. It will beappreciated by one skilled in the art from a reading of this disclosurethat various changes in form and detail can be made without departingfrom the true scope of the invention, which is to be defined by theappended claims rather than by the specific embodiments.

The patent and scientific literature referred to herein establishesknowledge that is available to those with skill in the art. Unlessotherwise defined, all technical and scientific terms used herein havethe same meaning as commonly understood by one of ordinary skill in theart to which this invention belongs. The issued patents, applications,and references that are cited herein are hereby incorporated byreference to the same extent as if each was specifically andindividually indicated to be incorporated by reference. In the case ofinconsistencies, the present disclosure, including definitions, willcontrol.

1-62. (canceled)
 63. A compound of the formula (v):

or a pharmaceutically acceptable salt thereof, wherein Ring A issubstituted with 0-2 independently selected R^(b); Ring B is substitutedwith 0-2 independently selected R^(c); each R^(b) independently isselected from the group consisting of C₁₋₆ aliphatic, R^(2b),R^(7b)-T¹-R^(2b), and -T¹-R^(7b); each R^(2b) independently is halo,—NO₂, —CN, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵,—OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, —P(O)(R⁵)₂, or —P(O)(OR⁵)₂; each R^(7b)independently is an optionally substituted aryl, heterocyclyl, orheteroaryl group; each R^(c) independently is selected from the groupconsisting of C₁₋₆ aliphatic, R^(2c), R^(7c), T¹-R^(2c), and -T¹-R^(7c);each R^(2c) independently is halo, —NO₂, —CN, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵,—OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶, —SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵,—NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R, —OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵,—C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂, —C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵,—N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂, —N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂,—P(O)(R⁵)₂, or —P(O)(OR⁵)₂; each R^(7c) independently is an optionallysubstituted aryl, heterocyclyl, or heteroaryl group; T¹ is a C₁₋₆alkylene chain optionally substituted with R³ or R^(3b), wherein T¹ or aportion thereof optionally forms part of a 3- to 7-membered ring; eachR³ independently is selected from the group consisting of halo, —OH,—O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl), —CO₂H, —CO₂(C₁₋₃alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl); each R^(3b) independently isa C₁₋₃ aliphatic optionally substituted with R³ or R⁷, or twosubstituents R^(3b) on the same carbon atom, taken together with thecarbon atom to which they are attached, form a 3- to 6-memberedcarbocyclic ring; each R⁴ independently is hydrogen or an optionallysubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or twoR⁴ on the same nitrogen atom, taken together with the nitrogen atom,form an optionally substituted 5- to 8-membered heteroaryl orheterocyclyl ring having, in addition to the nitrogen atom, 0-2 ringheteroatoms selected from N, O, and S; each R⁵ independently is hydrogenor an optionally substituted aliphatic, aryl, heteroaryl, orheterocyclyl group; each R⁶ independently is an optionally substitutedaliphatic or aryl group; and each R⁷ independently is an optionallysubstituted aryl, heterocyclyl, or heteroaryl group.
 64. The compound ofclaim 63, wherein Ring A has the structure:

Ring B has the structure:

and R^(b1), R^(b2), R^(b3), R^(c1), R^(c2), R^(c3), R^(c4) and R^(c5)are as defined in row a, b, c, d, e, g, h, i, j, k, 1, m, n, p, q, r, s,t, u, v, w, x, y, z, aa, ab, ac, ad, ae, af, ag, ah, ai, aj, ak, al oram as set out below: Substituent R^(b1) R^(b2) R^(b3) R^(c1) R^(c2)R^(c3) R^(c4) R^(c5) a H H H H H H H H b Me H H F H H H H c H F H F H HH H d H Cl H F H H H H e H Br H F H H H H g H Me H F H H H H h H OMe H FH H H H i H CO₂Me H F H H H H j H H F F H H H H k H H Cl F H H H H l H HCl Cl H H H H m H H Cl Me H H H H n H H Cl OMe H H H H p H H Cl CO₂Me HH H H q H H Cl CH₂N(Me)₂ H H H H r H H Cl H F H H H s H H Cl H OMe H H Ht H H Cl H H F H H u H H Cl H H OMe H H v H H Cl F F H H H w H H Cl F HF H H x H H Cl OMe H OMe H H y H H Cl F H H F H z H H Cl OMe H H OMe Haa H H Cl F H H H F ab H H Cl F H H H Cl ac H H Cl F H H H OMe ad H ClCl F H H H H ae H H H F H H H H af H H Me F H H H H ag H H iPr F H H H Hah H H OMe F H H H H ai H H CO₂Me F H H H H aj H H CH₃ F H H H F ak H HCO₂Me F H H H F al H H Cl -(pyridyl) H H H H am H H Cl -(pyridyl) H H H F.


65. The compound of claim 64, wherein Ring A has the structure:

Ring B has the structure:

and R^(b1), R^(b2), R^(b3), R^(c1), R^(c2), R^(c3), R^(c4) and R^(c5)are as defined in row a, b, c, d, e, g, h, i, j, k, 1, m, n, p, q, r, s,t, u, v, w, x, y, z, aa, ab, ac, ad, ae, af, ag, ah, ai, aj, ak, al oram as set out below: Substituent R^(b1) R^(b2) R^(b3) R^(c1) R^(c2)R^(c3) R^(c4) R^(c5) a H H H H H H H H b Me H H F H H H H c H F H F H HH H d H Cl H F H H H H e H Br H F H H H H g H Me H F H H H H h H OMe H FH H H H i H CO₂Me H F H H H H j H H F F H H H H k H H Cl F H H H H l H HCl Cl H H H H m H H Cl Me H H H H n H H Cl OMe H H H H p H H Cl CO₂Me HH H H q H H Cl CH₂N(Me)₂ H H H H r H H Cl H F H H H s H H Cl H OMe H H Ht H H Cl H H F H H u H H Cl H H OMe H H v H H Cl F F H H H w H H Cl F HF H H x H H Cl OMe H OMe H H y H H Cl F H H F H z H H Cl OMe H H OMe Haa H H Cl F H H H F ab H H Cl F H H H Cl ac H H Cl F H H H OMe ad H ClCl F H H H H ae H H H F H H H H af H H Me F H H H H ag H H iPr F H H H Hah H H OMe F H H H H ai H H CO₂Me F H H H H aj H H CH₃ F H H H F ak H HCO₂Me F H H H F al H H Cl -(pyridyl) H H H H am H H Cl -(pyridyl) H H H F.


66. The compound of claim 65, wherein Ring A has the structure:

Ring B has the structure:

and R^(b1), R^(b2), R^(b3), R^(c1), R^(c2), R^(c3), R^(c4) and R^(c5)are as defined in row a, b, c, d, e, g, h, i, j, k, 1, m, n, p, q, r, s,t, u, v, w, x, y, z, aa, ab, ac, ad, ae, af, ag, ah, ai, aj, ak, al oram as set out below: Substituent R^(b1) R^(b2) R^(b3) R^(c1) R^(c2)R^(c3) R^(c4) R^(c5) a H H H H H H H H b Me H H F H H H H c H F H F H HH H d H Cl H F H H H H e H Br H F H H H H g H Me H F H H H H h H OMe H FH H H H i H CO₂Me H F H H H H j H H F F H H H H k H H Cl F H H H H l H HCl Cl H H H H m H H Cl Me H H H H n H H Cl OMe H H H H p H H Cl CO₂Me HH H H q H H Cl CH₂N(Me)₂ H H H H r H H Cl H F H H H s H H Cl H OMe H H Ht H H Cl H H F H H u H H Cl H H OMe H H v H H Cl F F H H H w H H Cl F HF H H x H H Cl OMe H OMe H H y H H Cl F H H F H z H H Cl OMe H H OMe Haa H H Cl F H H H F ab H H Cl F H H H Cl ac H H Cl F H H H OMe ad H ClCl F H H H H ae H H H F H H H H af H H Me F H H H H ag H H iPr F H H H Hah H H OMe F H H H H ai H H CO₂Me F H H H H aj H H CH₃ F H H H F ak H HCO₂Me F H H H F al H H Cl -(pyridyl) H H H H am H H Cl -(pyridyl) H H H F.


67. The compound of claim 66, wherein Ring A has the structure:

Ring B has the structure:

and R^(b1), R^(b2), R^(b3), R^(c1), R^(c2), R^(c3), R^(c4) and R^(c5)are as defined in row a, b, c, d, e, g, h, i, j, k, l, m, n, p, q, r, s,t, u, v, w, x, y, z, aa, ab, ac, ad, ae, af, ag, ah, ai, aj, ak, al oram as set out below: Substituent R^(b1) R^(b2) R^(b3) R^(c1) R^(c2)R^(c3) R^(c4) R^(c5) a H H H H H H H H b Me H H F H H H H c H F H F H HH H d H Cl H F H H H H e H Br H F H H H H g H Me H F H H H H h H OMe H FH H H H i H CO₂Me H F H H H H j H H F F H H H H k H H Cl F H H H H l H HCl Cl H H H H m H H Cl Me H H H H n H H Cl OMe H H H H p H H Cl CO₂Me HH H H q H H Cl CH₂N(Me)₂ H H H H r H H Cl H F H H H s H H Cl H OMe H H Ht H H Cl H H F H H u H H Cl H H OMe H H v H H Cl F F H H H w H H Cl F HF H H x H H Cl OMe H OMe H H y H H Cl F H H F H z H H Cl OMe H H OMe Haa H H Cl F H H H F ab H H Cl F H H H Cl ac H H Cl F H H H OMe ad H ClCl F H H H H ae H H H F H H H H af H H Me F H H H H ag H H iPr F H H H Hah H H OMe F H H H H ai H H CO₂Me F H H H H aj H H CH₃ F H H H F ak H HCO₂Me F H H H F al H H Cl -(pyridyl) H H H H am H H Cl -(pyridyl) H H H F.


68. The compound of claim 67, wherein Ring A has the structure:

Ring B has the structure:

and R^(b1), R^(b2), R^(b3), R^(c1), R^(c2), R^(c3), R^(c4) and R^(c5)are as defined in row a, b, c, d, e, g, h, i, j, k, l, m, n, p, q, r, s,t, u, v, w, x, y, z, aa, ab, ac, ad, ae, af, ag, ah, ai, aj, ak, al oram as set out below: Substituent R^(b1) R^(b2) R^(b3) R^(c1) R^(c2)R^(c3) R^(c4) R^(c5) a H H H H H H H H b Me H H F H H H H c H F H F H HH H d H Cl H F H H H H e H Br H F H H H H g H Me H F H H H H h H OMe H FH H H H i H CO₂Me H F H H H H j H H F F H H H H k H H Cl F H H H H l H HCl Cl H H H H m H H Cl Me H H H H n H H Cl OMe H H H H p H H Cl CO₂Me HH H H q H H Cl CH₂N(Me)₂ H H H H r H H Cl H F H H H s H H Cl H OMe H H Ht H H Cl H H F H H u H H Cl H H OMe H H v H H Cl F F H H H w H H Cl F HF H H x H H Cl OMe H OMe H H y H H Cl F H H F H z H H Cl OMe H H OMe Haa H H Cl F H H H F ab H H Cl F H H H Cl ac H H Cl F H H H OMe ad H ClCl F H H H H ae H H H F H H H H af H H Me F H H H H ag H H iPr F H H H Hah H H OMe F H H H H ai H H CO₂Me F H H H H aj H H CH₃ F H H H F ak H HCO₂Me F H H H F al H H Cl -(pyridyl) H H H H am H H Cl -(pyridyl) H H H F.


69. A compound of the formula (iv):

or a pharmaceutically acceptable salt thereof, wherein Ring A issubstituted with 0-2 independently selected R^(b); Ring B is substitutedwith 0-2 independently selected R^(c); each R^(b) independently isselected from the group consisting of C₁₋₆ aliphatic, R^(2b),R^(7b)-T¹-R^(2b), and -T¹-R^(7b); each R^(2b) independently is halo,—NO₂, —CN, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵, —OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶,—SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵,—OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵, —C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂,—C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵, —N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂,—N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂, —P(O)(R⁵)₂, or —P(O)(OR⁵)₂; each R^(7b)independently is an optionally substituted aryl, heterocyclyl, orheteroaryl group; each R^(c) independently is selected from the groupconsisting of C₁₋₆ aliphatic, R^(2c), R^(7C)-T¹-R^(2c), and -T¹-R^(7c);each R^(2c) independently is halo, —NO₂, —CN, —C(R⁵)═C(R⁵)₂, —C≡C—R⁵,—OR⁵, —SR⁶, —S(O)R⁶, —SO₂R⁶, —SO₂N(R⁴)₂, —N(R⁴)₂, —NR⁴C(O)R⁵,—NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —O—CO₂R⁵, —OC(O)N(R⁴)₂, —O—C(O)R⁵, —CO₂R⁵,—C(O)—C(O)R⁵, —C(O)R⁵, —C(O)N(R⁴)₂, —C(═NR⁴)—N(R⁴)₂, —C(═NR⁴)—OR⁵,—N(R⁴)—N(R⁴)₂, —N(R⁴)C(═NR⁴)—N(R⁴)₂, —N(R⁴)SO₂R⁶, —N(R⁴)SO₂N(R⁴)₂,—P(O)(R⁵)₂, or —P(O)(OR⁵)₂; each R^(7c) independently is an optionallysubstituted aryl, heterocyclyl, or heteroaryl group; T¹ is a C₁₋₆alkylene chain optionally substituted with R³ or R^(3b), wherein T¹ or aportion thereof optionally forms part of a 3- to 7-membered ring; eachR³ independently is selected from the group consisting of halo, —OH,—O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃ alkyl), —CO₂H, —CO₂(C₁₋₃alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl); each R^(3b) independently isa C₁₋₃ aliphatic optionally substituted with R³ or R⁷, or twosubstituents R^(3b) on the same carbon atom, taken together with thecarbon atom to which they are attached, form a 3- to 6-memberedcarbocyclic ring; each R⁴ independently is hydrogen or an optionallysubstituted aliphatic, aryl, heteroaryl, or heterocyclyl group; or twoR⁴ on the same nitrogen atom, taken together with the nitrogen atom,form an optionally substituted 5- to 8-membered heteroaryl orheterocyclyl ring having, in addition to the nitrogen atom, 0-2 ringheteroatoms selected from N, O, and S; each R⁵ independently is hydrogenor an optionally substituted aliphatic, aryl, heteroaryl, orheterocyclyl group; each R⁶ independently is an optionally substitutedaliphatic or aryl group; and each R⁷ independently is an optionallysubstituted aryl, heterocyclyl, or heteroaryl group.
 70. A method forinhibiting Aurora kinase activity in a cell, comprising contacting acell in which inhibition of Aurora kinase is desired with a compound offormula (A):

or a pharmaceutically acceptable salt thereof; wherein: R^(f1) ishydrogen, or R^(n1) and R^(f2) together form a bond; R^(f2) is hydrogen,or R^(f2) forms a bond with either R^(f1) or R^(x); each of R^(x) andR^(y) independently is hydrogen, fluoro, or an optionally substitutedC₁₋₆ aliphatic; or R^(x) and R^(y), taken together with the carbon atomto which they are attached, form an optionally substituted 3- to6-membered cycloaliphatic ring; or R^(x) and R^(f2) together form abond; G is hydrogen, an optionally substituted aliphatic or Ring B whenR^(f1) is hydrogen; and G is hydrogen, —OR⁵, —N(R⁴)₂, —SR⁵, anoptionally substituted aliphatic, or Ring B when R^(f1) and R^(f2)together form a bond; Ring A is a substituted or unsubstituted 5- or6-membered aryl, heteroaryl, cycloaliphatic, or heterocyclyl ring; RingB is a substituted or unsubstituted aryl, heteroaryl, heterocyclyl, orcycloaliphatic ring; Ring C is a substituted or unsubstituted aryl,heteroaryl, heterocyclyl, or cycloaliphatic ring; R^(a) is hydrogen,—C(O)R¹, —CO₂R¹, —SO₂R¹, or a C₁₋₃ aliphatic having 0-2 substituentsindependently selected from R³ or R⁷; R^(e) is hydrogen, —OR⁵, —N(R⁴)₂,—SR⁵, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —N(R⁴)SO₂R⁶,—N(R⁴)SO₂N(R⁴)₂, or a C₁₋₃ aliphatic optionally substituted with R³ orR⁷; R¹ is C₁₋₆ aliphatic or an optionally substituted aryl, heteroaryl,or heterocyclyl group; each R³ independently is selected from the groupconsisting of -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃alkyl), —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl); eachR⁴ independently is hydrogen or an optionally substituted aliphatic,aryl, heteroaryl, or heterocyclyl group; or two R⁴ on the same nitrogenatom, taken together with the nitrogen atom, form an optionallysubstituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclylring having, in addition to the nitrogen atom, 0-2 ring heteroatomsselected from N, O, and S; each R⁵ independently is hydrogen or anoptionally substituted aliphatic, aryl, heteroaryl, or heterocyclylgroup; each R⁶ independently is an optionally substituted aliphatic oraryl group; and each R⁷ independently is an optionally substituted aryl,heterocyclyl, or heteroaryl group.
 71. A method for treating an Aurorakinase-mediated disorder in a patient in need thereof, comprisingadministering to the patient a therapeutically effective amount of acompound of formula (A):

or a pharmaceutically acceptable salt thereof; wherein: R^(f1) ishydrogen, or R^(f1) and R^(f2) together form a bond; R^(f2) is hydrogen,or R^(f2) forms a bond with either R^(n) or R; each of R^(x) and R^(y)independently is hydrogen, fluoro, or an optionally substituted C₁₋₆aliphatic; or R^(x) and R^(y), taken together with the carbon atom towhich they are attached, form an optionally substituted 3- to 6-memberedcycloaliphatic ring; or R^(x) and R^(f2) together form a bond; G ishydrogen, an optionally substituted aliphatic or Ring B when R^(f1) ishydrogen; and G is hydrogen, —OR⁵, —N(R⁴)₂, —SR⁵, an optionallysubstituted aliphatic, or Ring B when R^(f1) and R^(f2) together form abond; Ring A is a substituted or unsubstituted 5- or 6-membered aryl,heteroaryl, cycloaliphatic, or heterocyclyl ring; Ring B is asubstituted or unsubstituted aryl, heteroaryl, heterocyclyl, orcycloaliphatic ring; Ring C is a substituted or unsubstituted aryl,heteroaryl, heterocyclyl, or cycloaliphatic ring; R^(a) is hydrogen,—C(O)R¹, —CO₂R¹, —SO₂R¹, or a C₁₋₃ aliphatic having 0-2 substituentsindependently selected from R³ or R⁷; R^(e) is hydrogen, —OR⁵, —N(R⁴)₂,—SR⁵, —NR⁴C(O)R⁵, —NR⁴C(O)N(R⁴)₂, —NR⁴CO₂R⁶, —N(R⁴)SO₂R⁶,—N(R⁴)SO₂N(R⁴)₂, or a C₁₋₃ aliphatic optionally substituted with R³ orR⁷; R¹ is C₁₋₆ aliphatic or an optionally substituted aryl, heteroaryl,or heterocyclyl group; each R³ independently is selected from the groupconsisting of -halo, —OH, —O(C₁₋₃ alkyl), —CN, —N(R⁴)₂, —C(O)(C₁₋₃alkyl), —CO₂H, —CO₂(C₁₋₃ alkyl), —C(O)NH₂, and —C(O)NH(C₁₋₃ alkyl); eachR⁴ independently is hydrogen or an optionally substituted aliphatic,aryl, heteroaryl, or heterocyclyl group; or two R⁴ on the same nitrogenatom, taken together with the nitrogen atom, form an optionallysubstituted 5- to 6-membered heteroaryl or 4- to 8-membered heterocyclylring having, in addition to the nitrogen atom, 0-2 ring heteroatomsselected from N, O, and S; each R⁵ independently is hydrogen or anoptionally substituted aliphatic, aryl, heteroaryl, or heterocyclylgroup; each R⁶ independently is an optionally substituted aliphatic oraryl group; and each R⁷ independently is an optionally substituted aryl,heterocyclyl, or heteroaryl group.
 72. A method according to claim 71,wherein the Aurora kinase-mediated disorder is cancer.
 73. The methodaccording to claim 72, wherein the cancer is lung cancer.
 74. The methodaccording to claim 73, wherein the lung cancer is non-small cell lungcancer.